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T H E  H E M O S T A T I C  S Y S T E M
The hemostatic system is a complex balanced system that triggers clot formation to 
prevent blood loss after trauma. Adequate clot formation requires both the generation 
of a primary platelet plug (primary hemostasis) and fibrin-mediated clot stabilization 
and strengthening (secondary hemostasis). Finally, after wound healing, the thrombus 
is resolved to ensure continuous blood flow (fibrinolysis). Disturbance of the hemostatic 
balance can result in either hypocoagulability, associated with an increased bleeding 
risk, or hypercoagulability, associated with an increased risk of thrombosis.
T H R O M B O S I S
Thrombosis is the presence of a blood clot in an artery (arterial thrombosis) or vein 
(venous thrombosis) compromising distal blood flow. Importantly, thrombosis is the 
major underlying mechanism of cardiovascular diseases such as myocardial infarction, 
ischemic stroke and venous thromboembolism, with a major impact on worldwide 
morbidity and mortality (1). Three main components, together commonly known as 
Virchow’s triad, have been identified contributing to the pathogenesis of thrombosis: 
alterations in the constituents of the blood (hypercoagulability), diminished blood flow 
(stasis), and endothelial damage (vessel wall) (2). Historically, arterial and venous 
thrombosis were regarded as different diseases from a pathophysiological perspective, 
arterial thrombosis mediated primarily by platelet aggregation (primary hemostasis) 
and venous thrombosis mainly mediated by fibrin formation (secondary hemostasis). 
More recent studies have shown that arterial and venous thrombosis also share 
common risk factors such as increasing age, obesity, smoking, inflammatory markers 
and increased clotting factor levels (3-7). 
The treatment of arterial and venous thrombosis differs depending on the relative 
importance of different components of Virchow’s triad to its pathophysiology. For 
hypercoagulability due to altered blood composition or stasis, such as in patients with 
atrial fibrillation, venous thrombosis and mechanical heart valves, anticoagulant 
treatment is indicated, whereas for myocardial infarction, triggered by rupture of an 
atherosclerotic plaque and consequent platelet activation, antiplatelet therapy is the 
most commonly used treatment. This thesis will now further focus on anticoagulant 
treatment and monitoring and management of anticoagulant therapy.
A N T I C O A G U L A N T  T H E R A P Y
Anticoagulants exert their effect by downregulating thrombin-mediated fibrin 
formation, the endpoint of secondary hemostasis. Several anticoagulants are currently 
available, with different mechanisms of action. Unfractionated heparin, low-molecular-
weight heparin (LMWH) and the pentasaccharide fondaparinux bind to and activate 
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the natural anticoagulant antithrombin, thereby causing a conformational change and 
increasing its inhibition of both thrombin and factor Xa (unfractionated heparin) or 
primarily factor Xa (LMWH, fondaparinux) (8). The direct oral anticoagulants (DOACS) 
directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban) 
and have been registered for different indications in the last decade (9). Despite the 
increasing use of DOACS, vitamin K antagonists (VKA) are still the most commonly used 
anticoagulant worldwide. Vitamin K antagonists are inhibitors of the enzyme vitamin 
K epoxide reductase (VKOR) (10-12). This enzyme catalyzes the reduction of oxidized 
vitamin K to vitamin K hydroquinone, a necessary cofactor for vitamin K-dependent 
γ-carboxylation of clotting factors II (FII), VII (FVII), IX (FIX) and X (FX) and the natural 
anticoagulants protein C and protein S (10-13). Inhibition of VKOR by VKA results in a 
deficiency in these factors by inhibiting the recycling of oxidized vitamin K (10-12). 
Different VKA agents are widely available and used (warfarin, acenocoumarol and 
phenprocoumon), of which only acenocoumarol and phenprocoumon are registered 
and used in the Netherlands. The most important difference between these agents 
are their half-lives, ranging from 2-8 hours for the short acting acenocoumarol to up 
to 156-178 hours for the long-acting phenprocoumon (13). Due to many food and drug 
interactions, the variable dose-response between patients and within patients, and 
the relative narrow therapeutic window of these drugs, monitoring the anticoagulant 
effect of VKAs is pivotal for safe and effective treatment. 
A S S E S S M E N T  O F  T H E  A N T I C O A G U L A N T  E F F E C T  O F  V K A
Historically, the Quick and later the Owren’s prothrombin time (PT), as determined by 
mechanical or photo-optical clot detection, have been used to monitor the anticoagulant 
effect of VKA. The Quick prothrombin time evaluates the extrinsic and final common 
pathway of the coagulation cascade and is sensitive for deficiencies in fibrinogen, FII, 
FV, FVII and FX, while the Owren’s PT is only sensitive for deficiencies in FII, FVII, and FX 
due to the addition of adsorbed bovine plasma to its reagent (14). To measure the PT, 
calcium chloride and a thromboplastin reagent, containing tissue factor and 
phospholipids, are added to citrated platelet poor plasma in order to induce fibrin 
formation through activation of the extrinsic pathway. Thromboplastins can be isolated 
from tissue homogenates from animal or human source (tissue-extract thromboplastins) 
or prepared by reconstituting recombinant tissue factor in a synthetic phospholipid 
medium (recombinant thromboplastins). Due to lack of standardization in the 
preparation of tissue-extract thromboplastin reagents in the past, PT results between 
laboratories showed considerable discrepancies using identical plasma samples, which 
may partly be explained by differences in thromboplastin concentration and 
contamination during the preparation (15).  As a result, the required VKA dose, based 
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on the PT result, also differed between thromboplastins reagents. An early study 
showed substantial geographical differences in mean daily warfarin dosages between 
patient groups, which turned out to be due to differences in used thromboplastin 
reagents (16). To overcome differences between laboratories in PT results due to the 
use of different thromboplastins, a derivative of the PT, the INR, which is short for the 
‘International Normalized Ratio’, was adopted in the late 1970’s and is still considered 
the gold standard for monitoring treatment with VKA (15).  The INR is a ratio of the 
patient’s prothrombin time (PT) to the mean normal prothrombin time (MNPT) as 
determined in at least 20 healthy volunteers, corrected for the international sensitivity 
index of the used thromboplastin reagent;
INR=  (15).
The sensitivity index of the used thromboplastin is determined by calibration against 
the reference thromboplastin from the World Health Organization using the manual 
tilt-tube method (15). Since the 1990’s, several point-of-care (POC) devices have become 
available, measuring the INR directly in capillary whole blood using different test 
principles such as impedance measurement or electrochemical clot detection (17). 
Although different POC devices are currently available for POC INR measurement, the 
CoaguChek XS (Roche Diagnostics, Mannheim, Germany) is the most frequently used 
and studied POC device for INR measurement (17).
 
M O N I T O R I N G  O F  V K A  T H E R A P Y
During VKA therapy, the INR is regularly measured and the VKA dose adjusted based 
on the INR result to keep the INR of a patient within a therapeutic INR range. The 
therapeutic INR range depends on the treatment indication and the individual bleeding 
and thrombotic risk of the patient. For patients with atrial fibrillation or venous 
thrombosis, the therapeutic INR range is usually set at 2.0-3.0, while for patients with 
mechanical heart valves, the therapeutic INR range is normally set at 2.5-3.5 (18). Until 
recently, the upper limits of the therapeutic INR ranges in the Netherlands were set 
slightly higher (2.0-3.5 and 2.5-4.0, respectively) (19), but these have been adjusted to 
the international standards since January 2016 (20). Regular monitoring of the INR and 
adjustment of VKA therapy when the INR is out of range is necessary, since the risk of 
thrombotic complications sharply increases at subtherapeutic INR levels (INR <2.0), 
while the risk of bleeding complications significantly increases at supratherapeutic INR 
levels (INR >3.5) (21,22). The importance of monitoring and adjustment of VKA dose to 
keep patients within their therapeutic range is illustrated by the fact that INR stability 
and the quality of anticoagulation control during VKA therapy is strongly associated 
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with the risk of both thrombotic and bleeding complications (23). Quality of 
anticoagulation control can be assessed using different methods, of which the most 
frequently used is the percentage of time in therapeutic range (TTR in %), as determined 
using the Rosendaal linear interpolation method (24). A TTR of at least 70% is considered 
as good quality of anticoagulation control (23,25). 
In the Netherlands over 450,000 patients are currently receiving treatment with VKA 
(26). These patients are either monitored by a unique organization of anticoagulation 
clinics or measure their INR themselves using POC devices. In case of INR self-
monitoring, slightly more than half of these patients (56%) communicate their INR to 
an anticoagulation clinic, which adjusts the VKA dose for them when the INR is outside 
the therapeutic range (self-monitoring), while the other patients (44%)  also adjust the 
VKA dose themselves (self-management) (26). Although INR self-monitoring and self-
management are both associated with better anticoagulation control and clinical 
outcome, relatively few patients perform INR self-monitoring or INR self-management 
(approximately 15-20% in the Netherlands), due to many reasons such as comorbidity, 
inability to measure the INR, or cognitive impairment (26,27). 
A L T E R N A T I V E S  T O  A N T I C O A G U L A N T  T R E A T M E N T
The downside of anticoagulant therapy, irrespective of the chosen agent, is an increased 
risk of major bleeding during exposure. Major bleeding occurs in 2-5 per 100 patients 
per year during anticoagulant therapy of which approximately 5-10% are fatal. (28-30). 
Although the risk of thrombosis outweighs the bleeding risk in patients with mechanical 
heart valves and patients with non-valvular atrial fibrillation, justifying lifelong 
treatment, determining the optimal treatment duration after a first venous thrombotic 
event remains challenging (18). Patients with a first venous thrombotic event used to 
receive 3-6 months of therapy with anticoagulants after which anticoagulant treatment 
was discontinued. However, VTE recurrence rates after discontinuing anticoagulant 
therapy are high, and recurrent VTE is associated with significant morbidity and 
mortality (3,31).  Although prediction models for recurrent VTE have been developed, 
and the nature of the index event (provoked or unprovoked) and male sex have been 
identified as important risk factors for recurrence, individualized treatment based on 
reliable prediction is still difficult to achieve (3). Nowadays, patients with unprovoked 
VTE without a high bleeding risk receive anticoagulant treatment for an indefinite time 
due to their high risk of recurrence, but safer anticoagulant drugs that lower the risk 
of recurrent VTE and have fewer bleeding complications are urgently needed.  Safer 
anticoagulant drugs should substantially reduce the number of major and fatal 
bleedings in these patients (28-30).
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As mentioned earlier, increasing evidence suggests pathophysiological overlap between 
arterial and venous thrombosis. Apart from shared risk factors, patients with a recent 
arterial thrombotic event are also exposed to an increased risk of venous thrombosis 
and vice versa (32-34).  More importantly, the use of HMG-CoA reductase inhibitors, 
or statins, known for their protective effects on primary and recurrent arterial 
thrombosis, has also been associated with a decreased VTE risk (35). In the Jupiter trial, 
healthy individuals with high C-reactive protein serum levels but normal cholesterol 
levels were randomized between 20mg rosuvastatin once daily or placebo (36). 
Remarkably, in this trial rosuvastatin was not only associated with a significant reduction 
of arterial thrombosis, but also significantly reduced the risk of a first symptomatic VTE 
by approximately 40% (36). Since then several observational studies have linked statin 
use to a reduced risk of both first and recurrent VTE (37). However, the mechanism 
behind this risk reduction is not clear since high cholesterol levels are not associated 
with an increased VTE risk (5,38). Furthermore, a meta-analysis of randomized clinical 
trials, comparing statin use to no use and with other end points than VTE, showed no 
significant association between statin use and reduced VTE risk (39). Several 
antithrombotic effects of statins have since then been shown in animal models and 
in-vitro studies, including enhanced fibrinolysis and antiplatelet effects (40). However, 
most of these studies were small, non-randomized studies, none of which performed 
in VTE patients, or specifically investigating risk factors for recurrent VTE, such as high 
FVIII levels. Therefore, more research is needed before statin therapy can be considered 
as candidate for VTE prevention.
A I M  A N D  O U T L I N E  O F  T H E  T H E S I S
The aim of this thesis is to investigate several issues related to monitoring and 
management of anticoagulant therapy. More insight into these factors, amongst others, 
the safety of POC INR monitoring in unselected patients, thromboplastin-mediated 
INR stability and different calculation methods for quality assessment of VKA treatment, 
may improve both the quality of anticoagulation control as well as experienced 
treatment quality in these patients and may therefore improve long-term clinical 
outcome. This thesis consists of three parts.
The first and second part of this thesis focus on the monitoring and management of 
therapy with vitamin K antagonists. Point-of-care (POC) devices can rapidly provide INR 
results and are less invasive compared to traditional laboratory INR measurement for 
which venipuncture is necessary to obtain a plasma sample.  Despite advantages for 
both patients and anticoagulation clinics, POC devices have almost exclusively been 
used by patients performing INR self-monitoring, which is only a minority (approximately 
15-20%) of patients treated with VKA in the Netherlands  (26). Quality of anticoagulation 
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control should be adequate during POC INR monitoring and clinical outcome at least 
comparable to laboratory INR monitoring, both in self-monitoring patients as well as 
in patients monitored with POC devices by anticoagulation clinics.  First, we assess the 
analytical and clinical agreement between INR results derived from a point-of-care 
device (CoaguChek XS using capillary blood) and a frequently used laboratory method 
in the Netherlands (Hepato Quick, using citrated plasma) in a large cohort of VKA users 
(Chapter 2). Agreement between measurement methods is pivotal, since significant 
INR discrepancies between methods can directly affect dosing decisions and therefore 
INR stability during VKA treatment. Therefore, we investigate the variability, defined 
as the coefficient of variation (CV in %) of the INR, in both self-monitoring and non-self-
monitoring patients during CoaguChek XS monitoring, who receive a constant dose of 
VKA (Chapter 3).  The average biological within-subject variation (CVb in %) of the INR 
can be used to derive imprecision goals for POC devices and to determine if this 
monitoring method is precise enough for patient monitoring in daily practice. The 
precision of a measurement method (CV%) should not exceed 50% of the biological 
within-subject variation of the analyte. Subsequently, we investigate the impact of 
introduction of point-of-care INR monitoring on quality of treatment in non-self-
monitoring patients (Chapter 4). In this study, both the quality of anticoagulation control 
as well as clinical outcome during point-of-care will be compared to outcomes during 
standard laboratory INR monitoring. Hereby we will assess both the safety and efficacy 
of POC monitoring by anticoagulation clinics compared to current standards. Then, we 
explore the sensitivity of different commercially used thromboplastins reagents to 
clotting factor VII (Chapter 5). This is studied since differences between thromboplastin 
reagents regarding sensitivity to FVII have been suggested as explanation for INR 
discrepancies between different measurement methods. Furthermore, INR stability 
during VKA treatment has also shown to be thromboplastin reagent dependent. Our 
hypothesis is that recombinant human thromboplastins are more sensitive to FVII than 
tissue-derived thromboplastins, which could affect stability of VKA treatment depending 
on the thromboplastin used for patient monitoring. Regarding management of patients 
during VKA treatment, we analyze the bleeding risk associated with the use of different 
low-molecular-weight heparin (LMWH) agents during combined treatment with VKA 
and LMWH, in a large cohort of patients with acute venous thrombosis (Chapter 6). 
Due to the high number of patients treated with LMWH worldwide, recognizing 
differences in bleeding risk associated with the use of different LMWH agents may 
reduce the number of bleedings in the future. In chapter 7 we compare two different 
methods (linear interpolation method and the cross-sectional proportion of INR results 
within the therapeutic range) for assessment of therapeutic quality control in patients 
on VKA using data from the Federation of Dutch Thrombosis Services. Monitoring the 
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quality of anticoagulation control in their patients is essential for clinics. Both methods 
have been used to report treatment quality but their level of agreement has not been 
extensively studied. Finally, we will try to identify predictors of bleeding and evaluate 
clinical outcome after dental procedures in patients on VKA (Chapter 8), because dental 
procedures are among the most common invasive procedures performed in these 
patients. Therefore, identification of risk factors and improving perioperative 
management may improve outcome in daily practice. Furthermore, insight in risk 
factors for adverse outcomes may also be extrapolated to other surgical procedures.
The third part of this thesis focuses on the potential use of statins for secondary 
prevention of venous thromboembolism (VTE) after discontinuation of anticoagulant 
therapy. The recurrence rate after stopping anticoagulant therapy after a first VTE is 
approximately 30% within 5 years (3) and is, amongst others, influenced by the nature 
of the index event (provoke/unprovoked), gender, and site of origin. Although statin 
use has been linked to a reduced risk of recurrent VTE in several observational studies, 
the mechanism behind this risk reduction is currently unclear and the quality of the 
currently available evidence low, based on the observational nature of these studies 
(36). Furthermore, the lack of a clear pathophysiological mechanism through which 
statins may decrease VTE risk has been an important reason for a lack of clinical trials 
in this area. First, a general introduction will be given describing current evidence for 
statin use for VTE prevention from a pathophysiological and epidemiological point of 
view (Chapter 9). Second, we investigate the impact of initiation of statin therapy during 
VKA treatment on VKA maintenance dose (Chapter 10). Alterations in VKA maintenance 
dose after initiation of statin therapy could suggest anticoagulant properties of statins 
or a significant drug-drug interaction. By comparing the effect of different statins on 
VKA maintenance dose, both immediately and after several months, more insight can 
be obtained whether statins exert anticoagulant effects. Finally, we study the effect of 
statin therapy on platelet reactivity (Chapter 11) and several different coagulation 
factors associated with recurrent VTE, in patients with a history of VTE  (Chapter 12), 
in order to unravel potential mechanism through which statins may reduce VTE risk. 
Finally, we will discuss the findings of this thesis, put them in a clinical perspective and 
reflect on the implications of these findings for future anticoagulant treatment and 
research (Chapter 13).
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A B S T R A C T
Introduction
Introducing point-of-care (POC) INR measurement to monitor anticoagulant therapy 
may be beneficial for both patients and anticoagulation clinics. However, agreement 
between POC and laboratory INR results is still unclear, especially at sub- and 
supratherapeutic levels. Therefore we investigated the analytical and clinical agreement 
between POC INR results of the CoaguChek XS and laboratory INR results of the STA-R 
Evolution. 
Materials and Methods
Paired POC and laboratory INR results were obtained and analyzed in 3257 patients 
aged 18-104 years between August 2008 and March 2014. 
Results
Mean difference between POC and laboratory results ranged from -0.18 (95%CI -0.20;-
0.16) INR point for POC results 2.0-3.0, up to 1.14 (95%CI 0.87;1.42) INR point for POC 
results 7.1-8.0. In the therapeutic range (POC INR 2.0-4.0), mean difference between 
POC and laboratory results was -0.13 (95%CI -0.15;-0.12) INR point. At subtherapeutic 
(POC INR <2.0) and supratherapeutic (POC INR >4.0) INR levels, mean differences were 
-0.13 (95%CI -0.15;-0.11) and 0.72 (95%CI 0.63;0.80) INR point, respectively. Clinical 
agreement regarding therapeutic range was present in 92.0% (POC within range), 67.7% 
(POC below range) and 87.6% (POC above range) of the paired measurements. We 
observed ≥15% INR difference between the POC and laboratory result in 14.8% (POC 
INR 2.0-4.0), 17.0% (POC INR<2.0) and 47.8% (POC INR >4.0) of the paired measurements.
Conclusions
POC and laboratory INR results were strongly correlated within the therapeutic range 
and differences between results become larger with increasing INR. Clinical 
disagreement between laboratory and POC results occurs often at both sub- and 
supratherapeutic INR levels.  
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I N T R O D U C T I O N
Anticoagulant therapy with vitamin K antagonists (VKA) is monitored by measuring the 
International Normalized Ratio (INR). The INR is a ratio between the prothrombin time 
measured in the patients’ blood sample and the mean normal prothrombin time, 
corrected for the sensitivity of the used thromboplastin reagent (1). The required VKA 
dose to achieve or maintain a therapeutic INR can vary considerably since INR levels 
fluctuate during treatment and are sensitive to numerous endogenous and exogenous 
factors (2). Regular INR measurement and dose adjustment of VKA is important for 
treatment quality since overanticoagulated patients have an increased risk of bleeding 
complications, while underanticoagulated patients have an increased risk of thrombotic 
events (3,4).
Traditionally, the INR is measured in a laboratory in a venous blood sample. However, 
point-of-care (POC) devices have become available that make it possible to measure 
the INR directly in a single drop of capillary blood. These devices do not require venous 
blood sampling, which can be problematic, especially in frail elderly patients. With POC 
INR measurement patients can self-monitor (dosed by the physician or anticoagulation 
clinic) and even self-manage (self-dosing) VKA treatment. Moreover, INR self-monitoring 
using POC devices is associated with increased patient satisfaction and quality of life 
compared to routine care by anticoagulation clinics, without increasing the risk of 
bleeding or thrombotic events (5). Although several papers have been published 
discussing the accuracy and reproducibility of these devices, it is difficult to extrapolate 
the results when other laboratory methods or POC devices are used (6). Furthermore, 
agreement between POC and laboratory INR results at sub- or supratherapeutic INR 
levels is not well established. As POC INR measurement may offer advantages for both 
patients and anticoagulation clinics, knowledge of systematic differences between POC 
and laboratory results is crucial. Moreover, differences between POC and laboratory 
results could affect treatment quality like time in therapeutic range since dose 
adjustment protocols are still based on laboratory INR results. Therefore, we 
investigated the level of analytical and clinical agreement between POC INR results 
measured on the CoaguChek XS system and laboratory INR results measured on the 
STA-R Evolution in a large population of over 3000 patients on long-term anticoagulant 
treatment.
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M A T E R I A L S  A N D  M E T H O D S
 
Study population
All patients aged ≥ 18 years were included in whom a paired POC and laboratory INR 
measurement had been performed between August 2008 and March 2014 at the 
anticoagulation clinic of the STAR-Medical Diagnostic Center (Rotterdam, the 
Netherlands). In case multiple paired measurements had been performed in a patient, 
only the first pair was included, since patient-bound factors influencing the agreement 
between POC and laboratory results could not be excluded. Trained nurses of the clinic 
had obtained simultaneous capillary and venous blood samples, for POC and laboratory 
INR measurement respectively, in two different ways. Firstly, Point-of-care INR 
measurement, immediately followed by venous blood sampling for laboratory INR 
measurement, was performed in all patients eligible for self-monitoring between 
August 2008 and July 2013. Secondly, since 29 May 2013, all non-self-monitoring 
patients of one of the divisions managed by the Star-medical diagnostic center were 
from then on monitored using only the CoaguChek XS system. An additional venous 
sample for laboratory INR measurement was taken directly in all patients in case a 
POC INR was ≥6.0. Finally, a venous sample was also obtained in patients with a POC 
INR <6.0, who had reported unstable INR results since the introduction of POC INR 
monitoring. The study protocol was in accordance with the Helsinki II declaration and 
approved by the Medical Board of the anticoagulation clinic of the Star-Medical 
Diagnostic Center. Due to the observational nature of our study, waiver of informed 
consent was acquired from the medical ethical commission of the Erasmus University 
medical center.
POC INR assessment
POC INR measurements were performed using the CoaguChek XS system (Roche 
Diagnostics, Mannheim, Germany). The CoaguChek XS system consists of the 
CoaguChek XS measuring system and the CoaguChek XS test strips and has a measuring 
range of 0.8-8.0 INR. The test strips contain a lyophilized reagent that consists of a 
human recombinant thromboplastin with an ISI of 1.01 and a peptide substrate. The 
test principle is based on the conversion of an electrochemical signal generated by 
thrombin-mediated cleavage of this peptide substrate. All different lots of test strips 
used during the study were approved for use and validated by the Dutch Reference 
Laboratory for Anticoagulant Control (RELAC) to exclude lot-to-lot variation (7). In 
compliance with the manufacturer’s instructions, one drop of capillary whole blood 
was applied to the test strip immediately after a finger stick procedure performed on 
the 3rd or 4th finger of the non-dominant hand. In terms of reproducibility, we found a 
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coefficient of variation (CV) of 2.9% in a validation study, which is consistent with CVs 
of 1.4-5.2% described in prior studies (6).
Laboratory INR assessment
For the laboratory INR measurement, approximately 2.7 ml blood was drawn by 
venipuncture into a BD Vacutainer® 0.109M (3.2%) Sodium Citrate blood collection 
tube. Blood samples were centrifuged at room temperature for 8 minutes at 2369xg. 
INR was determined using the STA Hepato Quick reagent on the STA-R Evolution 
automated coagulation system (Diagnostica Stago S.A.S, Asnières sur Seine, France), 
which uses a mechanical end-point detection method and can measure INR levels up 
to 12.5. The STA Hepato Quick reagent is a tissue-extract thromboplastin with an ISI 
of approximately 0.9 that uses an Owren-based method to determine the prothrombin 
time. ISI and mean normal prothrombin times were used according to the 
recommendations of RELAC after calibration for each lot number Hepato Quick that 
was used.
Assessment of clinical agreement 
We interpreted INR results according to the patients’ therapeutic range. In accordance 
with the guideline of the Dutch Federation of Anticoagulation Clinics, two target ranges 
are used in the Netherlands, which differ slightly from international guidelines (8). For 
each target range a somewhat wider acceptable therapeutic range is used. In the low 
intensity group, the target INR is 2.5–3.5 and the therapeutic range is between 2.0-3.5. 
In the high intensity group, the target INR is 3.0–4.0 and the therapeutic range is 
between 2.5-4.0. For patients with deviant target ranges, there is no difference between 
target and therapeutic range. We considered clinical agreement present if both the 
POC and laboratory result was either below, within or above the therapeutic range. 
Additionally, we determined paired measurements with a clinically relevant difference 
between the POC and laboratory result according to the definition by Poller et al.  (≥15% 
INR difference) (9).
Statistical analysis
Analytical agreement between POC and laboratory results was analyzed using linear 
regression analysis and Bland-Altman Plots (10). Since non-linearity can occur when 
comparing INR results of systems using different thromboplastin reagents, orthogonal 
regression analysis was used to fit the data according to Tomenson’s model using the 
Hepato Quick INR measurement as the reference system (11). Pearson’s correlation 
coefficient was determined to assess the correlation between POC and laboratory 
results. A paired T-test was used to determine the mean INR difference between POC 
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and laboratory results, both overall and also for different POC INR cut-off values. All 
statistical tests were two-tailed and P-values <0.05 were considered significant. Analyses 
were performed using SPSS version 21.0 (IBM Corp. Armonk, NY, USA).
R E S U L T S
Between August 2008 and March 2014, paired POC and laboratory INR measurements 
had been performed in 3257 patients aged 18-104 years. Of these measurements, 
2567 (78.8%) paired measurements were performed in self-monitoring candidates. 
The other 690 (22.2%) paired measurements were performed in patients who were 
monitored by the anticoagulation clinic using the CoaguChek XS system. Patient 
characteristics at moment of sampling are shown in table 1. In 326/3257 (10.0%) paired 
measurements, POC INR results >8.0 were found, which were analyzed separately, 
since they exceed the upper measurement level of the CoaguChek XS. Therefore, 2931 
paired POC and laboratory INR results were included for final analyses. 
Analytical agreement between POC and laboratory INR 
A Bland-Altman plot showing the agreement between POC and laboratory INR results 
is shown in figure 1. Overall, there was a significant and strong correlation between 
the CoaguChek XS and STA-R Evolution using Hepato Quick  (R=0.901, p<0.001). INR 
differences between POC and laboratory results are shown in table 2 and figure 2 
for different POC INR cut-off levels. In the therapeutic range (POC INR 2.0-4.0, n=2092) 
mean difference between the POC and laboratory result was -0.13 (95%CI -0.15 to 
-0.12) INR point. At subtherapeutic INR levels (POC INR <2.0), mean difference 
between results was -0.13 (95%CI -0.15 to -0.11) INR point. At supratherapeutic INR 
levels (POC INR >4,0), mean difference between POC and laboratory results was 0.72 
(95%CI 0.63 to 0.80) INR point. Calibration according to Tomenson, slightly improved 
the agreement between POC and laboratory INR results with a correlation coefficient 
of 0.903 between the adjusted POC and laboratory INR result and 95% limits of 
agreement of -1.34 to 1.03 
Clinical agreement between POC and laboratory INR
Clinical agreement between POC and laboratory INR results is shown in table 3 and 
the proportion of paired measurements with 15% or more difference between results 
is shown in figure 3 for different POC INR cut-off values. In the therapeutic range (POC 
INR 2.0-4.0, n=2092), we observed a difference of 15% or more between results in 
309/2092 (14.8%) paired measurements. Below the therapeutic range (POC INR <2.0, 
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n=320) 30/230 (17.0%) of the paired measurements had a difference of 15% or more 
between the POC and laboratory result. At supratherapeutic INR levels (POC >4.0, 
n=609), we found a difference of 15% or more in 291/609 (47.8%) paired measurements. 
Table 1. Patient characteristics (n=3257) 
Age, years 66.6  (18-104) * 
Sex 
Male, n (%) 1887 (57.9) 
Vitamin K antagonist
Acenocoumarol, n (%) 3037  (93.2) 
Phenprocoumon, n (%) 220 (6.8)
Treatment indication
Atrial fibrillation, n (%) 1779 (54.6)
Venous thrombosis, n (%) 538 (16.5)
Heart valve replacement, n(%) 312 (9.6) 
Other, n (%) 628 (19.3) 
Treatment duration, years 2.0  [0.3-6.9] † 
Therapeutic range, n (%)
2.0-3.5 2469  (75.8) 
2.5-4.0 701 (21.5) 
Other, n (%)  87 (2.7) 
Data are mean (range) * or median [interquartile-range] †.
Table 2. INR difference between POC and laboratory results by POC IN 
POC INR n Mean POC Mean lab Mean difference (95% CI)
1.0-1.9 230 1.70 1.82 -0.13 (-0.15 to -0.11) 
2.0-3.0 1345 2.55 2.72 -0.18 (-0.20 to -0.16) 
3.1-4.0 747 3.48 3.53 -0.06 (-0.08 to -0.03) 
4.1-5.0 193 4.41 4.29 0.12 (0.05 to 0.19)
5.1-6.0 86 5.70 5.06 0.64 (0.51 to 0.78)
6.1-7.0 188 6.47 5.43 1.05 (0.94 to 1.16)
7.1-8.0 142 7.66 6.52 1.14 (0.87 to 1.42) 
POC = Point-of-care. A negative mean difference indicates that POC results are lower than laboratory results, 
a positive difference indicate that POC results are higher than laboratory results.
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Figure 1. Bland-Altman plot of the difference between POC and laboratory results. Bland-Altman plot 
showing the difference in INR between POC and laboratory results against the average INR (n=2931). The dashed 
lines indicate the 95% limits of agreement (mean ± 1.96 SD) between test results.
Figure 2. Mean difference between POC and laboratory results stratified by POC INR. Error bars represent 
the 95% confidence interval of the difference in INR between POC and laboratory results (n=2931).
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INR results >8.0
Of the 326 POC measured INR’s >8.0, 83/326 (25.5%) of the laboratory results were 
also >8.0, 58/326 (17.8%) were between 7.1-8.0, 99/326 (30.4%) were between 6.1-7.0 
and 64/326 (19.6%) were between 5.1-6.0. In 22/326 (6.7%) the laboratory result was 
5.0 or lower. 
D I S C U S S I O N
The aim of our study was to investigate the analytical and clinical agreement between 
POC INR results of the CoaguChek XS and laboratory INR results in a broad INR range, 
in order to assess, in a real world setting, whether POC INR measurement can replace 
laboratory INR measurement of venous samples. We analyzed paired measurements 
in over 3000 patients and observed that the CoaguChek XS underestimated the INR 
below and within the therapeutic range (≤INR 4.0). In addition, above the therapeutic 
range (INR >4.0), the CoaguChek XS increasingly overestimated the INR with increasing 
INR levels compared to the STA-R Evolution using Hepato Quick.
Figure 3. Fraction of paired INR results with 15% difference in INR or more. Bars indicate the fraction of 
paired measurements with a clinically significant difference (≥ 15% or more) between POC and laboratory 
results.
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Only a few studies have compared CoaguChek XS INR results with results of the STA-R 
Evolution (12,13). Our results are in line with earlier observations by Christensen et al. 
who found lower average INR results in a small study of 141 measurements on the 
CoaguChek XS compared to the STA-R Evolution, most of which were within the 
therapeutic range (12). Interestingly, Hur et al. found higher average INR results on the 
CoaguChek XS compared to the STA-R Evolution in 118 paired measurements of which 
94% had a result of 3.0 or lower on the Coaguchek XS (13). This opposite finding 
compared to ours can be explained due to the difference in the thromboplastin reagent 
used for the INR measurement on the STA-R Evolution, since differences in sensitivity 
for circulating clotting factors have been described between recombinant and tissue-
extract thromboplastin reagents (14). Both in our study and in the study by Christensen 
et al. a tissue-extract thromboplastin (Hepato Quick and SPA 50 respectively) was used 
on the STA-R Evolution, whereas in the study by Hur et al. the recombinant STA-
Neoplastin was used. Furthermore, similar patterns in INR difference have been 
described when evaluating agreement between laboratory methods using recombinant 
versus tissue-extract thromboplastins (15,16). These findings, combined with our own, 
suggest that the agreement between methods can be estimated beforehand based 
on the sources of thromboplastin used in the investigated methods. Although venous 
whole blood was used for the CoaguChek measurement in Hur’s study, this is not likely 
to explain the different results, since it has been shown that the bias between capillary 
and venous INR results on the CoaguChek XS system is negligible in the therapeutic 
range (17). Other possible explanations for the discrepancy are differences between 
study populations and the limited number of measurements included in the analyses.
Although the mean INR difference between POC and laboratory results in our study 
was relatively small within or around the therapeutic range, even these small differences 
in clinically important INR ranges can significantly influence dosing decisions (18). This 
was illustrated by the fact that despite the small INR difference between both methods 
in the lower INR range, almost a third (32.3%) of the subtherapeutic POC results had 
a paired laboratory result within the therapeutic range, automatically resulting in a 
discrepancy in dosing-decision depending on which result is used to guide dosing. On 
the contrary, we observed increasing absolute INR differences at supratherapeutic 
levels and especially at POC INR levels ≥6.0 (n=369), i.e. a difference of 15% or more in 
over half (64.0%) of the paired samples. This was even more pronounced in the POC 
INR>8.0, of which only 25% of the paired laboratory INR results were also above 8.0. 
In this setting, dose reductions based on the POC INR result would often be excessive. 
However, it is important to emphasize that only plasma samples of patients with an 
INR between 1.5 and 4.5 may be used for INR calibration according to recommendations 
from the World Health Organization. Therefore the INR is only strictly valid up to an 
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INR of 4.5 regardless of which method is used. Since there is no absolutely true INR 
and it is not known which INR result is best to dose on, one could only speculate about 
the clinical consequences if patients would be routinely dosed on POC INR results. 
Besides, all data on the efficacy and safety of VKA and the determination of the target 
ranges are based on studies in which a laboratory INR was assessed and guided dosing. 
Future studies should determine the outcome of introduction of POC INR measurement 
in patients managed by physicians or anticoagulation clinics regarding the quality of 
treatment with VKA, since most trials on this subject have been performed in well-
functioning patients capable of self-monitoring (19). 
A drawback of our study is that we compared INR results using only one type of point-
of-care device and with only Hepato Quick as reagent on the STA-R Evolution. Therefore, 
the differences between POC and laboratory results found in our study have to be 
interpreted prudently, especially when comparing INR results using other point-of-care 
devices or when a recombinant thromboplastin reagent, such as Innovin, is used to 
determine the laboratory INR result. In general, clinicians should be aware of potential 
INR differences when comparing systems using different thromboplastin sources, 
especially at supratherapeutic INR levels.  Another limitation is the relatively small 
number of measurements in the higher INR range. However, although the number of 
supratherapeutic results was indeed relatively small compared to the number of results 
within the therapeutic range, 95% confidence intervals were robust, indicating adequate 
precision.
In conclusion, we found increasing INR differences between POC INR results of the 
CoaguChek XS compared to INR results of the STA-R Evolution using Hepato Quick with 
increasing INR levels in patients treated with vitamin K antagonists. Although absolute 
INR differences were small at (sub) therapeutic INR levels, dosing decisions would often 
be different, both at sub- and supra therapeutic INR levels. 
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S U M M A R Y
Many patients treated with vitamin K antagonists (VKA) determine their INR using 
point-of-care (POC) whole blood coagulation monitors. The primary aim of the present 
study was to assess the INR within-subject variation in self-testing patients receiving a 
constant dose of VKA. The second aim of the study was to derive INR imprecision goals 
for whole blood coagulation monitors. Analytical performance goals for INR 
measurement can be derived from the average biological within-subject variation. 
Fifty-six Thrombosis Centres in the Netherlands were invited to select self-testing 
patients who were receiving a constant dose of either acenocoumarol or 
phenprocoumon for at least six consecutive INR measurements. In each patient, the 
coefficient of variation (CV) of INRs was calculated. One Thrombosis Centre selected 
regular patients being monitored with a POC device by professional staff. Sixteen Dutch 
Thrombosis Centres provided results for 322 selected patients, all using the CoaguChek 
XS. The median within-subject CV in patients receiving acenocoumarol (10.2 %) was 
significantly higher than the median CV in patients receiving phenprocoumon (8.6 %) 
(P=0.001). The median CV in low-target intensity acenocoumarol self-testing patients 
(10.4 %) was similar to the median CV in regular patients monitored by professional 
staff (10.2 %). Desirable INR analytical imprecision goals for POC monitoring with 
CoaguChek XS in patients receiving either low-target intensity acenocoumarol or 
phenprocoumon were 5.1 % and 4.3 %, respectively. The approximate average value 
for the imprecision of the CoaguChek XS, i. e. 4 %, is in agreement with these goals.
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I N T R O D U C T I O N
In the Netherlands, patients receiving long-term treatment with vitamin K-antagonists 
(VKA) are managed and controlled by Thrombosis Centres (1). Increasing numbers of 
patients are trained to determine their INR by themselves using a point-of-care whole-
blood coagulation monitor. By the end of the year 2013, approximately 13% of all 
patients in the Netherlands were using whole blood coagulation monitors for INR 
self-testing at home (2). Also in other European countries and the United States large 
numbers of patients perform INR self-measurement (3,4). The quality of self-testing 
depends partly on the analytical performance of the whole blood monitor. By increasing 
the quality of INR measurements, the quality of treatment can potentially be further 
increased (5).
It is widely accepted that analytical performance goals of a laboratory method should 
be based on biological variation of the analyte. Fraser et al introduced the concept of 
minimum, desirable and optimum quality goals for imprecision and inaccuracy of 
laboratory methods and point-of-care testing (6,7). In previous studies, the biological 
within-subject variation of the INR was assessed using conventional laboratory 
determinations of the prothrombin time in plasma samples from patients who were 
stabilized on long-term treatment with VKA (8-11). It is well known that there are INR 
differences between assay systems. The reasons for discrepancies between INR results 
determined by point-of-care instruments and laboratory measurements are not fully 
understood (12). It is not known whether within-subject variation of INR determined 
by conventional laboratory methods is different from the within-subject variation of 
INR determined by point-of-care whole blood monitors.
The aim of the present study was to assess the INR within-subject variation in patients 
taking a constant dose of either acenocoumarol or phenprocoumon and who used a 
point-of-care whole blood coagulation monitor for INR self-testing. All self-testing 
patients used the same type of whole blood coagulation monitor, i.e. the CoaguChek 
XS (Roche Diagnostics, Mannheim, Germany). The second aim of the study was to derive 
the desirable imprecision goal for the whole blood coagulation monitor.
M A T E R I A L S  A N D  M E T H O D S
All members of the Netherlands Federation of Thrombosis Centres were invited to 
participate in the study. At the time of the study there were 56 member centres. 
Recruitment of participants and collection of data started in February 2014 and was 
concluded in August 2014. Each centre was requested to select at least 24 patients from 
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the centre’s total patient population according to criteria described below. Centres were 
instructed to review the patients’ files in alphabetical order of their surnames. The 
selected patients data were provided anonymously to the authors for statistical analysis. 
Hence the data could not be traced back to the patients’ identification and informed 
consent was not required. Patients received either acenocoumarol or phenprocoumon. 
Depending on the indication for treatment, one of two different therapeutic target 
ranges were applied, i.e. either INR 2.0-3.5 (low intensity) or INR 2.5-4.0 (high intensity). 
The target range in the Netherlands is set higher than the internationally advised target 
range to prevent inadequate anticoagulation, i.e. INR < 2.0 (13).
The following criteria were used for patient selection: 
 - VKA treatment period was 6 months or longer;
 - Self-testing by the patient with a home whole blood INR monitor using capillary blood 
samples;
 - After the initial treatment period of 6 months or longer, a period of constant dose 
of VKA was achieved during which at least six consecutive INRs were recorded;
 - The interval between consecutive INR determinations was two weeks or longer;
 - In the period of constant dose of VKA and at least six consecutive INR determinations, 
there were no changes in conditions that may influence the INR such as intercurrent 
diseases, invasive procedures, or starting/stopping other drugs interacting with VKA.
Four groups of selected patients were formed from all centres:
 - Patients receiving acenocoumarol, low target intensity;
 - Patients receiving acenocoumarol, high target intensity;
 - Patients receiving phenprocoumon, low target intensity;
 - Patients receiving phenprocoumon, high target intensity.
Each centre was requested to select at least six patients for each group. For a 
comparison between self-testing patients and patients regularly pricked by professional 
staff, one centre selected an additional group of 123 patients receiving acenocoumarol 
with low target intensity who were pricked and monitored with the CoaguChek XS Pro 
by professional staff. The latter group of patients is denoted as “regular” patients. The 
regular patients, apart from being pricked and tested by professionals, were selected 
with the same criteria as those for the self-testing patients. The CoaguChek XS Pro 
instrument has been developed by Roche Diagnostics (Mannheim, Germany) using the 
same measurement principle as the CoaguChek XS (14).
For each patient, we calculated the coefficient of variation (CV) of the INRs of the 
constant dose period. CVT represents the median CV for a group of patients with the 
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same drug and target intensity. For calculation of the average biological within-subject 
variation (CVB), we used the formula given by Lassen et al (8):
 
CVB = √(CVT
2 – CVA
2)
CVA is the mean analytical imprecision coefficient of variation of the capillary blood INR 
determination using the CoaguChek XS. We used CVA = 4% which is an average value 
derived from previous reports (15-18). 
The Kolmogorov-Smirnov test was used to test the null hypothesis that the CV data 
came from a normally distributed population. Pearson’s correlation and Spearman’s 
rank correlation were used to analyse the correlation between patient age and CV. 
Differences in CV between the above mentioned patient groups were analysed using 
Student’s t-test and the Mann-Whitney test. P values of less than 0.05 were considered 
statistically significant. All statistical analyses were performed with SPSS 20 (IBM 
Corporation, Armonk, NY, USA) for Windows.
Time in therapeutic range was calculated using an approach in which the INR of an 
individual patient is gradually increasing or decreasing between two successive 
measurements (19). Person-time was allocated to the therapeutic range using linear 
interpolation between two successive INR measurements and summed over all 
patients.
R E S U L T S
Sixteen out of fifty-six Thrombosis Centres in the Netherlands responded and 
participated in the study. Each participating centre was requested to select patients 
according to the above-mentioned criteria. All selected patients used the CoaguChek 
XS for self-testing. The number of selected patients in each of the four groups varied 
from centre to centre.  The total number of the patients in each group is given in Table 
1. The numbers of patients in the low target intensity groups were greater than those 
in the high target intensity groups, because some Thrombosis Centres could hardly 
find patients with high intensity treatment. There was a wide range of patients’ ages 
and treatment times prior to the period of constant dose. There was also a wide range 
in observation periods varying between 70 and 638 days. The midterm calendar month 
was determined for each patient. The major part of the selected self-testing patients 
(58.4 %) were observed mainly in the winter season (i.e., midterm calendar months 
December, January or February). Only 9.6% of the selected patients were observed 
mainly in the summer (i.e., midterm calendar months June, July or August).
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According to the selection criteria, the minimum number of INR’s for each patient 
was 6 but some Thrombosis Centres found patients with more than 6 INR’s in the 
period of constant dose (Table 2). For each patient, the mean INR in the period of 
constant dose was calculated. As expected, the mean INR’s for patients in the high 
target intensity groups were higher than those in the low intensity groups (Table 2). 
The differences in mean INR’s between low-target and high-target groups were 
statistically significant for both acenocoumarol (t-test, P < 0.001) and phenprocoumon 
(t-test, P < 0.001).  For each patient, the CV of INR’s in the period of constant dose 
was calculated. Histograms of CV’s are shown in Figure 1. The null hypothesis of a 
normal distribution was not rejected (P=0.091 for high target phenprocoumon, 
P=0.200 for other patient groups). For each of the two VKA drugs, there was no 
significant difference in the mean CV’s between low and high intensity treatment 
(t-test: P=0.650 for acenocoumarol; P=0.155 for phenprocoumon). For this reason 
the results of low and high target intensities were combined. The median CV was 
greater for patients receiving acenocoumarol (CVT = 11.0%) than the median CV for 
patients receiving phenprocoumon (CVT = 9.5%) (Table 2). The CV’s were compared 
and the differences between the acenocoumarol (n = 165) and phenprocoumon 
(n=157) groups were significant (t-test: P=0.001; Mann-Whitney test: P=0.002). The 
median within-subject CVB for patients receiving acenocoumarol and for patients 
receiving phenprocoumon was 10.2% and 8.6%, respectively. There was no correlation 
between the mean testing interval and the within-subject CV, either for acenocoumarol 
(n=165, Spearman’s rho=0.047, P=0.550) or for phenprocoumon (n=157, Spearman’s 
rho = 0.125, P=0.120). 
Table 1. Basic characteristics of selected patients
Drug INR 
Target
Self-
testing
N Male 
(%)
Age (years) Treatment time 
prior to entry 
(months)
Mean Range Mean Range
Acenocoumarol low yes 93 75.3 65.7 22-85 74.9 11-291
Acenocoumarol high yes 72 66.7 63.3 29-84 105.2 12-291
Phenprocoumon low yes 94 60.6 62.1 35-83 79.9 6-332
Phenprocoumon high yes 63 66.7 62.4 28-85 141.5 24-386
Acenocoumarol low no* 123 56.9 72.1 35-95 82.7 7-292
  
* All patients in this group were selected by a single centre.  N = number of patients.
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Figure 1. Histogram of patients’ INR coefficient of variation. Panels A, B, C, and D refer to self-testing patients 
receiving acenocoumarol (low target intensity), acenocoumarol (high target intensity), phenprocoumon (low 
target intensity) and phenprocoumon (high target intensity), respectively. Panel E refers to patients receiving 
acenocoumarol (low target intensity) being pricked and monitored by professional staff.
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There was a significant correlation between age and CV for patients receiving 
acenocoumarol (n=165, Spearman’s rho = -0.202, P=0.009). The CV tended to lower 
values with increasing age (Figure 2). There was neither a significant correlation 
between age and CV for patients receiving phenprocoumon (n=157, Spearman’s rho 
= -0.075, P=0.353), nor for regular patients receiving low-intensity acenocoumarol 
(n=123, Spearman’s rho = -0.093, P=0.304).
We compared the group of self-testing patients receiving low-target acenocoumarol 
to a group of regular low-target acenocoumarol patients who were pricked and tested 
by professionals using the CoaguChek XS Pro. It should be noted that self-testing 
patients were instructed to perform the test and report the results every two weeks. 
The regular patients were less frequently pricked and tested by professionals. The 
frequency difference between self-testing and regular patients is reflected by the 
longer time interval between tests for the regular patients (Table 2). The mean CV of 
the self-testing patients was not statistically different from the mean CV of the regular 
patients pricked and tested by the professionals (t-test: P=0.409; Mann-Whitney test: 
P=0.690).
Figure 2. Scatter plot of total variation of INR in self-testing patients receiving acenocoumarol as a 
function of age (n=165, Spearman’s rho = -0.202, P=0.009). The data of low target and high target intensity 
patients are shown, as well as a linear regression line. 
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D I S C U S S I O N
The aim of the present study was to determine the overall within-subject variation of 
the INR in a sample of self-testing patients receiving a constant dose of VKA. The 
selection of the patients was entrusted with the Netherlands Thrombosis Centres. 
Apart from the selection criteria mentioned in the Materials and Methods, no 
restrictions were made with regard to indications for anticoagulation, comedication of 
antiplatelet agents, gender, time of year, and ethnicity. Although information about 
indications for anticoagulation was not provided, it is likely that all major indications 
were represented. Self-testing is primarily performed by patients who are receiving 
VKA for an indefinite length of time or lifelong. The relatively high percentage of male 
patients in our study (Table 1) might be explained by the fact that a greater proportion 
of male patients is associated with atrial fibrillation and artificial heart valves (2,3). 
The majority of the selected patients were observed mainly in the winter season. When 
the Thrombosis Centres received the invitation to participate they probably were 
inclined to select patients observed in the most recent months, i.e., February, January, 
and December. Previous studies have shown that there were significant seasonal 
variations in the mean INR measurements, with the lowest values in summer and the 
highest values in autumn (20). Seasonal effects might have contributed to the within-
Table 2. Variation of INR in selected patients
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Mean Range Mean Range Mean Range
Acenocoumarol low yes 6.6 6-12 18.2 14-39 2.88 2.4-3.7 97.3 11.1 10.4
Acenocoumarol high yes 6.4 6-13 18.1 14-34 3.39 3.0-3.8 97.9 11.0 10.2
Phenprocoumon low yes 7.0 6-22 19.0 14-33 2.84 2.2-3.3 98.9 9.7 8.8
Phenprocoumon high yes 6.5 6-13 18.9 14-31 3.37 2.8-3.8 97.5 9.1 8.1
Acenocoumarol low no* 6.7 6-10 30.9 15-42 2.91 2.6-3.4 99.6 11.0 10.2
* All patients in this group were selected by a single centre.  CVT is de median of total variation. 
CVB is   the average biological within-subject variation. TTR is the mean time in therapeutic range.
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subject variation CV observed in the present study, but the study was not designed to 
assess the contribution of seasonal effects. 
In the present study, we observed a wide range of within-subject CV’s of INR’s among 
patients receiving a constant dose of either acenocoumarol or phenprocoumon. The 
wide ranges are similar to those observed in stable patients monitored with a 
conventional laboratory prothrombin time system (9). Within-subject variation of the 
INR in patients receiving a constant dose of VKA is partially due to variation of vitamin 
K in the diet (21). It is not known whether the observed differences in CV between 
individual patients are systematic or time dependent. The Netherlands Thrombosis 
Centres use common guidelines for dosing and monitoring of their patients. For this 
reason it was justified to combine the patient data from various centres for analysis.
The patients included in the present study were all treated for six months or longer 
before their INRs were analysed. We did not observe a correlation between within-
subject CV and the treatment time prior to the study observation period. In a systematic 
review and meta-analysis of self-monitoring, the time in therapeutic range improved 
and standard deviations decreased over time (22). The main part of improvements 
was observed in the first six months of intervention (22).
The total variation of the INR in patients on acenocoumarol was slightly, but significantly, 
greater than in patients receiving phenprocoumon (Table 2). This finding is in agreement 
with previous results in patients monitored with conventional laboratory prothrombin 
time systems (10,11,23). Greater within-subject variation of the INR in patients receiving 
acenocoumarol could be explained by the shorter half-life of acenocoumarol (i.e. 
compared to that of phenprocoumon) leading to greater variation of the drug 
concentration and of residual factor VII activity (24,25). It is interesting to note that the 
average within-subject variation in self-testing patients receiving acenocoumarol (CVT 
= 10.2 – 10.4%, table 2) is similar or slightly lower than the average variation in steady-
state patients receiving the same VKA monitored by a conventional laboratory method 
(CVT = 10.5 – 10.9%) (9).
We observed a significant correlation between age and the total variation of the INR 
for self-testing patients receiving acenocoumarol (Figure 2). Age was not a selection 
criterium in our study and a wide range of ages between 22 and 85 years was obtained 
(Table 1). In contrast, we did not find a significant correlation in self-testing patients 
receiving phenprocoumon nor in regular patients receiving acenocoumarol with low-
target intensity. We can only speculate why age might have an influence on the CV of 
the INR in self-testing patients receiving acenocoumarol. Better adherence to 
acenocoumarol treatment regimens among older patients might have been a factor. 
Other studies have shown that independent predictors of stable INR were age>70 
years, male gender and the absence of heart failure (26).
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Little is known about the imprecision of INR determined by patients using a home 
whole blood coagulation monitor. Estimating the precision of a whole blood 
coagulometer presents problems, as it is not possible to perform ordinary within-run 
or between-run estimations (5). In one report on the imprecision of the CoaguChek XS, 
it was stated that the CV was 5.92% at the start of determinations by patients and 5.16% 
at the final session (15). In subsequent reports, the values for imprecision of capillary 
blood INR by the CoaguChek XS were lower: 3.9-4.0% (16), 2.24% (17), 3.2% (18).  The 
magnitude of the contribution by preanalytical errors to the total variation is uncertain. 
It is not known whether preanalytical errors are more prominent in self-testing patients 
as compared to professional staff. However, we did not observe a significant difference 
in CVT between self-testing patients and patients pricked by professional staff (Table 
2). This observation suggests that the imprecision, including preanalytical errors, is 
similar in both groups of patients. Self-testing patients may have achieved similar 
technical skills as professional staff.
Another factor which may contribute to the total within-subject variation is the between-
lot variation of test strips. Minor differences between strip lots have been observed 
(27). We did not control the switching from one lot of strip lot to another in the present 
study. It cannot be excluded that patients changed test strip lots during the period of 
constant dose of anticoagulant.
In conclusion, our results have important consequences for the analytical performance 
goals of the INR determination by means of whole blood point-of-care coagulation 
monitors like the CoaguChek XS. For patients receiving acenocoumarol, the desirable 
imprecision goal according to Fraser et al (3,4) is 0.50×CVB = 5.1%. Likewise, the desirable 
imprecision goal for patients receiving phenprocoumon is 4.3%. The approximate 
average value for the imprecision of the CoaguChek XS reported in the literature, i.e. 
4%, is in agreement with these goals.
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A B S T R A C T
Background
Point-of-care (POC) international normalized ratio (INR) monitoring by healthcare 
professionals could eliminate the need for venous blood sampling in non-self-
monitoring (NSM) patients on vitamin K antagonists (VKA). However, few studies have 
investigated the impact of POC INR monitoring on the quality of treatment in these 
patients and real-world data on this issue are lacking.
Objectives
To investigate the safety, efficacy and quality of anticoagulant control during POC INR 
monitoring as compared with laboratory INR monitoring in NSM patients.
Methods
We performed a retrospective cohort study using data from the anticoagulation clinic 
of the Star-Medical Diagnostic Center (Rotterdam, the Netherlands). Patients who 
received treatment with VKA between 29 May 2012 and 29 May 2014 were eligible. 
Percentage of time in therapeutic range (TTR) and incidence rates of major clinical 
events (all-cause mortality, hospitalization, major bleeding and ischemic stroke) were 
compared for the year before and year after introduction of POC monitoring. Cox 
proportional hazard models were used to estimate hazard ratios and 95% confidence 
intervals for major clinical events between exposure groups.
Results
In total, 1973 patients during the 1-year laboratory-monitoring observation period and 
1959 patients during the 1-year POC-monitoring observation period were included. 
Median TTR was significantly lower during POC monitoring (77.9%; 95% CI, 67.2-87.4) 
than during laboratory INR monitoring (81.0%; 95% CI, 71.1-90.5). Adjusted hazard 
ratios for major clinical events were all around unity.
Conclusions
Although associated with lower TTR, POC INR monitoring is a safe and effective 
alternative to laboratory INR monitoring in NSM patients on VKA
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I N T R O D U C T I O N
The goal of anticoagulant therapy with vitamin K antagonists (VKA) is to reduce the risk 
of thrombotic events while keeping the treatment-related risk of bleeding complications 
as low as possible. To achieve this goal, the International Normalized Ratio (INR) must 
be maintained within a narrow therapeutic range, which requires INR monitoring and 
dose adjustment of VKA (1). During VKA treatment, the most commonly used indicator 
for quality of anticoagulation control is the percentage of time in therapeutic range 
(TTR): a low TTR is associated with an increased risk of major bleeding, ischemic stroke, 
and mortality (2-4). In 2013, more than 450,000 patients were treated with VKA in the 
Netherlands, of whom 87% were monitored by professionals at anticoagulation clinics 
and 13% performed INR self-monitoring using point-of-care (POC) devices (5). An 
advantage of using a POC device is the instantaneous measurement of the INR in just 
a single drop of capillary blood. Furthermore, POC devices enable patients to participate 
more actively in their VKA treatment, either through self-monitoring (measurement by 
the patient and dosing by a physician) or even through self-management (self-
measurement and self-dosing) (6). The INR of most of the non-self-monitoring (NSM) 
patients is measured in a laboratory after venous blood sampling, which is more 
invasive, more painful and sometimes problematic, especially in the elderly (7). 
Although POC devices were originally developed for self-monitoring, POC INR 
measurement by trained professionals could eliminate the need for venous blood 
sampling in these NSM patients. However, since most trials regarding POC monitoring 
have been performed in relatively young and well-functioning patients, capable and 
willing to perform INR self-monitoring, it is essential to know whether in NSM patients 
POC monitoring is equally effective and safe as laboratory INR monitoring and whether 
the quality of anticoagulant control is as good before POC INR measurement can be 
implemented on a large scale (7).  To this day, two randomized controlled trials have 
evaluated POC INR monitoring by professionals in NSM patients and real-world data 
to confirm its efficacy and safety in these patients is lacking, which may contribute to 
the relatively limited implementation of POC INR testing in clinical practice (7-9). 
Furthermore, in both these trials patients were on warfarin and the impact of POC 
monitoring by professionals in NSM patients on acenocoumarol or phenprocoumon 
has not been investigated yet. Therefore, we investigated the efficacy, safety, and the 
quality of anticoagulant control during POC INR monitoring by trained professionals, 
as compared with routine laboratory monitoring, in NSM patients of a specialized 
anticoagulation clinic. 
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M A T E R I A L  A N D  M E T H O D S
Study population 
POC INR measurement by trained staff of the anticoagulation clinic fully replaced 
laboratory INR measurement on 29 may 2013 for all NSM patients in the suburbs 
Capelle aan den IJssel and Krimpen aan den IJssel (Rotterdam, The Netherlands). The 
study population consisted of two independent cohorts who were each followed up 
for 1 year. All adult NSM patients were included who received low (therapeutic INR 
range 2.0-3.5) or high intensity (therapeutic INR range 2.5-4.0) treatment with VKA in 
these suburbs at 29 May 2012 (laboratory cohort) and at 29 May 2013 (POC cohort). 
These therapeutic ranges are slightly wider than the internationally advised target 
ranges (2.0-3.0 and 2.5-3.5 respectively), since the target INR is set higher in the 
Netherlands (2.5-3.5 and 3.0-4.0) to prevent inadequate anticoagulation (10). Patients 
were excluded for analysis if they performed self-monitoring during the study period, 
had less than two valid INR measurements during the 1-year observation period or 
changed to a deviant therapeutic range during follow-up.  
Data collection
We retrieved data from patient records of the Star-Medical Diagnostic Center 
(Rotterdam, The Netherlands). During each patient visit, nurses of the anticoagulation 
clinic obtained information regarding complications and changes in medication since 
the previous visit. INR results, changes in VKA dose, and information obtained during 
patient visits were registered in the clinics’ electronic medical database. In case an 
appointment for scheduled INR measurement was missed, the clinic contacted the 
patient, and in case of no contact after several attempts, information regarding current 
health status was obtained from the patients’ general practitioner. Major clinical events 
(major bleeding, ischemic stroke, hospitalization or death) were either registered during 
patient visits or reported directly or in retrospect to the clinic by the treating physician. 
All major adverse events occurring during the course of this study were collected from 
the medical database six months after follow-up of the POC monitoring cohort ended 
to minimise the risk of missing any late reported major clinical events. Outcome and 
severity of all adverse events were registered by specialised physicians of the clinic 
who were not involved in the study as part of usual medical care. The medical board 
of the Star-Medical Diagnostic Center approved the use of coded patient data and the 
study was conducted in accordance with the Helsinki Declaration. The ethics committee 
of the Erasmus University Medical Center granted a waiver for informed consent due 
to the observational nature of the study. 
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Exposure and follow-up
The aim of the study was to compare the safety and quality of anticoagulant control 
during laboratory and POC INR monitoring in NSM patients. To compare both methods, 
we included patients who were monitored by the anticoagulation clinic at the start of 
the laboratory (May 29th 2012) and/or POC (May 29th 2013) observation period. All 
patients were followed until they ended treatment with VKA, died, or reached the end 
of the observation period (28 May of the subsequent year). In the analyses regarding 
clinical outcomes, follow-up ended also when a major clinical event occurred as defined 
in the section “Outcomes”. During both observation periods, monitoring frequency 
and VKA dosage were based on the patients’ INR results, and adjusted if necessary 
according to the same acenocoumarol and phenprocoumon dosing schedules, which 
are based on the guidelines of the federation of Dutch Thrombosis Services (10). 
INR measurement
For the laboratory INR measurements, 2.7 ml blood was drawn, after venipuncture of 
the antecubital vein, in to a Becton Dickinson Vacutainer® collection tube (Becton 
Dickinson, Plymouth, England) containing 0.109M (3.2%) Sodium Citrate. After 
centrifugation of the venous blood sample for 8 minutes at 2369xg at room temperature, 
plasma INR was determined on the STA-R Evolution automated coagulation system 
(Diagnostica Stago S.A.S, Asnières sur Seine, France) using the STA Hepato Quick 
reagent (Roche Diagnostics, Mannheim, Germany). POC INR measurements were 
performed by trained staff of the anticoagulation clinic using the CoaguChek XS Pro 
system (Roche Diagnostics, Mannheim, Germany). After a finger stick procedure, the 
first drop of capillary blood was applied to the CoaguChek XS test strip. All different 
lots of CoaguChek XS test strips and Hepato Quick reagents used during the course of 
this study were validated and approved for use by the Dutch Reference Laboratory for 
Anticoagulant Control (RELAC). 
Outcomes
To compare the quality of anticoagulant control, we calculated the percentage of time 
in therapeutic range (TTR) for each patient during the POC and laboratory INR 
monitoring period. The TTR was calculated using the Rosendaal method (11). If 
consecutive INR measurements were more than 56 days apart, the monitoring period 
was censored and not included in the TTR analyses (12). In addition, we made three 
categories to describe the anticoagulant control of both exposures further: good (TTR 
>75.0%) moderate (TTR 60-75%) or poor (TTR<60.0%) (2). 
To determine the safety of POC INR monitoring, we computed incidence rates of major 
bleeding, ischemic stroke, hospitalization, and all-cause mortality during laboratory 
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and POC INR monitoring. Major bleeding was defined as any fatal, or intra-articular or 
intracranial hemorrhage, or a bleeding that required hospitalization or blood 
transfusion. 
Secondary outcomes were INR testing frequency, percentage of INR results within 
therapeutic range, and percentage of INR results followed by a significant dose 
adjustment, defined as any dose adjustment of 10% or more. 
Statistical analysis
We used descriptive statistics to summarize baseline characteristics of both exposure 
groups. The laboratory and POC monitored exposure groups were considered 
independent samples. We compared TTRs between groups by means of a t-test (in 
case of a normal distribution) or by Mann-Whitney U test (in case of a skewed 
distribution). For clinical events, incidence rates and 95% confidence intervals were 
calculated based on the Poisson distribution. Also, Kaplan-Meier curves were 
constructed for each exposure group to compare the cumulative incidence of major 
clinical events and hazard ratios and 95% confidence intervals were estimated by 
means of a Cox proportional hazard model. 
Sensitivity analysis
We performed three sensitivity analyses to verify the validity of our findings. Firstly, a 
sensitivity analysis was performed on patients who were treated with VKA for at least 
6 months at baseline of laboratory and/or POC monitoring, because TTR in the inception 
period (first 6 months of treatment with VKA) is significantly lower (13). Secondly, we 
stratified by treatment intensity, as TTR in the low intensity treatment group is higher 
than in the high intensity treatment group during laboratory monitoring (5). Finally, we 
stratified by the type of VKA the patients were treated with (acenocoumol or 
phenprocoumon) because higher TTR levels are reported in patients on phenprocoumon 
than in patients on acenocoumarol, which may also depend on which method is used 
for INR monitoring (5).  All analyses mentioned above were performed using SPSS 
version 21.0 (IBM Corp. Armonk, NY, USA).
R E S U L T S
We included 1973 out of 2006 (98.4%) patients who were registered at baseline of 
laboratory monitoring and 1959 out of 1999 (98.0%) patients who were registered at 
baseline of POC monitoring for analysis (see figure 1). Table 1 shows the patient 
characteristics at baseline of laboratory and POC INR monitoring.  Patients were older 
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during POC monitoring than during laboratory monitoring (76.2 vs. 75.3, P=0.02). All 
other characteristics (sex, INR target range, VKA indication, type of VKA) were similar 
between exposure groups.
TTR analyses
 38,813 INR measurements were performed in 1973 patients during the laboratory-
monitoring period, of which 63 INR measurements were excluded from TTR analyses 
because the maximum interval of 56 days between consecutive measurements was 
exceeded. During POC monitoring, 41,152 INR measurements were performed in 1959 
patients, of which 76 measurements were excluded for TTR analysis for the same 
reason. TTR levels during laboratory and POC monitoring are shown in table 2. 
The median number of evaluated days per patient was 336 (IQ range 307-350) during 
both exposure periods. Overall, median TTR was lower during POC monitoring (77.9% 
[95% CI 67.2-87.4]) than during laboratory INR monitoring  (81.0%, [95% CI 71.1-90.5]; 
P<0.001). The proportion of patients achieving a poor TTR (TTR<60.0%) was higher 
during POC monitoring than during laboratory monitoring, which is shown in table 3.
Clinical events
Incidence rates and hazard ratios of major clinical events during POC and laboratory 
INR monitoring are shown in table 4. Kaplan-Meier curves for all clinical events were 
Figure 1.  Study flow chart
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similar for POC and laboratory monitoring (figure 2, all log-rank P values >0.5). The 
incidence rate for major bleeding was 17.0 per 1000 patient years (95% CI 11.9-24.3) 
during POC monitoring and 18.2 per 1000 patient years  (95% CI 12.9-25.6) during 
laboratory monitoring. Incidence rates for ischemic stroke were 6.8 per 1000 patient 
years (95% CI 3.9-11.9) during POC monitoring and 7.4 per 1000 patient years (95% CI 
4.3-12.6) during laboratory monitoring. Adjusted hazard ratios of POC monitoring as 
compared with laboratory monitoring were 0.93 (95% CI 0.56-1.52) for major bleeding, 
0.92 (95% CI 0.42-2.02) for ischemic stroke, 0.94 (95% CI 0.79-1.12) for hospitalization 
and 1.00 (95% CI 0.78-1.29) for all-cause mortality.
Secondary outcomes
Percentage of INR results within therapeutic range was lower during POC monitoring 
than during laboratory monitoring (66.8% vs. 70.1%, P<0.001). INR testing frequency 
(21.0 vs. 19.7 per patient per year, P<0.001) and percentage of INR followed by a 
significant adjustment in VKA dose (3.8% vs. 3.3%, P<0.001) were higher during POC 
monitoring than during laboratory monitoring. 
Table 1. Patient characteristics
Laboratory monitoring Point-of-care monitoring
(n=1973) (n=1959)
Mean age (SD), years 75.3 (11.9) 76.2 (11.3)
Male, n (%) 1029 (52.2) 1006 (51.4)
Treatment duration, n (%)
< 6 months 241 (12.2) 242 (12.4)
≥ 6 months 1732 (87.8) 1717 (87.6)
Therapeutic range, n (%)
2.0-3.5 1639 (83.1) 13 (85.1)
2.5-4.0 334 (16.9) 292 (14.9)
Treatment indication, n (%)
Atrial fibrillation 1272 (64.5) 1308 (66.8)
Valve prosthesis 113 (5.7) 105 (5.4)
VTE 238 (12.0) 224 (11.4)
Other 350 (17.8) 322 (16.4)
Type of VKA, n (%)
Acenocoumarol 1852 (93.9) 1852 (94.5)
Phenprocoumon 121 (6.1) 107 (5.5)
SD=Standard Deviation, VTE=Venous thromboembolism, VKA=Vitamin K antagonist 
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Sensitivity analyses
Sensitivity analyses showed that TTR was lower during POC monitoring as compared 
with laboratory monitoring, except in phenprocoumon users (see table 2). Also, the 
proportion of phenprocoumon users achieving a good TTR (>75%) during POC 
monitoring was higher as compared with laboratory monitoring, while other subgroups 
showed similar results as the main analyses (i.e. lower TTR during POC monitoring than 
during laboratory monitoring, see table 3). 
Table 2. Time in therapeutic range during laboratory and point-of-care monitoring
Laboratory Point-of-care
Patients Median TTR  [IQR] Patients Median TTR [IQR] P-value *
Overall 1973 81.0 [71.1-90.5] 1959 77.9 [67.2-87.4] <0.001
Treatment duration
<  6 months 241 78.6 [65.8-90.7] 242 76.8 [65.1-86.0] 0.101
≥  6 months 1732 81.2 [71.8-90.5] 1717 78.0 [67.4-87.5] <0.001
Therapeutic range
 2.0-3.5 1639 82.0 [72.1-91.2] 1667 78.7 [68.2-88.3] <0.001
 2.5-4.0 334 76.1 [66.6-85.2] 292 73.1 [59.7-81.0] <0.001
Type of VKA
Acenocoumarol 1852 80.9 [71.1-90.4] 1852 77.8 [66.9-87.3] <0.001
Phenprocoumon 121 82.4 [71.0-92.6] 202 81.3 [74.9-92.2] 0.704
* Mann-Whitney U. TTR= Time in therapeutic range in %, VKA= Vitamin K antagonist
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Table 3. Number of patients achieving poor, moderate and good anticoagulation control
Laboratory Point-of-care
Patients Proportion (95% CI) Patients Proportion (95% CI)
Overall
Poor 212 10.7 (9.4 - 12.2) 284 14.5 (13.0 - 16.1)
Moderate 452 22.9 (21.1 - 24.8) 536 27.4 (25.4 - 29.4)
Good 1309 66.3 (64.2 - 68.4) 1139 58.1 (55.9 - 60.3)
Treatment duration
 < 6 months
Poor 47 19.5 (15.0 - 25.0)  48 19.8 (15.2 - 25.2)
Moderate 50 20.7 (16.1 - 26.3)  59 24.4 (19.4 - 30.2)
Good 144 59.8 (53.5 - 65.7) 135 55.8 (49.5 - 61.9)
≥ 6 months
Poor 165 9.5 (8.2 - 11.0) 236 13.7 (12.2 - 15.5)
Moderate 402 23.2 (21.3 - 25.3) 477 27.8 (25.7 - 30.0)
Good 1165 67.3 (65.0 - 69.4) 1004 58.5 (56.1 - 60.8)
Therapeutic range
2.0-3.5
Poor 155 9.5 (8.1 - 11.0) 211 12.7 (11.2 - 14.3)
Moderate 356 21.7 (19.8 - 23.8) 445 26.7 (24.6 - 28.9)
Good 1128 68.8 (66.5 - 71.0) 1011 60.6 (58.3 - 63.0)
2.5-4.0
Poor 57 17.1 (13.4 - 21.5) 73 25.0 (20.4 - 30.3)
Moderate 96 28.7 (24.2 - 33.8) 91 31.2 (26.1 - 36.7)
Good 181 54.2 (48.8 - 59.5) 128 43.8 (38.3 - 49.6)
Type of VKA
Acenocoumarol
Poor 195 10.5  (9.2 - 12.0) 272 14.7 (13.2 - 16.4)
Moderate 432 23.3  (21.5 - 25.3) 521 28.1 (26.1 - 30.2)
Good 1225 66.1  (64.0 - 68.3) 1059 57.2 (54.9 - 59.4)
Phenprocoumon
Poor 17 14.0  (9.0 - 21.4) 12 11.2 (6.5 - 18.6)
Moderate 20 16.5  (11.0 - 24.2) 15 14.0 (8.7 - 21.9)
Good 84 69.4  (60.7 - 76.9) 80 74.8 (65.8 - 82.0)
*Poor = TTR<60.0%, †Moderate=TTR 60.0-75.0, ‡Good= TTR >75.0%. CI=Confidence Interval, VKA = Vitamin K 
antagonist
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D I S C U S S I O N 
The aim of our study was to determine whether point-of-care (POC) INR monitoring 
by professionals is a safe and effective alternative to laboratory INR monitoring in 
non-self-monitoring (NSM) patients on vitamin K antagonists (VKA). In such NSM 
patients, we observed that time in therapeutic range (TTR) was significantly lower during 
POC monitoring than during laboratory monitoring. Despite the lower TTR, risk 
estimates indicated that the risk of clinical events such as major bleeding or ischaemic 
stroke was not increased. 
The fact that the TTR was lower during POC monitoring than during laboratory 
monitoring may be explained by the current dosing algorithms, which are based on 
laboratory INR results rather than on POC INR results. Although in general agreement 
between POC and laboratory results has shown to be satisfactory for clinical practice, 
Figure 2. Kaplan Meier curves of major clinical events
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we recently have shown that, relative to laboratory results, the Coaguchek XS 
underestimates INRs ≤ 4.0 and overestimates INRs > 4.0 (14,15). When POC results are 
interpreted as laboratory results, these discrepancies, especially at sub- and 
supratherapeutic INR levels, could cause over- or under-dosing of VKA, potentially 
resulting in a greater degree of INR instability. Such an increase in INR instability was 
observed in our study, since fewer patients had a good TTR (with the exception of the 
phenprocoumon users), and more patients required a significant VKA dose adjustment 
after INR measurement during POC monitoring. Furthermore, we also observed a 
significantly higher INR testing frequency during POC monitoring, also suggesting less 
stabile anticoagulation control. The lower TTR and higher testing frequency during POC 
monitoring might also be explained by the difference in thromboplastin source (tissue-
extract in laboratory test versus recombinant in POC test). A previous study has shown 
method-dependent differences in INR variability during VKA treatment, caused by the 
differences between thromboplastin reagents in sensitivity to circulating clotting factors 
II and VII, which fluctuate during VKA treatment (16).
Although TTR was lower during POC monitoring, the most important question remains 
whether or not there is a negative impact of POC monitoring on patient outcome. The 
fact that the hazard ratios of clinical events were all around unity indicates that POC 
monitoring was not associated with an increased risk of adverse events after 1 year of 
follow-up, although the absolute number of major bleedings and ischemic strokes that 
Table 4. Hazard ratios of major clinical events during laboratory and point-of-care INR monitoring
Patients Events Person 
years
Incidence per
1000 py (95% CI)
Hazard ratio (95% CI)
Crude Adjusted *
Mortality (all-cause)
Laboratory 1973 119 1773 67.1 (56.4 - 79.8) Reference Reference
Point-of-care 1959 123 1773 69.4 (58.5 - 82.3) 1.03 (0.80 - 1.33) 1.00 (0.78 - 1.29)
Hospitalization (any)
Laboratory 1973 261 1658 157.4 (140.8 - 176.0) Reference Reference
Point-of-care 1959 252 1669 151.0 (134.8 - 169.2) 0.96 (0.81 - 1.14) 0.94 (0.79 - 1.12)
Major bleeding
Laboratory 1973  32 1759 18.2 (12.9 - 25.6) Reference Reference
Point-of-care 1959 30 1761 17.0 (11.9 - 24.3) 0.94 (0.57 - 1.54) 0.93 (0.56 - 1.52)
Ischemic stroke
Laboratory 1973 13 1768 7.4 (4.3 - 12.6) Reference Reference
Point-of-care 1959 12 1767 6.8 ( 3.9 - 11.9) 0.92 (0.42 - 2.02) 0.92 (0.42 - 2.02)
* adjusted for age, py= patient-years
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occurred during the study period were relatively low. The similarity in patient outcome 
may be explained by the fact that, overall, anticoagulant control was still adequate 
during POC monitoring. According to Dutch guidelines, in long-term patients an average 
TTR of at least 70% (for a low-intensity treatment group) or 65% (for a high-intensity 
treatment group) indicates good quality of care (10). In our study, median TTR levels 
in long-term patients during POC monitoring were well above these thresholds (79.1% 
in the low-intensity group and 73.2% in the high-intensity group), confirming that, 
although TTR was lower during POC monitoring, anticoagulant control remained good. 
However, it should be mentioned that on an individual level, there was an obvious shift 
in anticoagulant control, with more patients achieving a poor (<60%) or moderate (60-
75%) TTR and fewer patients achieving a good TTR (>75%) during POC monitoring as 
compared with laboratory monitoring. Since poor TTR remains the most important 
predictor of long-term patient outcome during VKA therapy, methods to optimize 
anticoagulant control during POC monitoring should be a topic of future research. 
Comparison with other studies
To our knowledge, this is the first study using real-world data to investigate the safety 
and efficacy of POC INR monitoring by professionals at an anticoagulation clinic in NSM 
patients. Two prior randomized controlled trials in NSM patients on warfarin have 
reported conflicting results regarding the effect of POC monitoring on TTR, but both 
studies reported non-inferiority regarding clinical outcome, which is in agreement with 
our results (8,9). The impact of POC monitoring on TTR has also been studied in clinical 
trials evaluating INR self-monitoring and management (17-23). A recent meta-analysis 
of these studies also showed heterogeneous results between trials (24): when after 1 
year of follow-up the intervention group was compared with controls receiving standard 
care, some studies reported higher TTR, while others reported lower TTR (17-23). 
Potential explanations for these differences could be differences between the trials in 
INR monitoring frequency, used reference laboratory method, instructions for the POC 
device or the use of VKA with different half-lives. Our results are in line with those of 
previous studies that have evaluated self-monitoring and self-management in patients 
on acenocoumarol and phenprocoumon (21,25). In these trials, POC monitoring was 
associated with lower TTR in patients on the short-acting VKA acenocoumarol (half-life 
2-8h) and higher TTR in patients on the long-acting VKA phenprocoumon (half-life 156-
178h) compared to controls receiving laboratory monitoring (21,25,26). Taken together 
with the results of these trials, our findings suggest that the effect of POC INR 
monitoring on the TTR may be better when the patient is taking a VKA with a longer 
half-life (21,25). It would be of interest to investigate whether switching patients to a 
long-acting VKA improves TTR during POC monitoring.
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Strengths and limitations
Our study has three main strengths. Firstly, we had access to a large cohort with 
complete follow-up and known clinical end points. The large size of the study population 
enabled us to answer our research question using statistical analyses that had adequate 
power and robustness, particularly in the case of subgroup analyses. A second strength 
is that the cohort consisted of an unselected population. This means that our results 
are generalizable to the real world setting, which consists mainly of elderly patients 
with atrial fibrillation. Third, due to the large study population, we were able to study 
clinical endpoints and not only a surrogate for those endpoints (TTR). However, it is 
important to remark that the duration of follow-up was limited to one year for both 
monitoring groups and therefore the number of major bleedings and ischemic strokes 
that occurred during the study period were relatively low.
Our study has three main limitations. First and most importantly, physicians were 
aware of the implementation of POC monitoring and knew whether the INR result they 
used to determine dosage was a POC or laboratory result. This could have caused 
physicians – consciously or subconsciously – to dose differently and monitor patients 
more intensively during POC monitoring, which may have biased our results.  Indeed 
the higher number of INR measurements during POC monitoring as compared with 
laboratory monitoring may partly be explained by this bias. However, dosing algorithms 
and monitoring frequency guidelines were not adjusted during the course of this study 
and we found no evidence for changes in physicians’ adherence to dosing schedules 
between the two periods of monitoring, suggesting that the impact of this bias on our 
results was relatively limited. Second, our study was an observational study, meaning 
that other factors could have influenced the results. Patient characteristics were very 
similar though in the laboratory and POC monitoring groups and are unlikely to have 
caused the consistently observed differences in TTR. Finally, laboratory INR 
measurements were performed using only one type of reagent (Hepato Quick, a tissue-
extract thromboplastin) and POC monitoring was performed using only one type of 
point-of-care device (Coaguchek XS). Therefore our findings cannot be extrapolated 
directly to settings where a different POC or laboratory method is used. The use of a 
recombinant thromboplastin for laboratory INR measurements or of another POC 
device may have a different effect on TTR (5). 
In conclusion, we observed that TTR in NSM patients was lower during POC INR 
monitoring than during laboratory INR monitoring. However, overall TTR remained 
good and risk estimates indicated similar risks for clinical outcomes (i.e. major bleeding, 
ischemic stroke, hospitalization and mortality) in the POC and laboratory monitoring 
groups. Our results indicate that in NSM patients POC INR monitoring by professionals 
is a safe, effective, and adequate alternative to laboratory INR monitoring.
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A B S T R A C T
Background
Differences regarding sensitivity to factor VII (FVII) have been suggested for recombinant 
human and tissue-extract thromboplastins used for International Normalized Ratio 
(INR) measurement, but evidence is scarce. Differences in FVII sensitivity are clinically 
relevant since they can affect INR stability during treatment with vitamin K antagonists 
(VKA).
Objectives
To determine if commercial thromboplastins react differently to changes in FVII. 
Methods
We studied the effect of addition of FVII on the INR in plasma using three tissue-extract 
(Neoplastin C1+, Hepato Quick, Thromborel S) and three recombinant human 
(Recombiplastin 2G, Innovin, Coaguchek XS) thromboplastins. Three different 
concentrations of purified human FVII (0.006, 0.012, and 0.062 µg/mL plasma), or buffer, 
were added to five certified pooled plasmas of patients using VKA (INR 1.5-3.5). Changes 
in FVII activity were measured with two bioassays (Neoplastin and Recombiplastin) and 
relative INR changes were compared between reagents.
Results
After addition of 0.062 µg/mL FVII, FVII activity in the pooled plasmas increased by 
approximately 20% (Neoplastin) or 32% (Recombiplastin) relative to the activity in 
pooled normal plasma. All thromboplastins showed dose-dependent INR decreases. 
The relative INR change in the pooled plasmas significantly differed between the six 
thromboplastins. No differences were observed amongst recombinant or tissue-extract 
thromboplastins. Pooled results indicated that the FVII-induced INR change was greater 
for recombinant than for tissue-extract thromboplastins. 
Conclusions
Differences regarding FVII sensitivity exist between various thromboplastins used for 
VKA monitoring. Recombinant human thromboplastins are more sensitive to FVII than 
tissue-extract thromboplastins. Therefore, thromboplastin choice may affect FVII-
mediated INR stability. 
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I N T R O D U C T I O N
Millions of people worldwide are currently treated with vitamin K antagonists (VKA) for 
the primary or secondary prevention of arterial and venous thrombosis. Furthermore, 
VKA will remain the anticoagulant of choice in selected patients, such as those with 
mechanical heart valves prostheses or with a contraindication to direct oral 
anticoagulants (DOACS) (1). Treatment with VKA requires monitoring via the 
international normalized ratio (INR), which is a ratio of the patient’s prothrombin time 
(PT) to the mean PT of healthy individuals, raised to the power of the international 
sensitivity index (ISI) of the used thromboplastin reagent and instrument (2). During 
VKA treatment, the INR fluctuates due to several endogenous and exogenous factors 
such as an intercurrent illness, use of interacting co-medication, and food intake (3). 
A previous study by Solvik and colleagues has shown that INR variability during VKA 
treatment can largely be explained by the (residual) activity of clotting factor VII (FVII) 
and to a lesser extent to plasma levels of clotting factors II (FII) and X (FX) (4). In addition, 
FVII, the clotting factor with the shortest half-life of approximately 6 hours, fluctuates 
more than FII and FX during treatment, and the magnitude of its fluctuation also 
depends on the half-life of the used VKA (5). Pronounced fluctuations have been 
observed in patients on the short-acting acenocoumarol compared to minimal 
fluctuations in patients on the long-acting phenprocoumon (5). 
The activity of FVII is usually determined by bioassays that use FVII-deficient plasmas 
and tissue factor (thromboplastin) preparations. It has been shown that the sensitivity 
of the Factor VII assay system depends on the origin of the thromboplastin; human 
(placenta-derived) thromboplastin was more sensitive than rabbit thromboplastin (6). 
Other investigators have reported that recombinant human tissue factor is more 
sensitive to FVII deficiency than other thromboplastin reagents (7,8). Differences in 
sensitivity to FVII between recombinant human and tissue-extract thromboplastins 
used for INR measurement has also been suggested as a source of INR inconsistency, 
especially during unstable anticoagulation, such as in the initial phase of oral 
anticoagulant therapy (9,10). If present, these differences in sensitivity to FVII could 
have a significant effect on the INR and may explain INR discrepancies between 
methods reported in prior studies (9-12). More importantly, differences in sensitivity 
to FVII could also directly influence the requirement for VKA dose adjustment, if 
significant INR discrepancies are present, especially in patients on short-acting VKA 
(9-11). The conditions of a bioassay specific for FVII are different of those of INR 
measurement in samples of patients treated with VKA. The purpose of the present 
study was to determine whether thromboplastins from different sources (e.g. tissue-
extract or recombinant human) used in the diagnostic laboratory, react differently to 
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a fixed increase in FVII. To do so, we measured the INR change in plasma from patients 
on VKA, induced by spiking the plasma with FVII. We added purified human FVII to 
patients’ plasma and determined the INR change using six different commercially 
available thromboplastin reagents.
M A T E R I A L S  A N D  M E T H O D S
Five commercially available thromboplastin reagents were used: Dade Innovin, 
Thromborel S (Siemens Healthcare Diagnostics Products, Marburg, Germany), STA 
Hepato Quick and Neoplastin C1+ (Diagnostica Stago, Asnières-sur-Seine, France) and 
Recombiplastin 2G (Instrumentation Laboratory Company, Bedford, Massachusetts). 
Plasma prothrombin times (PT) were determined in polystyrene tubes using a semi-
automatic coagulometer (H. Amelung, Lemgo, Germany) according to Schnitger and 
Gross (13). Each PT was determined in duplicate on the same coagulometer and the 
average of the two duplicates were used for further calculations. In addition, PT was 
also determined using the CoaguChek XS PT Test system, which contains recombinant 
human thromboplastin (Roche Diagnostics, Mannheim, Germany) (14). 
Six certified deep-frozen pooled citrated plasmas were used for the experiments. Of 
these, one had been prepared by pooling plasmas obtained from 35 healthy individuals. 
The pooled normal plasma sample was used in the FVII assay to quantify the change 
in FVII activity after spiking with FVII. Each of the other plasmas had been prepared by 
pooling approximately 200 plasmas obtained from patients treated with VKA. Individual 
patients’ plasmas were selected according to their INR determined by the Leiden 
Anticoagulant Clinic and pooled in the following INR intervals: 1.5–2.0, 2.0–2.4, 2.4–2.8, 
2.8–3.2, and 3.2–3.6. The pooled plasmas had been stored in 0.5 ml aliquots at -70 °C. 
All plasmas were thawed for 3 minutes in a water bath at 37 °C before use. Certified 
PTs and INRs of these plasmas had been determined by three laboratories using the 
international standards for rabbit thromboplastin (RBT/05) and for recombinant human 
thromboplastin (rTF/09), according to procedures described previously (15). PTs for 
the international standards were determined with the manual (tilt-tube) technique in 
a water bath at 37 °C.  Certified INRs were calculated using the ISI values established 
for the international standards (16,17). The certified INRs were used to calculate 
instrument-specific ISI and mean normal PT (MNPT) values for the above-mentioned 
commercial thromboplastins (15). Briefly, logarithms of certified INR were plotted 
versus logarithms of PTs determined with the commercial thromboplastin and an 
orthogonal regression line was calculated. ISI and MNPT were calculated from the slope 
and intercept of the orthogonal regression line (15).
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Purified FVII (origin: human blood) was obtained from Haematologic Technologies Inc. 
(Essex Junction, Vermont). It had a specific activity of 2393 U/mg according to the 
manufacturer. It was prediluted in buffer (0.15 M NaCl, 20 mM Tris.HCl, pH 7.4, 1% 
BSA). The diluted FVII solution was stored at 6 ℃ and used for all experiments between 
November 2015 and February 2016. The activity was checked regularly and no 
significant change was observed during this period. The following FVII concentrations 
were made: 0.16 µg/mL, 0.32 µg/mL, and 1.60 µg/mL. These dilutions of FVII (10 µL) 
were added to plasma (250 µL), giving a calculated FVII increase of 0.006, 0.012 and 
0.062 µg/ml plasma respectively. In control experiments, only buffer was added to 
plasma. CoaguChek XS measurements were performed by mixing plasma (50 µL) with 
16 mM calcium chloride solution (50 µL) in a polystyrene tube, immediately applying 
30 µL of the mixture to a test strip that had been inserted in the instrument. PTs were 
read from the screen and transformed to INR using the instrument-specific ISI and 
MNPT.  FVII activity was determined using Recombiplastin 2G, Neoplastin C1+, pooled 
normal plasma and FVII-deficient plasma (18). FVII activity in pooled normal plasma 
was set at 100%. FVII activity and 95% confidence intervals were calculated using a 
computer program for parallel line assays (CombiStats, version 5.0, European 
Directorate for the Quality of Medicines and Healthcare, Strasbourg, France).
Statistical analysis
FVII activity in the pooled plasmas of patients on VKA, before and after spiking with the 
highest concentration of FVII, was compared between Recombiplastin 2G and 
Neoplastin C1+ using the Wilcoxon signed rank test. Absolute changes in FVII activity 
in the pooled plasmas were also calculated and compared between reagents using the 
Wilcoxon signed rank test. INRs obtained for plasmas spiked with FVII were compared 
with the same plasmas spiked with the same volume of buffer without FVII. The 
coefficients of variation (imprecision) for each reagent system were calculated by 
dividing the standard deviation by the means from the duplicate INR results. For further 
statistical analyses, the mean PT and INR of duplicate measurements were used. 
Absolute and relative INR changes after addition of different concentrations of FVII 
were calculated for all pooled plasmas on each reagent system. The Wilcoxon signed 
rank test and the Friedman test were used to compare the differences in relative INR 
change between reagent systems. Statistical analyses were performed using SPSS 
version 22.0  (IBM Corp. Armonk, NY, USA) and figures were constructed using 
GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
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R E S U L T S
Certified plasma INR results and FVII activity
Baseline INR values for the certified pooled plasmas are shown in table 1, as well as 
FVII activities before and after spiking with FVII.  Baseline FVII activity levels in these 
plasmas were significantly higher when measured with Neoplastin C1+ compared to 
Recombiplastin 2G (P=0.043). The increase in Factor VII activity, as measured using 
Recombiplastin 2G, was approximately 32% (median change 32.5%, interquartile range 
31.5 to 33.4) following addition of 0.062 µg/mL Factor VII. Using Neoplastin C1+, the 
measured increase in FVII activity was approximately 20% (median change 20.0%, 
interquartile range 17.0 to 21.0). Considering all five samples of patients on VKA, the 
absolute increase in FVII activity was significantly greater when measured with 
Recombiplastin 2G compared to Neoplastin C1+ (P=0.043). 
 
INR change after FVII addition using different commercial thromboplastins
Imprecision coefficients of variation for duplicate INR measurement using the 
coagulometer according to Schnitger and Gross were 0.6% (Hepato Quick), 1.3% 
(Innovin), 1.7% (Neoplastin C1+), 2.3% (Thromborel S) and 4.5% (Recombiplastin 2G) 
respectively.  The coefficient of variation for the calculated Coaguchek XS INR results 
was 3.4%. Prothrombin times shortened and INR values decreased with addition of 
increasing FVII concentrations in all five pooled plasmas of patients on VKA, irrespective 
of the used thromboplastin reagent (Figure 1). Mean PT and mean INR results of each 
plasma sample of patients using VKA, after addition of different concentrations of FVII 
or buffer, are also shown in supplemental table 1 for all reagent systems. Absolute and 
Table 1. Mean INR and Factor VII activity in pooled plasmas before and after addition of 0.062 μg/mL 
purified FVII 
Plasma Mean INR* Mean INR* Factor VII activity (95% CI) Factor VII activity (95% CI)
(rTF/09) (RBT/05) Recombiplastin 2G Neoplastin C1+
Before After Before After
12-1 1.51 1.69 40.0 (37.1-43.1) 73.0 (67.5-79.1) 61.3 (57.8-65.1) 79.7 (74.6-85.2)
12-2 2.05 2.27 26.8 (24.3-29.6) 57.7 (53.4-62.4) 43.2 (40.7-45.8) 63.2 (59.7-66.9)
12-3 2.42 2.64 20.1 (18.6-21.7) 51.6 (47.8-55.7) 32.8 (30.8-35.0) 54.9 (51.4-58.6)
12-4 2.77 2.87 17.4 (16.0-18.9) 51.0 (46.5-56.0) 30.2 (28.6-31.9) 44.6 (42.3-47.1)
12-5 3.17 3.28 15.1 (13.9-16.4) 47.4 (44.0-51.1) 25.8 (24.4-27.2) 46.4 (41.7-51.6)
* Mean of the three INR values assigned by the three references laboratories using the manual tilt tube method.
INR=International Normalized Ratio, CI=Confidence interval.
73
DIFFERENCES IN FVII SENSITIVITY BETWEEN COMMERCIAL THROMBOPLASTINS
5
Fi
gu
re
 1
. I
N
Rs
 o
f 
po
ol
ed
 p
la
sm
as
 a
ft
er
 a
dd
it
io
n 
of
 d
if
fe
re
nt
 F
VI
I c
on
ce
nt
ra
ti
on
s 
or
 b
uf
fe
r.
 E
ac
h 
ba
r 
in
di
ca
te
s 
th
e 
m
ea
n 
IN
R 
va
lu
e 
of
 d
up
lic
at
e 
re
su
lts
 fr
om
 
di
ff
er
en
t c
er
tif
ie
d 
po
ol
ed
 p
la
sm
as
 s
pi
ke
d 
w
ith
 F
VI
I o
r 
bu
ff
er
.
PART TWO  |  CHAPTER 5
74
relative INR changes after addition of FVII increased with increasing INR level, 
independent of the administered FVII concentration or the used reagent system (Figure 
1). The median proportional INR change and interquartile ranges for the different 
reagents after spiking with FVII were -13.5% [-26.7 to -7.8] (Recombiplastin 2G), -11.9% 
[-19.3 to -7.3] (Innovin), -11.9% [-19.9 to -7.4] (Coaguchek XS), -10.3% [-17.3 to -9.0] 
(Thromborel S), -10.2% [-17.4 to -7.3] (Neoplastin C1+) and -9.1% [-17.0 to -6.0] (Hepato 
Quick) respectively.  Overall, there was a significant difference (P=0.004) between the 
six thromboplastins regarding the relative change in INR after FVII addition (Figure 2). 
In contrast, no differences were observed amongst the recombinant human (P=0.085) 
or tissue-extract (P=0.575) thromboplastins (Figure 2). After combining the data of the 
three recombinant human and three tissue-extract thromboplastins, the relative INR 
changes as measured by the recombinant human thromboplastins were significantly 
higher (P<0.001) than the INR changes as measured using the tissue-extract 
thromboplastins (Figure 3).
Figure 2. Relative INR changes in pooled plasmas after FVII addition for different thromboplastin 
reagents. Each dot represents the mean proportional INR change from duplicate results after spiking pooled 
plasmas from patients on VKA with FVII (n=15).  P-value for differences in rank by Friedman test.
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D I S C U S S I O N
In our study, we found that, despite optimal calibration, the relative INR change after 
FVII addition significantly differed between the six used thromboplastin reagents used 
for INR measurement of patients on VKA. One of these thromboplastins was used in an 
electrochemical point-of-care device and the other five in a mechanical coagulometer. 
Furthermore, the INR change after FVII addition was greater when measured using a 
recombinant human thromboplastin than when measured using a tissue-extract throm-
boplastin, suggesting higher sensitivity of recombinant human thromboplastins to FVII. 
Our findings are in agreement with previous results from Smith and colleagues (19). 
In their study, recombinant human thromboplastins (Innovin and Recombiplastin) were 
more sensitive to FVII deficiency than tissue-extract thromboplastins (Thromborel S 
and Neoplastin C1+) (19). However, as stated by these authors, differences regarding 
FVII sensitivity, as measured in FVII deficient plasma, may not directly be extrapolated 
to patients on VKA, since FII and FX levels are also decreased in these patients. As in 
our study, Smith also added purified human FVII to plasma of patients on VKA, but only 
reported the change in prothrombin time measured in individual patient plasmas using 
Figure 3. Relative INR changes in pooled plasmas after FVII addition for recombinant versus tissue-
extract thromboplastins. Each dot represents the mean proportional INR change from duplicate results after 
spiking different pooled plasmas with FVII (n=45).  P-value for differences in rank by Wilcoxon-signed rank test.
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synthetic non-commercially available thromboplastins, which complicates the 
translation to clinical practice. Differences regarding FVII sensitivity between reagents 
is of clinical importance since it has been shown that patients monitored with the 
tissue-extract thromboplastin Hepato Quick achieve better anticoagulation control 
than patients monitored with the recombinant human thromboplastins Innovin and 
Recombiplastin (20). Furthermore, in a previous study we reported a significant 
difference in percentage of time in therapeutic range between patients monitored with 
a laboratory method using Hepato Quick, compared to patients monitored by 
professionals using the Coaguchek XS point-of-care system (21). The fact that most 
patients in the Netherlands (19), as well as in the previously mentioned cohort study 
(21), are treated with the short-acting VKA acenocoumarol may help explain the 
observed differences in anticoagulation control between patients monitored with 
reagents of different sources. Circulating FVII levels can fluctuate strongly in these 
patients and recombinant human thromboplastins seem to be very sensitive to changes 
in FVII, thus directly affecting measured INR stability (5,22). However, method or 
reagent-dependent differences in INR stability have also been reported in patients on 
the longer acting warfarin, emphasizing the importance of our findings beyond patients 
treated with acenocoumarol (4,23). It has been suggested that the pharmacodynamic 
effects of warfarin regarding INR variability are more similar to acenocoumarol than 
to phenprocoumon (24).  Also, similar daily FVII fluctuations have been observed in 
patients on warfarin and on acenocoumarol (25). Clinicians should be aware of these 
reagent-dependent differences regarding INR stability and include this knowledge in 
their evaluation of quality of anticoagulation control in their patients. However, it 
should be noted that reagent-dependent differences in anticoagulation control have 
not yet been directly translated into higher thrombotic or bleeding complication rates 
between patients in these studies (21,23). Therefore there is currently no direct 
requirement for switching to a specific thromboplastin or monitoring method. 
Strengths and limitations
We used pooled patients’ plasmas for our experiments rather than individual patient 
plasmas. Pooled patients’ plasmas have the advantage that differences between 
individuals in clotting factor concentrations are averaged. In pooled plasmas, the 
relationship between INR and clotting factor activity is less variable than the same 
relationship determined in individual patient plasmas (26). The influence on INR of a 
given dose of added FVII to pooled plasma is therefore more representative than that 
of the same dose added to a plasma sample of an individual patient. In an individual 
patient’s plasma, there is greater probability that an INR change is also influenced by 
variation in other clotting factors. 
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A limitation of our study is that we used citrated plasma for the Coaguchek XS 
measurements. The CoaguChek XS system has been designed for non-citrated whole 
blood rather than for recalcified citrated plasma. Ideally, the sensitivity of the 
CoaguChek XS system to FVII should be investigated by adding purified FVII to non-
citrated whole blood. However, it should be mentioned that the INRs for recalcified 
pooled plasmas read from the screen of the CoaguChek XS were similar to the certified 
INR values determined with the International Standard Thromboplastins using the 
manual tilt tube method. Furthermore, in another study, the overall paired values of 
recalcified plasma INR values from the CoaguChek XS and a laboratory INR method 
showed good correlation (27). Good agreement between certified INR and CoaguChek 
XS values for recalcified plasmas has also been observed in an external quality 
assessment scheme (28).  These findings indicate that recalcified plasma is an 
acceptable substitute for whole blood for INR measurement on the CoaguChek XS. 
Another limitation of our study is that we do not know the exact phospholipid 
composition of the thromboplastins used in our study. It was stated by Smith that the 
differences in sensitivity to FVII between tissue-derived and recombinant human 
thromboplastins can be explained by differences in phospholipid composition between 
reagents, and that the dissimilar sensitivity to FVII may become more apparent when 
clotting factor deficiencies become more severe (19). However, even if we would know 
the exact phospholipid composition of the commercial reagents, they would still be 
different from the compositions used by Smith, thus hampering a direct comparison. 
Alternatively, the apparent difference in FVII activity between recombinant and tissue-
derived thromboplastins (Table 1) might be explained by the influence of other factors 
present in the plasma of patients on VKA. It has been suggested that rabbit 
thromboplastin is not sensitive to non-carboxylated proteins induced by VKA (PIVKA), 
whereas clotting induced by human thromboplastin can be inhibited by PIVKA (29). 
Inhibition of clotting by PIVKA might reduce the apparent FVII activity measured with 
recombinant human thromboplastin. Our findings suggest that knowledge of the 
thromboplastin source (recombinant human or tissue-derived) helps to predict factor 
FVII sensitivity.  Apart from the above-mentioned possible explanations, another 
explanation for differences in FVII sensitivity between recombinant human and tissue-
extract thromboplastins could be that tissue-derived thromboplastins may be 
contaminated with traces of FVII and FVII(a) (22).  It has previously been shown that 
when traces of FVIIa were added to recombinant human thromboplastins, sensitivity 
to FVII decreased (22). Furthermore, significant differences regarding FVII sensitivity 
have been reported between tissue-derived thromboplastins from normal and FVII 
deficient animals, also suggesting FVII contamination as explanation for differences in 
FVII sensitivity between thromboplastins (22,30).  
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In conclusion, we found significant differences in sensitivity to clotting factor VII 
between commercially available thromboplastins reagents used for INR measurement 
in patients on VKA. These differences in sensitivity to FVII can explain INR discrepancies 
between methods reported in prior studies and observations of differences regarding 
anticoagulation control between patients monitored with thromboplastins from 
different sources. 
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A B S T R A C T 
Background
Low-molecular-weight-heparins (LMWHs) are considered members of a class of drugs 
with similar anticoagulant properties. However, pharmacodynamics and pharmaco-
kinetics between LMWHs differ, which may result in different bleeding risks. As these 
agents are used by many patients, small differences may lead to a large effect on 
numbers of major bleeding events.
Objectives
To determine major bleeding risks for different LMWH agents and dosing schedules.
Methods
Cohort with acute venous thrombosis patients from four anticoagulation clinics who 
used a LMWH and a vitamin K antagonist. Patients were followed until they ceased 
LMWH treatment or until major bleeding. Exposures were classified according to 
different types of LMWHs and for b.i.d. and o.d. use. Cumulative incidences for major 
bleeding per 1000 patients and risk ratios were calculated and adjusted for study 
center. 
Results
The study comprised of 12934 patients with a mean age of 59 years;  6218 (48%) men. 
The cumulative incidence for major bleeding was 2.5 per 1000 patients (95% confidence 
interval [CI] 1.7-3.5). Enoxaparin b.i.d. or o.d. was associated with a relative bleeding 
risk of 1.7 (95% CI, 0.2-17.5) compared with nadroparin o.d. In addition, a nadroparin 
b.i.d. dosing schedule was associated with a 2.0-fold increased major bleeding risk 
(95% CI, 0.8-5.1) as compared with a nadroparin o.d. dosing schedule.
Conclusions
Absolute major bleeding rates were low for all LMWH agents and dosing schedules in 
a large unselected cohort. Nevertheless, twice-daily dosing with nadroparin appeared 
to be associated with an increased major bleeding risk as compared with once-daily 
dosing, as also suggested in a meta-analysis of controlled clinical trials. 
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B A C K G R O U N D
Low-molecular-weight-heparins (LMWHs) are widely used for prevention and treatment 
of venous thrombosis (the composite of deep vein thrombosis and pulmonary 
embolism) (1). The LMWHs currently on the market are considered members of a class 
of drugs with similar anticoagulant properties. However, pharmacodynamics and 
pharmacokinetics between LMWHs differ. For example, the half-life of the anti-Xa 
activity is 4.3 h for enoxaparin as compared with 2.4 h for dalteparin (2). Such 
differences in duration of anticoagulant effect could result in different bleeding risks 
between LMWH agents. For the acute treatment of venous thrombosis, a head-to-head 
trial was conducted that compared two different LMWHs, i.e. (dalteparin omni die [o.d., 
i.e. once daily] vs. tinzaparin o.d.). In this randomized study, with 505 patients, the 
relative bleeding risk of dalteparin versus tinzaparin was 0.40 (95% confidence interval 
[CI], 0.08 to 2.07) but as the confidence intervals included unity the authors concluded 
that the bleeding rate was similar for both LMWHs (3). To prevent venous thrombosis 
after a spinal cord injury with an LMWH, head-to-head trials were performed to 
compare dalteparin with enoxaparin, which showed that overall bleeding rates were 
similar (4,5), whereas others showed that enoxaparin had a more favorable risk profile 
with respect to major bleeding as compared with dalteparin (6). It is currently unclear 
whether one LMWH should be preferred over the other in the treatment of venous 
thrombosis, even though small differences in major bleeding rates may lead to a large 
reduction in major bleeding events, because these agents are used by many patients 
on an annual basis.
We therefore set out to perform a cohort study in 12 934 patients with acute venous 
thrombosis who were treated with LMWH (and concurrently received a vitamin K 
antagonist [VKA]) to determine the major bleeding risk for several LMWH agents and 
dosage schedules.
 
M E T H O D S
Study population and data collection
All patients over 18 years of age, with a new onset of venous thrombosis between 2006 
and 2013, who received initial treatment with an LMWH (nadroparin o.d., nadroparin 
bis in die [b.i.d., i.e. twice daily], tinzaparin o.d., enoxaparin o.d. or b.i.d., dalteparin 
o.d.) and a VKA and were treated at one of the four participating anticoagulation clinics 
in the Netherlands (Leiden, Rotterdam, The Hague and Utrecht) were included. 
Enoxaparin o.d. and b.i.d. treatments were combined because numbers were too small. 
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New onset was defined as an acute diagnosis of a first or recurrent venous thrombosis. 
Diagnoses were made at hospitals and were based on the international diagnosis 
criteria, after which patients received therapeutic dosages of LMWHs for at least 5 days 
(7). At the anticoagulation clinics, patients with acute venous thrombosis are registered. 
There, the international normalized ratio (INR) is measured at least every 3 days when 
VKA and LMWH treatment are combined. LMWH treatment is ceased after at least 5 
days of treatment and when two consecutive INRs are in the target range (7). At each 
appointment blood is drawn to measure the INR and a standardized short questionnaire 
is administered (and electronically stored) by a nurse to list any changes in co-
medication or onset of new diseases and to enquire if patients experienced bleeding 
events or have any surgical procedures planned (8). If patients missed their 
appointment, they are contacted by nurses of the anticoagulation clinic and a new 
appointment is made at short notice. 
Patient characteristics and information regarding major bleeding events were derived 
from the computerized medical records of the anticoagulation clinics. Data included 
age, sex, indication for VKA treatment, type of LMWH, duration of LMWH exposure, 
concomitant drug use and date of major bleeding events. Patients were considered 
exposed to an LMWH from the subscription date at the anticoagulant clinic until ceasing 
treatment with the LMWH plus an additional two days wash-out period, or until a 
patient died, changed anticoagulation clinic or experienced a major bleeding, whichever 
occurred first. Of note, in this study it was not planned that the patient records were 
used before the data collection took place, which could have resulted in less exact data. 
However, the data needed for this study were necessary for patient care and 
systematically collected during treatment as part of patient care.
Outcome
The outcome of our study was non-traumatic major bleeding. Bleedings were 
considered major if they required blood transfusion (mainly red blood cells), were 
symptomatic in a critical area or organ, or led to death (9). In addition, bleedings for 
which patients were hospitalized were also considered major bleedings.  Bleedings 
were notified during the standardized short histories taken by specially trained nurses 
during every visit to the anticoagulation clinic. If patients mentioned any bleeding event 
or hospitalization related to a bleeding, the information was noted in the electronically 
stored patient system and trained physicians from the anticoagulation clinic who were 
not involved in the study obtained information from the hospital, patient or general 
practitioner to classify the bleeding event as minor or major.
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Statistical analysis
Patients were considered exposed to an LMWH from the subscription date at the 
anticoagulant clinic until date of ceasing treatment with LMWHs plus an additional 2 
days washout period. Risks (cumulative incidences) and risk ratios were calculated and 
adjusted for study center by Mantel–Haenszel methods (10). Nadroparin o.d. was a 
priori chosen as the reference category in these analyses, as this was the most 
frequently used type of LMWH treatment. We adjusted only for study center as the 
choice of an LMWH agent is determined hospital-wide and therefore not related to 
patient characteristics. Furthermore, the choice of the vitamin K antagonist is strongly 
associated with the anticoagulation clinic, on which basis we assume that no other 
confounding factors than the anticoagulation clinic are present. A sensitivity analysis 
was performed where results were restricted to first venous thrombotic events because 
patients with a recurrent venous thrombotic event have different patient characteristics 
that also relate to bleeding risk (11). As a second sensitivity analysis, we computed 
incidence rates per 100 person-years to confirm that incidence rates would yield a 
similar pattern of risk estimates as cumulative incidences. Follow-up started from 
registration at the anticoagulation clinic until LMWH treatment was ceased, or the 
patient moved to a city that was not covered by the participating anticoagulation clinics, 
died or experienced a major bleeding, whichever occurred first. The maximum follow-
up was 90 days.
All analyses were performed with R version 2.15.2 (R Core Team (2014). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/).
R E S U L T S
The study cohort comprised 12 934 patients who experienced an acute venous 
thrombotic event (Figure 1 and Table 1). The mean age at baseline was 59 years 
(standard deviation, 17 years) and 6218 (48%) patients were male. Most patients were 
treated at the anticoagulation clinic in Rotterdam (3883 patients; 30%). A deep vein 
thrombosis (DVT) was the indication of treatment for 8058 patients (62%) and 4889 
patients (38%) experienced a pulmonary embolism (PE). In 11 237 (87%) patients the 
thrombotic episode concerned a first event; 6735 of these experienced a DVT. The 
remaining 1697 (13%) patients had a recurrent thrombotic episode, of whom 1326 
experienced a DVT. The most frequently used LMWHs were nadroparin o.d. (5317 
patients) and tinzaparin o.d. (3338 patients). 
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The median duration of treatment with LMWH (i.e. follow-up) was 5 days (interquartile 
range, 2 to 9 days, Table 2). In total, 32 of the 12 934 patients (corresponding cumulative 
incidence 2.47 per 1000 patients; 95% CI 1.74 to 3.49) experienced a major bleeding 
event during combined VKA and LMWH treatment. The cumulative incidence (per 1000 
patients) of major bleeding during combined treatment was 2.07 (95% CI, 1.11 to 3.75) 
in nadroparin o.d. users, 3.37 (95% CI, 1.48 to 7.10) in nadroparin b.i.d. users, 2.70 (95% 
CI, 1.33 to 5.20) in tinzaparin o.d. users, 3.79 (95% CI, 0.00 to 23.34) in enoxaparin o.d. 
or b.i.d. users and 2.06 (95% CI, 0.60 to 5.50) in dalteparin o.d. users (Table 2). The 
sensitivity analysis with incidence rates showed a similar pattern of risk estimates as 
Table 1.  Patient characteristics 
Nadroparin Nadroparin Tinzaparin Enoxaparin Dalteparin
o.d. b.i.d. o.d. o.d.
General characteristics
Patients 5317 2076 3338 264 1939
Male sex, n (%) 2657 (50) 904 (44) 1638 (49) 125 (47) 894 (46)
Age, years, mean (SD) 58 (17) 61 (18) 59 (16) 57 (17) 57 (17)
Indication VKA treatment
Deep vein thrombosis, n (%) 3402 (64) 1302 (63) 2042 (61) 137 (52) 1175 (61)
First, n (%) 2735 (80) 1093 (84) 1735 (85) 115 (84) 1057 (90)
Recurrent, n (%) 667 (20) 212 (16) 307 (15) 22 (16) 118 (10)
Pulmonary embolism, n (%) 1924 (36) 776 (37) 1298 (39) 127 (48) 764 (39)
First, n (%) 1695 (88) 731 (93) 1220 (94) 122 (96) 761 (100)
Recurrent, n (%) 229 (12) 59 (8) 78 (6) 5 (4) 3 (0)
Vitamin K antagonist
Acenocoumarol, n (%) 1399 (26) 1059 (51) 2204 (66) 223 (84) 1861 (96)
Phenprocoumon, n (%) 3918 (74) 1017 (49) 1134 (34) 41 (16) 78 (4)
Co-medication
Antihypertensive(s), n (%) 1137 (21) 373 (18) 511 (15) 38 (14) 54 (3)
Antidiabetic(s), n (%) 376 (7) 179 (9) 248 (7) 20 (8) 151 (8)
NSAID(s), n (%) 384 (7) 135 (7) 248 (7) 21 (8) 187 (10)
Anti-platelet drug(s), n (%) 152 (3) 100 (5) 138 (4) 13 (5) 112 (6)
Anticoagulation clinic
The Hague, n (%) 2409 (45) 611 (29) 587 (18) 18 (7) 20 (1)
Leiden, n (%) 1873 (35) 544 (26) 729 (22) 62 (23) 30 (2)
Rotterdam, n (%) 347 (7) 561 (27) 1079 (32) 89 (34) 1807 (93)
Utrecht, n (%) 688 (13) 360 (17) 943 (28) 95 (36) 82 (4)
o.d., once daily; b.i.d., twice daily; NSAID, non-steroidal anti-inﬂammatory drugs; SD, standard deviation.
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analysis with cumulative incidences, although incidence rates of major bleeding were 
high (7.3 to 16.7 per 100 person-years) (Supplementary Table 1). Risk ratios for the 
different LMWH agents were between 1.00 and 1.83 using nadroparin o.d. as reference 
LMWH and increased after adjustment for study center (Table 2). The relative risk 
estimate for nadroparin b.i.d. was 1.98 (95% CI, 0.76 to 5.14) as compared with 
nadroparin o.d. treatment. Patients with a first venous thrombotic event had similar 
cumulative incidences of major bleeding as patients with recurrent events.
D I S C U S S I O N
In this study, the absolute risk of major bleeding was low among patients who were 
registered at the anticoagulation clinic with an acute venous thrombotic event (between 
2.0 to 3.5 per 1000 patients during combined treatment with VKA and LMWH), which 
is similar to cumulative incidences reported in clinical trials (12). These figures indicate 
that the combination of a VKA and LMWH for a short period is relatively safe for these 
patients. Nevertheless, incidence rates of major bleeding were high (7.3 to 16.7 per 
100 person-years), indicating that the combination of VKAs and LMWHs should be used 
Figure 1. Flow chart of patients. VT, venous thrombosis; LMWH, low-molecular-weight heparin.
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for as short a time as possible. The relative risk estimates for major bleeding events 
were highest in patients treated with nadroparin b.i.d. and enoxaparin o.d. or b.i.d.. 
These results should nevertheless be interpreted with caution because numbers were 
small and confidence intervals showed that a similar risk of bleeding events for these 
LMWHs as compared with the other LMWHs cannot be ruled out. Given the small 
numbers, enoxaparin o.d. or b.i.d. treatment was associated with a higher bleeding 
risk than nadroparin o.d., tinzaparin o.d. and dalteparin o.d. treatment. These results 
are similar to what was found in a meta-analysis (12), where all LMWHs gave lower 
bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio 
[OR], 0.41; 95% CI, 0.14-1.17; tinzaparin OR, 0.30; 95% CI, 0.12-0.73; dalteparin OR, 0.15; 
95% CI, 0.02-1.44), whereas enoxaparin gave risk estimates around unity (OR, 1.14; 
95% CI, 0.50-2.16). Our results also indicate that nadroparin o.d. users were at lower 
risk for bleeding complications than nadroparin b.i.d. users. Although we cannot say 
with certainty that nadroparin b.i.d. dosing is more harmful as compared with o.d. 
dosing, these results are in line with a Cochrane review from previous trials in acute 
venous thrombosis patients. This review suggested that b.i.d. treatment with an LMWH 
results in higher bleeding rates as compared with o.d. treatment (relative risk, 1.29; 
Table 2.  Bleeding events associated with LMWH treatment
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All venous thrombotic events
Nadroparin o.d. 5317 11 6 (3 to 10) 2.07 (1.11-3.75) reference reference
Nadroparin b.i.d. 2076 7 5 (2 to 10) 3.37 (1.48-7.10) 1.63 (0.63-4.20) 1.98 (0.76-5.14)
Tinzaparin o.d. 3338 9 5 (2 to 8) 2.70 (1.33-5.20) 1.30 (0.54-3.14) 1.24 (0.46-3.58)
Enoxaparin 264 1 5 (2 to 8) 3.79 (0.00-23.34) 1.83 (0.24-14.13) 1.74 (0.17-17.46)
Dalteparin o.d. 1939 4 4 (2 to 7) 2.06 (0.60-5.50) 1.00 (0.32-3.13) 4.19 (0.47-37.00)
First venous thrombotic event
Nadroparin o.d. 4425 9 6 (3 to 10) 2.03 (1.01-3.93) reference reference
Nadroparin b.i.d. 1805 7 5 (2 to 9) 3.88 (1.70-8.16) 1.91 (0.71-5.11) 2.32 (0.85-6.31)
Tinzaparin o.d. 2953 8 5 (2 to 8) 2.71 (1.27-5.44) 1.33 (0.51-3.45) 2.30 (0.92-5.78)
Enoxaparin 273 1 5 (2 to 8) 3.66 (0.00-22.58) 1.80 (0.23-14.16) 1.98 (0.19-21.09)
Dalteparin o.d. 1819 3 4 (2 to 7) 1.65 (0.32-5.08) 0.81 (0.22-2.99) 3.97 (0.42-37.59)
* Adjusted for study center and academic hospital by Mantel–Haenszel method. LMWH, low-molecular-weight 
heparin; IQR, interquartile
range; CI, conﬁdence interval; o.d., once daily; b.i.d., twice daily
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95% CI, 0.79-2.50) (13). In addition, another study showed that o.d. dosing of enoxaparin 
was associated with fewer major bleeding events as compared with b.i.d. dosing (14). 
Furthermore, one trial showed that nadroparin b.i.d. gave higher rates of bleeding 
complications as compared with o.d. (relative risk, 1.64; 95% CI, 0.74-3.57) (15). When 
combining results from our study and the latter study in a post hoc meta-analysis with 
a random effects model, the OR indicates a 1.77 increased risk (95% CI, 0.97-3.23) for 
patients using b.i.d. nadroparin as compared with o.d. nadroparin.
Some methodological aspects of our study need comment. First, this study evaluated 
bleeding risks in a large population of unselected venous thrombosis patients from 
four anticoagulation clinics, which makes our results generalizable to the community. 
However, as a limitation, patients were included after registration at the anticoagulation 
clinic, which is usually a couple of days after the diagnosis of a venous thrombotic event 
at the hospital. During these few days, we could have missed the bleeding events. If 
so, this would have influenced the absolute bleeding rates found in our study. 
Therefore, our results are only applicable to patients discharged from hospital. A 
second limitation is that few bleeding events occurred, which resulted in statically 
non-significant differences and prevented us from performing several subgroup 
analyses in patients who are potentially at high risk of major bleeding. The small 
numbers also hamper the robustness of our results and may have inflated the risk 
estimate of bleeding events in the enoxaparin o.d. or b.i.d. group. In addition, we were 
not able to stratify enoxaparin treatment by o.d. and b.i.d. use because of small 
numbers and we had no patients who used a dalteparin b.i.d. regimen. Another 
limitation is that we were only able to adjust for study center. However, the choice of 
LMWH is not based on patient characteristics, but based on the preference of the 
hospital where the patient presents him or herself for a specific type of LMWH. 
Therefore, we assume that patient characteristics are not associated with the type of 
LMWH prescribed and therefore consider it unlikely that residual confounding has 
influenced our results. Still, we cannot rule out that doctors may have opted, for 
example, to treat patient with low renal function with twice-daily LMWH instead of 
once-daily LMWH, which could have led to residual confounding in our study. Therefore, 
results might have been more precise if our study had been set up to specifically answer 
the question being asked in this study, as the dosing schedule of LMWH would have 
been more appropriately documented as well as other details.
In conclusion, the absolute risk for major bleeding complications during treatment 
with LMWH and VKA in patients with an acute venous thrombosis who were treated 
at an anticoagulation clinic was low, with an approximate risk of 2.5 per 1000 patients. 
These low risks prevented us from concluding whether one LMWH should be preferred 
over the other. Furthermore, nadroparin b.i.d. appeared to be associated with an 
increased risk of major bleeding as compared with nadroparin o.d., which is in 
accordance with the literature. 
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S U P P L E M E N T A R Y
Table 1. Bleeding events associated with LMWH treatment 
Follow-up 
(years)
Events Cumulative incidence 
per 1000
Incidence rate 
per 100 person-years
All venous thrombotic events
Nadroparin o.d. 151 11 2.07 (1.11-3.75) 7.3 (3.8-12.7)
Nadroparin b.i.d. 59 7 3.37 (1.48-7.10) 11.9 (5.2-23.5)
Tinzaparin o.d. 82 9 2.70 (1.33-5.20) 11.0 (5.4-20.1)
Enoxaparin 6 1 3.79 (0.00-23.34) 16.7 (8.3-82.2)
Dalteparin o.d. 40 4 2.06 (0.60-5.50) 10.0 (31.8-24.1)
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S U M M A R Y
Patients receiving vitamin K antagonists are monitored by regular assessment of the 
International Normalized Ratio (INR). There are two popular methods for therapeutic 
control of anticoagulation in patient groups: 1) Time in Therapeutic Range (TTR) 
assessed by linear interpolation of successive INR measurements; 2) the cross-sectional 
proportion (CSP) of all patients’ last INRs within range. The purpose of the present 
study is to compare the two methods using data from 53 Dutch Thrombosis Centres 
and to develop a semi-quantitative model for TTR based on different types of INR 
change. Different groups of around 400,000 patients in four consecutive years were 
evaluated: patients in the induction phase, short-term, long-term, low-target range, 
high-target range, receiving either acenocoumarol or phenprocoumon, and performing 
self-management. Each Centre provided TTR and CSP results for each patient group. 
TTR and CSP were compared using the Wilcoxon signed-rank test. Separately, we 
analysed the relationship between consecutive INR results regarding in or out of range 
and their frequency of occurrence in patients of two different cohorts. Good correlation 
was observed between TTR and CSP (correlation coefficient 0.694–0.950 in low-target 
range). In long-term acenocoumarol patients (low-target range) the median TTR was 
significantly higher than CSP (80.0 % and 78.7 %, respectively; p<0.001). In long-term 
phenprocoumon patients (low-target range) there was no significant difference 
between median TTR (83.0 %) and median CSP (82.6 %). In conclusion, the correlation 
between TTR assessed by linear interpolation and CSP was good. TTR assessed by 
linear interpolation was higher than CSP in patients on acenocoumarol.
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I N T R O D U C T I O N 
Effectiveness and safety of treatment with vitamin K antagonists (VKA) depends on the 
intensity and quality of control of anticoagulation (1,2). During VKA treatment, the 
prothrombin time expressed as international normalised ratio (INR) is monitored and 
VKA doses are adjusted if necessary in order to achieve INR values within a specified 
therapeutic or target range. Different methods have been used to assess the level of 
therapeutic control: a cross-sectional method based on the proportion of INR test 
results in range at one point in time (3), and a longitudinal method based on linear 
interpolation of successive INR measurements to obtain the proportion of person-time 
spent in range which is referred to as TTR (time in therapeutic range) (4–6). The cross-
sectional method is useful only for assessment of average therapeutic control for a 
group of patients and not for an individual patient (3). The longitudinal TTR method is 
useful for assessment in an individual patient as well as a group of patients. Apart from 
the two above-mentioned methods for assessment of the quality of anticoagulation 
there are other methods. One of these is the percentage of INRs within the therapeutic 
range (PINRR). The PINRR method utilizes the number of INRs within the target range 
divided by the overall number of INRs during the selected time interval (7–10). The 
PINRR is simple to calculate but more frequent testing in unstable patients may bias 
overall results (7). Other methods have been described that are modifications of the 
original longitudinal TTR method using imputation of INR values between pairs of INR 
measurements (11,12).
Observational studies have reported strong associations between group means of 
individual patients’ TTR and reduced risks of ischaemic stroke and major bleeding in 
patients with atrial fibrillation (12–14). For effective stroke prevention therapy in 
patients with atrial fibrillation it has been recommended to use either well-controlled 
VKA therapy with a high percentage of time in the therapeutic range (for example, at 
least 70%) or one of the novel direct-acting oral anticoagulant drugs (15,16).
In the Netherlands the vast majority of patients receiving VKA are monitored by 56 
Thrombosis Centres, which are members of the Dutch Federation of Thrombosis 
Centres. These centres achieved consensus on the intensity of anticoagulation for the 
various indications for treatment (17,18). Low-intensity anticoagulation (target range 
INR 2.5–3.5; therapeutic range INR 2.0–3.5) has been used for patients with atrial 
fibrillation and venous thromboembolism (VTE). High-intensity anticoagulation (target 
range INR 3.0–4.0; therapeutic range INR 2.5–4.0) has been used for primary and 
secondary prevention of arterial thromboembolism, in patients with mechanical heart 
valve prostheses, and in patients with recurrent VTE despite VKA treatment. The target 
range was set higher than the internationally advised target range to prevent 
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inadequate anticoagulation (6). Approximately 80 % of patients are treated with low-
intensity and 20 % with high-intensity anticoagulation. In the Netherlands, two different 
VKA drugs are used, i. e. acenocoumarol (short acting; half-life 12 hours [h]) and 
phenprocoumon (long acting; half-life 160h). Acenocoumarol is used for approximately 
77 % of patients, and phenprocoumon for approximately 23 % of patients. The majority 
of the Dutch Thrombosis Centres reported therapeutic quality control data both in 
terms of the cross-sectional method and in terms of the longitudinal method (19). It 
has not been established which of the two methods gives a better overall assessment 
of the control achieved by a Thrombosis Centre. The longitudinal method proposed 
by Rosendaal et al assumes that the INR between two measurements varies linearly 
from the first INR to the second INR (linear interpolation) (4). It is our hypothesis that 
the longitudinal method using linear interpolation of successive INR measurements is 
based on a simplification of the true time course and gives an overestimation of the 
TTR as will be explained in Methods. The purpose of the present study is to compare 
and evaluate the two methods using the data published by the Federation of the Dutch 
Thrombosis Centres for the years 2010, 2011, 2012 and 2013. A semi-quantitative 
model is presented to explain the overestimation of TTR.
M E T H O D S
Calculation of cross-sectional proportion of INRs in the therapeutic range and 
proportion of time in the therapeutic range
Each Thrombosis Centre reviewed INR results for all active patients and calculated the 
percentage of patients for whom the last INR was within the therapeutic range at two 
fixed dates (March 31 and October 31) each year (17,18). The mean of the two 
assessmentswas used for the statistical analysis. This method is referred to as the 
cross-section -of-the-files method because only one INR result – of each patient is used. 
The percentage calculated with this method is referred to as the cross-sectional 
proportion (CSP).
In addition, each Thrombosis Centre used a method to estimate the percentage of 
time that each patient spent in the therapeutic range (TTR). In the latter method, the 
time between two INR measurements is divided in days and small steps of 0.1 INR over 
the range of the time interval (4). In this approach, the INR is treated as gradually 
increasing or decreasing over the time interval. This method is referred to as TTR by 
linear interpolation (LI). TTR(LI) is expressed as the proportion of the total person-time 
that lies within the range. Advantages and disadvantages of the cross-section-of-the-
files method and the TTR are shown in Table 1. The cross-section-of-the-files method 
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is not useful for a single patient but can be used for a group of patients, e.g. all longterm 
patients monitored by one Thrombosis Centre. 
CSP and TTR(LI) were assessed for various groups of patients. Patients receiving vitamin 
K antagonists are classified as induction phase (first 6 weeks of treatment), as short-
term (longer than 6 weeks up to 6 months), or as long-term (longer than 6 months). 
Patients’ data were provided anonymously for statistical analysis. Hence the data could 
not be traced back to the patients’ identification and informed consent was not 
required. Thrombosis Centres used various (commercial) computer algorithms for 
anticoagulant dosing (20). At least five different computer systems were used by 
multiple Dutch Thrombosis Centres, e. g. Portavita, TDAS, Trodis, Glims, and Tromis 
(19). To study the influence of the computer algorithm used we compared TTR(LI) and 
CSP for Portavita centres only and for the non-Portavita centres using the combined 
data of four years.
Statistical methods
The Wilcoxon signed-ranks test was used to compare CSP with the TTR(LI) results 
obtained in each year. Spearman’s coefficient (rho) for bivariate correlation between 
CSP and TTR(LI) was calculated. In addition, the pooled results from 2010, 2011, 2012 
and 2013 were analysed with the above-mentioned statistical tests. P-values of less 
than 0.05 were considered statistically significant. Statistical analyses were performed 
with SPSS 20 (IBM Corporation, Armonk, NY, USA) for Windows.
 
Model for INR change
Here we develop a model which may assist us to explain the difference between TTR(LI) 
and the true TTR. Four hypothetical examples of the time course of INR between 
successive measurements are shown in Figure 1. In Figure 1A, two successive measure-
ments are both within the therapeutic range. Evidently TTR(LI) is 100 % for this case. 
Table 1. Advantages and disadvantages of methods to assess therapeutic control 
Method Advantage Disadvantage
Cross-section-of-the-files • Simple to calculate.
• Does not make assumptions about 
INR between actual tests.
• Only considers one point in time.
• Not useful for single patient.
TTR by linear interpolation • Takes into account estimated 
time in therapeutic range.
• Useful for single patient.
• Allows calculation of INR specific 
incidence rates of adverse events.
• Calculation more difficult.
• Makes assumptions about INR 
between actual tests.
TTR, Time in Therapeutic Range. Modified from Schmitt et al. (7).
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In reality, this patient’s INR may have been out of range for some time and the true 
TTR is less than 100 %. In Figure 1C, two successive measurements are both out of 
range at the same side of the range. Evidently TTR(LI) is 0 %. In reality, this patient’s 
INR may have been within the range for some time between measurements and the 
true TTR may be greater than 0 %. Figure 1B represents a situation where one 
measurement is within the range and the other out of range. In this case both TTR(LI) 
and the true TTR are between 0 and 100 %. The depicted true course in Figure 1B would 
give a lower TTR than TTR(LI). It should be realised that many other true courses are 
possible in Figure 1B but the mean true TTR of all possible courses cannot be predicted. 
Figure 1D represents a situation in which two successive measurements are both out 
of range on opposite sides of the range. The true course depicted in Figure 1D would 
give a lower TTR than TTR(LI). Again, there are many other possible true courses for 
two consecutive INR measurements on opposite sides of the range, but the mean true 
TTR cannot be predicted with certainty. The hypothetical examples shown in Figure 1 
refer to individual patients. To assess the total effect of linear interpolation for a group 
of real patients, we would like to know the frequency of the different types of INR 
Figure 1.  Schematic time-course of INR in individual patients. Four hypothetical examples are shown in 
panels A, B, C, and D, respectively. Horizontal lines at INR 2.0 and 3.5 represent the borders of the therapeutic 
range. Interrupted lines represent the linear interpolation between successive INR measurements. The drawn 
continuous lines represent  examples of the true course of INR between successive measurements.
101
CONTROL OF ANTICOAGULATION WITH VKA: AGREEMENT BETWEEN TTR AND CSP
7
change. This information is not available from the annual medical reports of the 
Netherlands Federation of Thrombosis Services (19) and was obtained from a previous 
study (see below).
Assessment of frequency of INR change
Recently, a retrospective cohort study was performed using the data from the 
anticoagulation clinic of the Star-Medical Diagnostic Center at Rotterdam (21). We used 
the data from this study to assess the relative frequency of the different types of INR 
change in each patient. The study population consisted of two independent cohorts 
that were followed up for one year. One cohort was monitored using a laboratory 
method for venous plasma (STA Hepato Quick) and the other cohort was monitored 
using a point-of-care method for capillary blood (CoaguChek XS Pro). 1555 Patients in 
the first cohort and 1589 patients in the second cohort were treated with acenocoumarol 
(therapeutic range: INR 2.0–3.5). The number of INR measurements in the 
aforementioned patients was 30,003 and 33,060, respectively. We assessed the 
relationships between consecutive INR results with respect to in or out of range in each 
patient and calculated their frequency of occurrence. Finally, we added the numbers 
of the different categories of INR change for all patients in each cohort to calculate the 
frequency of each category of change.
R E S U L T S
The total number of patients monitored by the members of the Dutch Federation of 
Thrombosis Centres was 398,312 in 2010, 408,869 in 2011, 417,594 in 2012 and 438,411 
in 2013 (19). The number of treated patients per year by each Thrombosis Centre varied 
from approximately 600 to approximately 27,000 (19). Table 2 shows some 
characteristics of the patients monitored by the members of the Dutch Federation of 
Thrombosis Centres. The majority of patients were treated for arterial indications (e.g. 
atrial fibrillation). In the period 2010–2013 there was a steady increase not only of the 
absolute number of patients treated for atrial fibrillation, but also as a percentage of 
all arterial indications.
Comparison of CSP and TTR(LI)
The majority of Thrombosis Centres provided results for CSP and TTR(LI) calculated 
with their own computer algorithms. The median CSP and TTR(LI) results stratified by 
treatment duration are shown in Table 3. In almost all cases, the median TTR(LI) was 
higher than the median CSP. The results shown in Table 3 were obtained irrespective 
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Table 2. Indications for Vitamin K antagonist treatment
Year N All venous 
indications
All arterial 
indications
Various arterial indications
Atrial 
fibrillation
Mechanical 
heart valve 
protheses
Other arterial 
indications
2010 58 15.9 ± 3.5 84.1 ± 3.5 69.3 ± 4.6 7.7 ± 1.7 23.0
2011 58 16.3 ± 3.9 83.7 ± 3.9 72.3 ± 4.6 7.4 ± 1.7 20.3
2012 55 15.2 ± 3.1 84.8 ± 3.1 74.0 ± 4.6 7.2 ± 1.8 18.8
2013 54 15.8 ± 3.2 84.2 ± 3.2 76.6 ± 3.9 6.7 ± 1.6 16.7
Mean percentages of patients with venous indications, arterial indications, atrial fibrillation (in % of arterial 
indications), mechanical heart valve prostheses (in % of arterial indications), and other arterial indications (e. 
g. coronary disease and surgery, cardiomyopathy, cerebral embolism). N is the number of Thrombosis Centres. 
SD is the between-centre standard deviation.
Table 3.  Therapeutic control in patients by duration of treatment
Treatment 
duration
Year N Therapeutic Range: INR 2.0 – 3.5 Therapeutic Range: INR 2.5 – 4.0
CSP 
(%)
TTRLI 
(%)
Wilcoxon Correlation 
coefficient
CSP 
(%)
TTRLI 
(%)
Wilcoxon Correlation 
coefficient
Induction 2010 48 62.5 67.5 P= 0.000 0.766 55.6 58.8 P= 0.001 0.552
2011 52 65.4 68.5 P= 0.000 0.769 57.8 58.1 P= 0.109 0.350
2012 53 65.0 70.0 P= 0.000 0.778 57.1 59.3 P= 0.102 0.282
2013 52 65.0 68.3 P= 0.000 0.694 55.8 58.0 P= 0.201 0.362
All 205 64.7 68.3 P= 0.000 0.765 56.7 58.9 P= 0.000 0.380
Short-term 2010 48 74.4 77.0 P= 0.001 0.793 65.4 69.2 P= 0.001 0.660
2011 52 76.4 78.6 P= 0.001 0.826 66.3 69.8 P= 0.001 0.605
2012 53 77.8 78.9 P= 0.002 0.851 71.0 70.9 P= 0.405 0.536
2013 52 77.2 78.1 P= 0.008 0.847 65.0 68.5 P= 0.013 0.555
All 205 76.2 78.0 P= 0.000 0.833 66.6 69.8 P= 0.000 0.597
Long-term 2010 48 77.9 78.9 P= 0.000 0.908 72.7 74.0 P= 0.000 0.771
2011 52 79.8 80.8 P= 0.000 0.856 73.2 75.3 P= 0.000 0.894
2012 53 80.3 81.5 P= 0.000 0.900 74.2 75.0 P= 0.000 0.890
2013 52 80.4 81.0 P= 0.019 0.950 73.3 75.0 P= 0.000 0.849
All 205 79.9 80.9 P= 0.000 0.910 73.4 75.0 P= 0.000 0.862
The median values of CSP and TTR(LI) are given. N is the number of Thrombosis Centres in each year for each 
therapeutic range or the total number of comparisons between CSP and TTR over all the years.
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of the type of VKA used.  The median CSP and TTR(LI) for long-term patients on either 
acenocoumarol or phenprocoumon are given in Table 4. For acenocoumarol, the 
median TTR(LI) was always significantly higher than the median CSP. As an example of 
the correlation between TTR(LI) and CSP, a scatterplot for long-term patients receiving 
acenocoumarol is shown in Figure 2. Practically all Thrombosis Centres had TTR(LI) and 
CSP values higher than 70%. For phenprocoumon, in seven out of eight comparisons 
during the years 2010-2013, differences between TTR(LI) and CSP were not significant 
(Table 4). Several Thrombosis Centres had only few long-term patients on 
phenprocoumon. To avoid conclusions based on inclusion of centres with few patients, 
a separate analysis was performed of centres with more than 1000 long-term patients 
per year in the 2.0 -3.5 INR therapeutic range. This analysis showed that TTR(LI) was 
significantly greater than CSP for the acenocoumarol patients (Table 4). Separately, we 
selected 9-12 centres with more than 1000 long-term phenprocoumon patients. TTR(LI) 
and CSP were not significantly different for the selected centres (Table 4). 
Figure 2. Scatterplot of TTR(LI) (%) versus CSP (%) . Data of long-term patients receiving acenocoumarol are 
shown. Therapeutic range: INR 2.0 – 3.5. Year: 2012. Each symbol represents the assessments of one Thrombosis 
Centre. The number of Thrombosis Centres is 53. Spearman’s coefficient of correlation is 0.915. The line of 
identity (Y = X) is shown for comparison.
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In the vast majority of the Thrombosis Centres, a proportion of the patients performed 
self-management using a point-of-care whole blood monitor for INR determination. 
This proportion varied from 2% to 15% of the patients. Patient self-management means 
that the patients are enabled to measure their own INR, to interpret the result, and to 
make adjustments to their VKA dosage by themselves (22).  Patients who measure their 
own INR but do not make dosage adjustments are considered as regular patients and 
their results are included in Tables 3 and 4. CSP and TTR(LI) for self-management 
patients are given in Table 5. TTR(LI) was significantly higher than CSP. The results 
shown in Table 5 were obtained irrespective of the type of VKA used.
In most cases, the correlation coefficients between TTR(LI) and CSP were higher for the 
low target patients (Therapeutic range: INR 2.0 – 3.5) than for the high target 
(Therapeutic range: INR 2.5 – 4.0). There was a trend of increasing correlation 
coefficients between TTR(LI) and CSP with increasing treatment duration (Table 3).
Different dosing algorithms were used by the Thrombosis Centres. Of all computer 
algorithms, the “Portavita” system was used by approximately 26% (in 2010) to 44% (in 
2013) of centres. We compared TTR(LI) and CSP for Portavita centres only and for the 
Table 4. Therapeutic control in long-term patients by type of vitamin K antagonist  
Vitamin K 
antagonist
Year Therapeutic Range: INR 2.0 – 3.5 Therapeutic Range: INR 2.5 – 4.0 
N CSP 
(%)
TTRLI 
(%)
Wilcoxon Corr. 
Coeff.
N CSP 
(%)
TTRLI 
(%)
Wilcoxon Corr. 
Coeff.
Acenocoumarol 2010 48 76.6 78.0 P= 0.000 0.795 48 71.2 73.7 P= 0.000 0.626
2011 52 79.1 80.2 P= 0.000 0.807 52 71.7 74.4 P= 0.000 0.667
2012 53 78.8 80.9 P= 0.000 0.915 53 72.7 74.4 P= 0.000 0.814
2013 52 79.9 80.2 P= 0.008 0.948 52 72.0 74.0 P= 0.001 0.870
All 205 78.7 80.0 P= 0.000 0.876 205 71.8 74.3 P= 0.000 0.741
All* 177 78.3 79.5 P= 0.000 0.893 39 73.0 75.0 P= 0.000 0.913
Phenprocoumon 2010 48 81.6 82.0 P= 0.948 0.695 48 77.6 78.0 P= 0.383 0.598
2011 52 82.3 82.5 P= 0.425 0.758 52 78.9 79.0 P= 0.750 0.550
2012 53 83.9 83.7 P= 0.296 0.792 53 79.1 80.2 P= 0.035 0.653
2013 52 83.2 83.1 P= 0.545 0.860 52 77.8 78.2 P= 0.332 0.714
All 205 82.6 83.0 P= 0.757 0.817 205 78.4 79.0 P= 0.249 0.626
All* 42 83.8 83.8 P= 0.756 0.924 - - - - -
The median values of CSP and TTR(LI) are given. N is the number of Thrombosis Centres in each year or the 
total number of comparisons between CSP and TTR over all the years. A separate analysis was performed for 
Thrombosis Centres with more than 1000 patients (All*). *Only Thrombosis Centres with more than 1000 
patients.
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non-Portavita centres and observed similar differences (not shown), suggesting that 
findings were independent of the computer dosing algorithm used.
Assessment of frequency of INR change
Table 6 shows the nine different categories of INR change between two consecutive 
measurements in patients on acenocoumarol (therapeutic range: INR 2.0 – 3.5) in a 
cohort study (21). For each patient and for each pair of consecutive INR measurements, 
the category of change was determined. Then the total number and proportion of 
cases in each category was determined. The proportion of paired measurements within 
the therapeutic range was 52.4% in the first cohort and 47.6% in the second. The 
proportion of paired measurements for which both INRs were out of the therapeutic 
range on the same side of the range was small (7.7% and 8.5%, respectively). As 
expected, the number of cases in which INRs crossed a border of the therapeutic range 
in one direction was similar to the number of cases in which INRs crossed the same 
border in the opposite direction. 
Table 5. Therapeutic control in long-term patients performing self-management
Year N Therapeutic Range: INR 2.0 – 3.5 Therapeutic Range: INR 2.5 – 4.0
CSP 
(%)
TTLI 
(%)
Wilcoxon Correlation 
coefficient
CSP (%) TTLI 
(%)
Wilcoxon Correlation 
coefficient
2010 32 80.3 82.8 P= 0.000 0.855 77.2 79.4 P= 0.002 0.519
2011 40 81.6 83.3 P= 0.000 0.566 76.9 79.6 P= 0.000 0.531
2012 45 82.7 84.7 P= 0.000 0.819 77.9 80.3 P= 0.000 0.702
2013 46 82.2 84.1 P= 0.000 0.837 77.6 79.4 P= 0.002 0.669
All 163 81.9 83.8 P= 0.000 0.757 77.6 79.9 P= 0.000 0.617
The median values of CSP and TTR(LI) are given. N is the number of Thrombosis Centres in each year for each 
therapeutic range or the total number of comparisons between CSP and TTR over all the years.
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D I S C U S S I O N
The present study was an analysis of data published by the Dutch Federation of 
Thrombosis Centres. The purpose of our study was to compare TTR(LI) with CSP using 
data from the majority of VKA users in the Netherlands. In general, there was good 
correlation between the two methods to evaluate control of anticoagulation in groups 
of patients, which is in agreement with a previous single-centre study (6). TTR(LI) was 
slightly higher than CSP in most comparisons. The greatest difference between the two 
methods was observed for patients in the induction phase of treatment (Table 3) and 
the smallest difference for long-term patients receiving phenprocoumon (Table 4).
Our working hypothesis is that the probability to find an individual patient’s INR at any 
time in the therapeutic range is equal to the true proportion of time spent in the 
therapeutic range. Therefore, CSP is expected to be equal to TTR. Why then is TTR(LI) 
slightly greater than CSP? It should be realized that the true TTR cannot be determined 
and that TTR(LI) is an approximation of the true TTR, because the assumed linear INR 
change is an approximation of the true time-course. In contrast, CSP is calculated 
independently from any model of the INR time-course in individual patients. CSP is 
always calculated for one point in time. TTR(LI) is calculated for a certain time interval, 
e.g. one year. The patients used for calculation of CSP were not completely the same 
as the patients used for calculation of TTR(LI) because some patients included in TTR(LI) 
may have stopped anticoagulation treatment before CSP was calculated. It is unlikely 
Table 6. Number of INR changes between two consecutive measurements in acenocoumarol patients 
with therapeutic range INR 2.0 – 3.5 
Type of INR change between two consecutive 
measurements
STA Hepato Quick 
(Cohort #1)
CoaguChek XS Pro 
(Cohort #2)
First measurement Second measurement Number (% of total) Number (% of total)
2.0 < INR < 3.5 2.0 < INR < 3.5 14,916 (52.4 %) 14,990 (47.6 %)
2.0 < INR < 3.5 INR > 3.5 3,500 (12.3 %) 4,049 (12.9 %)
2.0 < INR < 3.5 INR < 2.0 1,713 (6.0 %) 2,121 (6.7 %)
INR < 2.0 2.0 < INR < 3.5 1,939 (6.8 %) 2,366 (7.5 %)
INR < 2.0 INR < 2.0 754 (2.7 %) 868 (2.8 %)
INR < 2.0 INR > 3.5 370 (1.3 %) 593 (1.9 %)
INR > 3.5 2.0 < INR < 3.5 3,327 (11.7 %) 3,904 (12.4 %)
INR > 3.5 INR < 2.0 509 (1.8 %) 791 (2.5 %)
INR > 3.5 INR > 3.5 1,420 (5.0 %) 1,789 (5.7 %)
The frequency of INR changes is given in percent. Two independent cohorts were analysed, each cohort being 
monitored with a different prothrombin time reagent (STA Hepato Quick and CoaguChek XS Pro, respectively).
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that the difference in individual patients could completely explain the consistently 
observed pattern of differences between CSP and TTR(LI).
In this paper we present a model for the change of INR with regard to the calculation 
of TTR(LI). The relative frequency of the different types of INR change shown in Figure 
1 may help us to explain the difference between TTR(LI) and CSP. Since the majority of 
INR measurements is within the therapeutic range, situation 1A occurs more often 
than situation 1C, which is confirmed by observed frequencies in the cohort study 
(Table 6). INR changes within the therapeutic range (situation 1A) that may overestimate 
TTR(LI) occur approximately 5-7 times more frequently than INR changes that may 
underestimate TTR(LI) (Table 6).  As a result, the true TTR summed over all patients will 
be less than the TTR(LI) and therefore calculation of TTR(LI) will result in an 
overestimation of the true TTR. A limitation of our semi-quantitative model is that we 
cannot predict the exact magnitude of the difference between TTR(LI) and the true 
TTR. The difference between TTR(LI) and the true TTR will depend on the magnitude 
of INR variation over time. If the within-subject INR variation is increased, there will be 
an increased probability that the INR deviates from a straight-line path between 
successive measurements. INR variation will be greater in the induction phase of 
treatment than in patients who are treated for more than 6 months (i.e. long-term 
treatment). Therefore, the difference between TTR(LI) and the true TTR will be greater 
in the induction phase than in the long-term steady state of treatment. Other 
investigators concluded that the validity of the linear interpolation method could be 
improved by using a hybrid method that takes into account potential effects of dosage 
modifications when INRs are far out of the target range (11).
INR variation is also greater in patients receiving the short-acting acenocoumarol than 
in patients receiving the long-acting phenprocoumon (23). This can explain why the 
difference between TTR(LI) and CSP is smaller for phenprocoumon than for 
acenocoumarol. When there is more variation of INR, there is greater probability that 
the INR is out of therapeutic range between two successive measurements which are 
both within the range. In long-term patients receiving phenprocoumon, the variation 
of INR is smaller compared to acenocoumarol and the linear interpolation may be a 
good approximation of the true time course of INR.
Our study is limited to patients treated with acenocoumarol and phenprocoumon. 
Warfarin (half-life 40 h) is not used in the Netherlands. Other investigators compared 
therapeutic control in warfarin treated patients to that in acenocoumarol treated patients 
using the cross-sectional method (24). They reported that the cross-sectional method 
did not show any difference between the two drugs (24). Furthermore, daily fluctuations 
of factor VII levels were similar with both drugs (24). It seems that warfarin is more similar 
to acenocoumarol than to phenprocoumon with regard to the pharmacodynamics and 
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INR variability. Further studies should be performed to investigate whether the difference 
between CSP and TTR(LI) is also observed in warfarin patients. 
The strength of our study is the large number of Thrombosis Centres, patients and INR 
measurements used for the analysis. Because of the large numbers, the pattern of 
differences between TTR and CSP could consistently be evaluated with adequate power 
thereby reducing the risk of observations by chance. A limitation of our study is that 
the number of patients varied between the individual Thrombosis Centres but 
nevertheless the data from each centre were treated with equal weight. It has been 
stated that CSP determined for few patients may be unrealistic (5). However, when our 
analysis was limited to centres with a large number of patients, i.e. those with at least 
1000 long-term patients per year, similar differences between CSP and TTR(LI) were 
obtained and the statistical significance of the differences did not change. A second 
limitation of our study is that we cannot perform an analysis of the same data with 
other methods such as the PINRR (8-10) or a hybrid method that takes into account 
potential effects of dosage modifications when INRs are far out of the target range 
(11,12). We would like to emphasise that our data apply to the evaluation of the quality 
of anticoagulation of a Thrombosis Centre and cannot be applied to the single patient. 
Despite these limitations it is reassuring that in nearly all Dutch Thrombosis Centres 
the median of percentage long-term patients within the low-intensity therapeutic range 
was at least 70%. The high overall median TTR(LI) for long-term patients (Table 3) with 
respect to other reports (12, 25-27) may be explained in part by the use of long-acting 
phenprocoumon, and in part by the slightly wider therapeutic range (e.g. INR 2.0-3.5, 
rather than 2.0-3.0). By comparing Tables 3 and 5, it can be concluded that therapeutic 
quality of long-term patients performing self-management is at least as good or even 
better than the quality of long-term patients managed by the regular system, in 
agreement with a previous study (28). 
In conclusion, we have shown that there is good correlation between TTR assessed by 
linear interpolation and CSP obtained by Dutch Thrombosis Centres. Our model, which 
is based on observed frequencies of the relationship between consecutive INR 
measurements, predicts that the linear interpolation method overestimates the true 
TTR. The  difference between TTR and CSP is greater in the induction phase than in the 
long-term steady state phase of anticoagulation and is greater in acenocoumarol 
patients than in phenprocoumon patients.
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S U M M A R Y
Patients on vitamin K antagonists (VKA) often undergo invasive dental procedures. 
International guidelines consider all dental procedures as low-risk procedures, while 
bleeding risk may differ between standard low-risk (e.g. extraction 1-3 elements) and 
extensive high-risk (e.g. extraction of >3 elements) procedures. Therefore current 
guidelines may need refinement. In this cohort study, we identified predictors of oral 
cavity bleeding (OCB) and evaluated clinical outcome after low-risk and high-risk dental 
procedures in patients on VKA. Perioperative management strategy, procedure risk, 
and 30-day outcomes were assessed for each procedure. We identified 1845 patients 
undergoing 2004 low-risk and 325 high-risk procedures between 2013 and 2015. OCB 
occurred after 67/2004 (3.3%) low-risk and 21/325 (6.5%) high-risk procedures (P=0.006). 
In low-risk procedures, VKA continuation with tranexamic acid mouthwash was 
associated with a lower OCB risk compared to continuation without mouthwash 
[OR=0.41, 95%CI 0.23-0.73] or interruption with bridging [OR=0.49, 95%CI 0.24-1.00], 
and a similar risk as interruption without bridging [OR=1.44, 95%CI 0.62-3.64]. In high-
risk procedures, VKA continuation was associated with an increased OCB risk compared 
to interruption [OR=3.08, 95%CI 1.05-9.04]. Multivariate analyses revealed bridging, 
antiplatelet therapy, and a supratherapeutic or un-objectified INR before the procedure 
as strongest predictors of OCB. Non-oral cavity bleeding (NOCB) and thromboembolic 
event (TE) rates were 2.1% and 0.2%. Bridging therapy was associated with a two-fold 
increased risk of NOCB [OR=1.93, 95%CI 1.03-3.60], but not with lower TE rates. In 
conclusion, predictors of OCB were mostly related to perioperative management and 
differed between low-risk and high-risk procedures. Perioperative management should 
be differentiated accordingly.
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I N T R O D U C T I O N 
Due to the high prevalence of cardiovascular disease worldwide, millions of people 
currently receive oral anticoagulants such as vitamin K antagonists (VKA). Patients on 
VKA often require invasive dental procedures for which they require periprocedural 
VKA management. The bleeding risk after dental procedures in these patients is higher 
than in individuals without VKA therapy (1). Various studies have compared different 
management strategies in order to minimise the risk of oral cavity bleeding after dental 
procedures, without increasing the risk of thromboembolic complications (2-4). 
However, most of these studies included only small numbers of patients and were 
underpowered to detect differences in bleeding rates between different management 
strategies. Current guidelines and guidance documents have suggested that VKA 
therapy can safely be continued with co-administration of a local pro-haemostatic 
agent (e.g. tranexamic acid [TXA] mouthwash) during low bleeding risk dental 
procedures (5-8). However, these guidelines do not differentiate between low and high 
bleeding risk dental procedures in their recommendations on VKA-management. 
Differentiating into these categories may lead to clearer and safer perioperative 
strategies. The use of preoperative international normalised ratio (INR) values in these 
guidelines and standardised VKA management probably makes the bleeding risk in 
patients on warfarin similar to that of patients on acenocoumarol or phenprocoumon 
and vice versa. 
The goals of the present study were to evaluate, in a real world setting, VKA management 
and clinical outcome after low-risk and high-risk dental procedures in patients on VKA, 
and to identify predictors of oral cavity bleeding for both categories. 
M E T H O D S
Study Design and Setting
We used data from the anticoagulation clinic of the Star-Medical Diagnostic Centre 
(Rotterdam, the Netherlands). All registered dental procedures in patients on VKA 
between January 1, 2013 and January 1, 2015 were retrieved from the clinic’s medical 
database. These procedures were either reported beforehand by the patients or 
treating physicians or in retrospect by the patients during subsequent visits to the 
clinic. We collected information regarding patient and dental procedure characteristics, 
periprocedural VKA management. A waiver for informed consent was granted on behalf 
of the ethics committee of the Erasmus University Medical Centre based on the 
observational nature of our study. 
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Periprocedural VKA management
In the Netherlands, patients are treated with acenocoumarol or phenprocoumon and 
are monitored by anticoagulation clinics. Dental practitioners consult these clinics for 
advice regarding periprocedural VKA management. For standard low-risk procedures 
(e.g. extraction or implantation 1-3 elements), VKA management is based on the 
guideline from the Academic Centre for Dentistry Amsterdam (ACTA) (5). This guideline 
classifies dental procedures as low or high bleeding risk, and states that low-risk 
procedures can be safely performed under VKA continuation, provided that the INR is 
≤ 3.5, the wound is sutured, and a local pro-haemostatic agent (TXA-mouthwash 5.0%, 
10ml 4dd for 5 days) is prescribed (5). In order to follow this protocol, the patients must 
report the planned dental procedure to the anticoagulation clinic at least 24 h in 
advance. This guideline, however, does not provide guidance on perioperative 
management for high-risk procedures (e.g. extraction or implantation >3 elements and 
orthognatic chirurgery). For these high-risk procedures, anticoagulant therapy is usually 
interrupted without routine TXA prescription, and bridged with low-molecular-weight 
heparin (LMWH) if required, in line with international recommendations (6). Regardless 
of the bleeding risk of the elective dental procedure, when VKA therapy is interrupted, 
the INR is not routinely measured at the clinic prior to the procedure as discontinuation 
for several days in patients treated with the short-acting acenocoumarol is sufficient 
to ensure adequately low INR levels. 
Candidate predictors for oral cavity bleeding
Candidate predictors for oral cavity bleeding were selected beforehand based on 
literature and presumed clinical relevance (1,6). The following patient characteristics 
were analysed: age, sex, intensity of VKA treatment, type of VKA, and quality of 
anticoagulation control prior to the procedure defined as percentage of time in 
therapeutic range (TTR in %). The TTR was calculated using the Rosendaal method for 
each patient from 3 months until 1 week prior to the procedure (9).
Potential predictors related to periprocedural management were: concomitant 
exposure to antiplatelet agents (thrombocyte aggregation inhibitors, non-steroidal 
anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs)), 
whether VKA treatment was interrupted, whether the last INR result at the clinic was 
≤3.5, whether the procedure was reported at least 24 hours in advance, and whether 
a valid INR-measurement was performed at the anticoagulation clinic within 72 h before 
the procedure. Since patients are differently managed depending on the classification 
as low-risk or high-risk procedure, we identified the predictors for bleeding separately 
according to the ACTA classification.
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Study Outcomes
Our primary outcome was clinically relevant oral cavity bleeding (OCB) within 30 days 
after the procedure. Bleedings were considered clinically relevant if these: 1) were 
spontaneously reported by the patient to the anticoagulation clinic apart from planned 
visits, 2) required a second intervention or alteration in medication, or 3) caused 
hospitalisation or death. Minor bleedings such as small haematomas reported only 
during routine visits were not considered clinically relevant. Since patients at our 
thrombosis service are instructed at each visit to proactively report serious bleeding 
complications between visits, we considered this definition an adequate cut-off for 
clinically relevant bleeding with a low chance of missing these bleedings. 
Secondary outcomes were: clinically relevant non-oral cavity bleedings (NOCB) (using 
the previously mentioned definition for clinical relevance), objectified thromboembolic 
complications (transient ischaemic attack, ischaemic stroke, myocardial infarction or 
venous thrombosis), hospitalisation (any), and all-cause mortality within 30 days. Two 
different investigators (JB, WR) independently classified all procedures as low-risk or 
high-risk and evaluated periprocedural management for each procedure. All outcome 
events were independently classified by physicians of the anticoagulation clinic as part 
of routine care and reviewed by both investigators.
Statistical analysis
Standard descriptive statistics were performed to assess differences regarding patient 
characteristics, procedure characteristics, and clinical outcomes. Continuous covariates 
were compared between groups by Student’s t-test in case of a normal distribution 
and by Mann Whitney-U test for non-normally distributed covariates. Proportions were 
compared by Chi-square test. For all clinical outcomes, 30-day event rates with 95% 
confidence intervals (CI) were calculated in line with recommendations for reporting 
procedure-related outcomes (10). Univariate logistic regression analysis and 
multivariate backward conditional logistic regression analysis were used to identify 
predictors of oral cavity bleeding after low-risk and high-risk procedures. Odds ratios 
(OR) with 95% CI were calculated and compared between different management 
strategies regarding the risk of oral cavity bleeding. We performed a sensitivity analysis 
including only the first procedure of each patient during the study period. If the second 
intervention was a re-intervention, it is conceivable that this could also affect the risk 
of bleeding and therefore influence the results. P-value for model inclusion in the 
backward logistic regression models was set at p=0.10. Statistics were performed using 
SPSS version 23.0 (IBM Corp., Armonk, NY, USA).
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R E S U L T S
Study population
In total, 2666 dental procedures were identified, performed in 2181 patients between 
January 2013 and January 2015. Of these, 337 (14.1%) procedures performed in 336 
patients were excluded for analysis for various reasons (Figure 1). After exclusion, 2329 
procedures performed in 1845 patients were included for final analysis. Of these, 2004 
(86.0%) were low-risk procedures and 325 (14.0%) high-risk procedures. Most patients 
(n=1457, 79.0%) underwent one procedure during the study period. Procedure and 
patient characteristics, overall and by procedure risk, are shown in Table 1. 
Low bleeding risk procedures
Of the 2004 low-risk procedures, 1540 (77.8%) were reported to the clinic at least 
24 h in advance. In 1083/2004 (54.0%) procedures, a valid INR measurement was 
performed at the anticoagulation clinic within 72 h before the procedure. Treatment 
with VKA was continued in 1350/2004 (67.4%) procedures, of which 900/1350 (66.7%) 
with TXA mouthwash and 450/1350 (33.3%) without. Treatment with VKA was 
interrupted in 654/2004 procedures (32.6%), of which 246/654 (37.6%) were bridged 
Figure 1. Study flow chart. * E.g. annual check-up, prosthesis adjustments, radiographic imaging. N= number 
of procedures
119
PREDICTORS OF BLEEDING AND OUTCOME AFTER DENTAL PROCEDURES IN PATIENTS ON VKA
8
with LMWH. Clinically relevant oral cavity bleeding within 30 days occurred in 
67/2004 low-risk procedures (3.3%, 95%CI 2.6-4.2). Oral cavity bleeding rates, 
ordered by procedure risk and management strategy, are shown in Table 2. Oral 
cavity bleeding occurred significantly more often in patients using antiplatelet 
therapy (16/237, 6.8%), compared to non-users (51/1767, 2.9%) [p=0.002]. Overall, 
the bleeding risk after continuation of VKA with TXA mouthwash was similar to VKA 
interruption without bridging [OR 1.44, 95%CI 0.62-3.64]. Continuation of VKA with 
TXA mouthwash was, however, associated with a lower bleeding risk compared to 
VKA continuation without TXA mouthwash [OR=0.41, 95%CI 0.23-0.73] or VKA 
interruption with bridging [OR=0.49, 95%CI 0.24-1.00]. When VKA therapy was 
interrupted (n=654), bridging was associated with an increased bleeding risk 
compared to forgoing bridging [OR=2.94, 95%CI 1.14-7.57] (Table 2). Sensitivity 
analysis revealed similar results (Table 2). 
Table 1. Patient and procedure characteristics by procedure risk 
No. (%)
Overall 
(n=2329)
Low-risk 
(n=2004)
High-risk 
(n=325)
P 
Value
Characteristic
Patient
Age, median [IQR], y 73.0 [64.0-81.0] 73.0 [64.0-81.0] 73.0 [65.0-81.0] 0.254
Male sex 1297 (55.7) 1092 (54.5) 205 (63.1) 0.004
VKA treatment duration, median [IQR], y 4.4 [1.3-10.2] 4.4 [1.3-10.2] 4.5 [1.3-10.6] 0.537
VKA type  
  Acenocoumarol 2156 (93.1) 1853 (92.5) 303 (93.2) 0.829
  Phenprocoumon 173 (6.9) 151 (7.5) 22 (6.8)
Treatment indication
   Atrial fibrillation 1442 (61.9) 1235 (61.6) 207 (63.7) <0.001
   Venous thrombosis 301 (12.9) 270 (13.5) 31 (9.5)
   Heart valve replacement 154 (6.6) 146 (7.3) 8 (2.5)
   Arterial thrombosis 418 (17.9) 341 (17.0) 77 (23.7)
   Prophylaxis 14 (0.6) 12 (0.6) 2 (0.6)
Therapeutic INR range
    2.0-3.5 1855 (79.6) 1598 (79.7) 257 (79.1) 0.963
    2.5-4.0 404 (17.3) 346 (17.3) 58 (17.8)
    Other  70 (3.0) 60 (3.0) 10 (3.1)
TTR 82.0 [60.6-100.0] 82.9 [61.5-100.0] 77.4 [53.8-95.7] 0.004
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Table 1. Continued
No. (%)
Overall 
(n=2329)
Low-risk 
(n=2004)
High-risk 
(n=325)
P 
Value
Procedure
Type  
   Tooth extraction of 1-3 elements 1403 (60.2) 1403 (70.0) - -
   Endodontic therapy 68 (2.9) 68 (3.4) -
   Abscess incision 16 (0.7) 16 (0.8) -
   Tooth implantation of 1-3 elements 118 (5.1) 118 (5.9) -
   Scaling or root planning 259 (11.1)  259 (12.9)   -
   Tooth restauration 42 (1.8) 42 (2.1) -
   Apex resection 16 (0.7) 16 (0.8) -
   Wisdom tooth extraction 28 (1.2) 28 (1.4) -
   Periodontal flap surgery 17 (0.7) 17 (0.8) -
   Dental crown or tooth bridge 37 (1.6) 37 (1.8) -
   Tooth extraction of >3 elements 296 (12.8) - 296 (91.1) -
   Tooth implantation of >3 elements 13 (0.6) - 13 (4.0)
   Orthognathic surgery               16 (0.7) - 16 (4.9)
Reported at least 24h in advance 1834 (78.7) 1540 (76.8) 294 (90.5) <0.001
VKA interrupted for procedure 946 (40.6) 654 (32.6) 292 (89.8) <0.001
Bridging with LMWH 397 (17.0) 246 (12.3) 151 (46.5) <0.001
Tranexamic acid mouthwash prescribed 967 (41.5) 947  (47.3)   20  (6.2) <0.001
Valid INR at clinic within 72h 1144 (49.1) 1083 (54.0)   61 (18.8) <0.001
Last INR at clinic ≤ 3.5 1942 (83.4) 1658 (82.7) 284 (87.4)   0.037
Periprocedural exposure to antiplatelet drugs
   Thrombocyte aggregation inhibitors (any) 282 (12.1) 237 (11.8) 45 (13.8) 0.300
   Acetylsalicylic acid 170 (7.3) 141 (7.0) 29 (8.9) 0.546
   Clopidogrel 80 (3.4) 69 (3.4) 11 (3.4)
   Dipyridamol 26 (1.1) 21 (1.0) 5 (1.5)
   Prasugrel   6 (0.3)   6 (0.3)   -
  
   NSAID 268 (11.5) 232 (11.6) 36 (11.1) 0.793
   
   SSRI 141 (6.1) 122 (6.1) 19 (5.8) 0.865
IQR=Interquartile range, VKA=Vitamin K Antagonist, INR=International Normalized Ratio, TTR=Time in 
Therapeutic Range, LMWH=Low-Molecular-Weight Heparin, NSAID=Non-steroid anti-inflammatory drug, 
SSRI=Selective Serotonin Reuptake Inhibitor.
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Backward conditional modelling revealed that bridging therapy [OR=3.19, 95%CI 1.22-
8.35], a missing [OR=1.90, 95%CI 1.10–3.28] or supratherapeutic INR [OR=1.75, 95%CI 
0.98–3.12] before the procedure, procedures that were not reported to the clinic in 
advance [OR=2.60, 95%CI 1.52–4.46] and concomitant exposure to thrombocyte 
aggregation inhibitors [OR=2.40, 95%CI 1.33–4.32] were the factors most strongly 
associated with an increased risk of oral cavity  bleeding (Table 3).
Table 3. Predictors of oral cavity bleeding by procedure risk 
Beta OR (95% CI)
Low-risk (n=2004)
Bridging with LMWH 1.159 3.19 (1.22 - 8.35)
Exposure to platelet aggregation inhibitor 0.874 2.40 (1.33 - 4.32)
No valid INR before procedure 0.641 1.90 (1.10 - 3.28)
Last INR at clinic >3.5 0.557 1.75 (0.98 - 3.12)
Procedure not reported in advance 0.956 2.60 (1.52 - 4.46)
VKA interruption -0.880 0.42 (0.18 - 0.96)
Time in therapeutic range (per percent increase) 0.010 1.01 (1.00 - 1.02)
High-risk (n=325)
Exposure to NSAID 1.411 4.10 (1.38 - 12.20)
VKA interruption -1.992 0.14 (0.03 - 0.58)
No valid INR before procedure 1.658 5.25 (0.92 - 30.11)
Age at procedure (per year increase) 0.046 1.05 (1.00 - 1.09)
Time in therapeutic range (per percent increase) -0.018 0.98 (0.97 - 1.00)
Backward conditional logistic regression model.  OR=Odds Ratio, INR=International Normalized Ratio; 
NSAID=Non-Steroidal Anti-Inflammatory Drug; LMWH=Low-Molecular-Weight Heparin, VKA= Vitamin K 
Antagonist 
123
PREDICTORS OF BLEEDING AND OUTCOME AFTER DENTAL PROCEDURES IN PATIENTS ON VKA
8
High bleeding risk procedures
Of the 325 high-risk procedures, 294 (90.5%) were reported to the clinic at least 24 h 
in advance. Most high-risk procedures (n=296, 91.1%) were extractions of more than 
three elements (Table 1). VKA therapy was interrupted in 292/325 (89.8%) of these 
procedures, of which 151/292 (51.7%) were bridged with LMWH. Clinically relevant oral 
cavity bleeding within 30 days occurred in 21/325 (6.5%, 95%CI 4.3-9.7) of these 
procedures (Table 2). Oral cavity bleeding rates were significantly higher in patients 
using NSAIDs (6/36, 16.7%) compared to non-users (15/289, 5.2%) [p=0.008]. 
Overall, VKA continuation was associated with a significantly higher bleeding risk 
compared to VKA interruption [OR=3.08, 95%CI 1.05-9.04]. When VKA was interrupted, 
bridging with LMWH was not associated with a significantly higher bleeding risk 
compared to forgoing bridging [OR=1.60, 95%CI 0.56-4.51]. Sensitivity analysis revealed 
similar results (Table 2). 
Backward conditional modelling revealed that exposure to NSAIDs [OR=4.10, 95%CI 
1.38-12.20] and a missing INR before the procedure [OR=5.25, 95%CI 0.92-30.11] were 
associated with an increased risk of bleeding for high-risk procedures, while VKA 
interruption strongly lowered the risk of bleeding [OR=0.14, 95%CI 0.03-0.58] (Table 3).
Secondary clinical outcomes
Clinically relevant non-oral cavity bleeding within 30 days occurred in 50/2329 
procedures (2.1%, 95%CI 1.6-2.8%). Of these bleedings, one was an intracranial bleeding 
(2%), four were gastrointestinal bleedings (8%),  three patients reported haematuria 
(6%) and three bleedings were of vaginal origin (6%). All other bleedings were cutaneous 
bleedings (30/50, 60%) or nose bleedings (9/50, 18%).  
The bleeding rates after low-risk (41/2004, 2.0%) and high-risk (9/325, 2.8%) procedures 
were similar [p=0.40]. Non-oral cavity bleeding occurred more often after procedures 
that were bridged with LMWH (14/397, 3.5%) compared to those where VKA therapy 
was continued or interrupted without bridging (36/1932, 1.9%) [p=0.04]. Bridging 
therapy was associated with an almost two-fold increased risk of non-oral cavity 
bleeding compared to VKA continuation or interruption without bridging [OR=1.93, 
95%CI 1.03-3.60]. After correction  for age, sex, treatment intensity, indication, TTR 
percentage, treatment duration and use of antiplatelet drugs, perioperative bridging 
remained significantly associated with an increased non-oral cavity bleeding risk 
[OR=2.18, 95%CI 1.14-4.16].
A thromboembolic event within 30 days occurred in 5/2329 procedures (0.2%, 95%CI 
0.1-0.5%). Of these thromboembolic events, three occurred after a low-risk (3/2004, 
0.1%) and two after a high-risk procedure (2/325, 0.6%) [p=0.09]. Three occurred after 
VKA continuation (3/1383, 0.2%) and two after a procedure for which VKA therapy was 
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interrupted (2/946, 0.2%) [p=0.98]. Of the latter two events, one occurred in the non-
bridging group (1/549, 0.2%) and the other in the bridging group (1/397, 0.3%) [p=0.82]. 
Hospitalisation within 30 days occurred in 100/2329 procedures (4.3%, 95%CI 3.5-5.2). 
Reasons for hospitalisation were: intracranial bleeding (1/100), ischaemic event (6/100), 
post-dental treatment haemorrhage (8/100), and 85/100 were unrelated to dental 
treatment or perioperative management. 
A fatal event within 30 days occurred in 5/2329 procedures (0.2%, 95%CI 0.1-0.5). None 
of these were related to the dental procedure or management. 
D I S C U S S I O N
We evaluated the periprocedural management and clinical outcome after dental 
procedures in patients on VKA, in a real-world setting, and identified predictors for 
post-procedural oral cavity bleeding. Depending on the procedure risk, we observed 
an oral cavity bleeding rate of 3% after low-risk procedures and 6% after high-risk 
procedures. These rates are in accordance with previously reported bleeding rates 
(1,3,11). In contrast to international guidelines, the ACTA guideline incorporates the 
number of teeth involved in the procedure as a factor for bleeding risk. A previous 
study in 439 patients on VKA showed that for every extra extracted tooth the risk of 
bleeding increased by 28% (12). We also observed differences in bleeding rates after 
low-risk and high-risk procedures, which suggest that it is justifiable to categorise dental 
procedures accordingly. The specification of the number of teeth (1-3 low-risk, >3 high-
risk) makes it easier for the dental practitioner and anticoagulation clinics to assess 
the bleeding risk of the procedure, which should be incorporated in decision making 
regarding periprocedural VKA management (5,7).
In our study, patient-related factors associated with an increased risk of bleeding were: 
increasing age (high-risk procedures) and concomitant exposure to antiplatelet therapy 
(low-risk procedures) or NSAIDs (high-risk procedures), which have also been reported 
in previous studies (1,13). Therapeutic quality control (e.g. lower TTR%) was not 
associated with an increased bleeding risk in our multivariate models, irrespective of 
the procedure risk, making it unlikely that TTR differences could explain the difference 
in bleeding risk between high-risk and low-risk procedures. Despite the well-known 
increased risk of bleeding associated with NSAID use (14), dental practitioners often 
prescribe these drugs for management of dental pain and swelling. Based on guideline 
recommendations (15) and our own findings, we discourage the use of NSAIDs for pain 
relief after invasive dental treatment, especially after high-risk procedures, in patients 
using VKA.
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Considering periprocedural VKA management, like prior studies (16-18), our results 
indicate that VKA can be continued safely in low-risk procedures, in combination with 
a local pro-haemostatic agent, provided that the INR is at a therapeutic level before 
the procedure, since a supra-therapeutic INR before the procedure (INR>3.5) or absence 
of an objectified INR from the clinic within 72 h before the procedure, were independent 
predictors for bleeding. Furthermore, our data clearly indicates a risk reduction 
(approximately 50%) of bleeding when TXA mouthwash is prescribed during VKA 
continuation. The exact effect of TXA has been a point of discussion. Some studies 
(16,19), reported a lower bleeding rate when used after dental procedures, while 
another (20), found no differences in bleeding between exposure groups. Most of these 
studies were relatively small though, with heterogeneous periprocedural management 
and with very few bleeding complications, thus likely to be underpowered to find 
differences in outcomes between exposures if present.
In low risk-procedures, the risk of oral cavity bleeding was lower in patients who 
continued VKA treatment in combination with TXA compared to those bridged with 
LMWH, but similar compared to patients in whom VKA therapy was interrupted without 
bridging therapy. In one-third of the low-risk procedures, VKA therapy was temporarily 
interrupted where it should have been continued according to the guidelines. The most 
likely explanation for this finding is that anticoagulation clinics interrupt VKA therapy 
if deemed necessary by the dental practitioner. Assuming that the anticoagulation 
clinic will guard the thromboembolic safety of the patient, the dental practitioner often 
advocates an INR as low as possible before invasive treatment to prevent bleeding 
(21).  On the other hand, anticoagulation clinics assume that the low INR is necessary 
to prevent bleeding and try to meet the request of clinicians by interrupting VKA 
therapy. On a population level, this causes heterogeneous VKA management, and in 
the end exposes a part of the patients to a higher bleeding risk if bridging therapy is 
initiated. Clear communication between dental practitioners and anticoagulation clinics 
is therefore required before deviating from management guidelines. 
For high-risk procedures, we advise to interrupt VKA treatment and to avoid the use 
of NSAIDs as analgesics. The beneficial effect of TXA mouthwash was not statistically 
significant in high-risk procedures, likely due to a lack of power. We suggest that, in 
line with low-risk procedures, its use may lower the bleeding risk and should be 
considered regardless of management strategy. 
Another important observation is that where VKA therapy was interrupted, bridging 
therapy was initiated by the anticoagulation clinic in a substantial proportion of both 
the low-risk (~1/3) and high-risk (~1/2) procedures. A previous study, evaluating both 
dental and other surgical procedures (n=222), showed that in daily practice adherence 
to bridging guidelines at anticoagulation clinics is suboptimal and LMWH therapy is 
PART TWO  |  CHAPTER 8
126
frequently initiated without a proper indication (22). Furthermore, these authors even 
concluded that the decision for bridging was often not based on the thromboembolic 
risk of the patient or the bleeding risk of the procedure, despite the increased bleeding 
risk associated with bridging (22). We also found an increased risk of clinically relevant 
oral and non-oral-bleeding associated with bridging therapy, and very low 
thromboembolic event rates, irrespective of the procedure risk or chosen management 
strategy. Since it has been shown that perioperative bridging therapy is associated 
with an increased risk of bleeding without lowering the risk of thromboembolic events 
(23-25), we advise that bridging should be kept to a minimum and only used in patients 
at the highest risk of thromboembolic complications during VKA interruption, such as 
recent stroke or venous thromboembolism, mechanical mitral valves and isolated atrial 
fibrillation with CHA2DS2Vasc > 7), in accordance with the Dutch guideline (26).
It is expected that direct oral anticoagulants will continue to increasingly replace VKA 
for the majority of patients requiring anticoagulation therapy. Due to their predictable 
pharmacokinetics, rapid onset of action, and short half-lives, these drugs can be 
interrupted for a shorter time than VKA  and require no bridging with LMWH during 
interruption, irrespective of the patient’s thrombotic risk (26). Although this simplifies 
perioperative management, dental surgeons and dentists should be aware of direct 
oral anticoagulants (DOAC) use by their patients and take adequate precautions to 
prevent bleeding in case of DOAC continuation.
Strengths and limitations
An important strength of our study is the large number of included dental procedures, 
which allowed us to compare clinical outcomes after different management strategies 
in both low and high bleeding risk procedures. The fact that these procedures were 
not performed in a trial setting enhances the generalizability of our findings. It is 
estimated that one in every six patients on chronic anticoagulant therapy is annually 
assessed for periprocedural VKA management for an elective procedure, which 
illustrates the importance of our findings beyond only dental procedures (6). 
A few limitations of our study should be mentioned. First, we had no data on local 
dental influences that may affect the risk of oral cavity bleeding, such as the condition 
of the extracted teeth, the state of the surrounding gums, and local pro-haemostatic 
measures undertaken by the dentist or oral surgeon to prevent bleeding (e.g. proper 
sutures) (1). This impaired us to correct our models for these potential confounding 
factors. However, these factors are usually not communicated between dental 
practitioners and anticoagulation clinics, and it is safe to assume that dental 
practitioners always try to achieve primary haemostasis during treatment, making our 
results representative for daily practice. 
127
PREDICTORS OF BLEEDING AND OUTCOME AFTER DENTAL PROCEDURES IN PATIENTS ON VKA
8
To specifically relate these local factors to clinical outcome, in combination with the 
perioperative management strategy, a prospective study should be conducted in which 
both anticoagulation clinics, dentists, and oral surgeons provide the required 
information.
Second, given the retrospective study design and use of administrative data, we cannot 
definitively exclude the possibility of omission or misclassification of procedures and 
outcomes. We minimised the risk of misclassification by manually checking individual 
patient files independently by two investigators and by excluding procedures if these 
were inadequately described. In case of omission of bleeding events, it is unlikely that 
these bleedings are systemically related to a specific dental procedure or management 
strategy. Therefore we deem the chance of significant bias of our results due to the 
omission of bleeding events as low.  
Conclusions 
Most predictors of oral cavity bleeding were specifically related to periprocedural 
management and differed between low-risk and high-risk dental procedures, justifying 
different bleeding risk categories. Our observations emphasise the importance of 
adherence to VKA management guidelines, in which dental procedures should be 
categorised into low-risk and high-risk, each with specific perioperative management 
strategies. Overall, the concomitant use NSAIDs during dental treatment as analgesics 
should be avoided. VKAs can safely be continued in low-risk dental procedures in 
combination with tranexamic acid mouthwash provided that the INR≤3.5. In high-risk 
procedures, VKA should be interrupted and combined with tranexamic acid mouthwash. 
Bridging should only be applied in patients at highest risk of thromboembolic 
complications. 
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A B S T R A C T
Introduction
Statins may be causally associated with a decreased risk of venous thrombosis. If so, 
this could be a substantive breakthrough since statins do not increase the risk of 
bleeding and could therefore be used as a safer antithrombotic drug. However, 
scepticism exists on the observed reduction of venous thrombosis by statins, as it may 
have been confounded by healthy user effects or other biases.
Areas covered
The main focus of this review will be the biases that may have arisen in clinical studies 
that investigated the relationship between statin use and risk of venous thrombosis. 
We also discuss the suggested causal association from a pathophysiological perspective. 
Furthermore, we integrate the knowledge from clinical and pathophysiological studies 
into a proposal for new study designs that are needed to sufficiently answer the 
question whether we can, and should, prevent recurrent venous thrombosis with 
statins.
Expert Commentary
A drug to prevent recurrent venous thrombosis in patients at risk of bleeding that does 
not induce bleeding and in which the number needed to treat for the prevention of 
venous thrombosis is sufficiently high, is a remedy that we should continue to look for, 
and for which statin therapy might be a suitable candidate.
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I N T R O D U C T I O N
Venous thrombosis (deep vein thrombosis or pulmonary embolism) is a common 
and potentially lethal disease that occurs each year in about 1-2/1000 people (1). The 
condition can be prevented and treated with anticoagulants, but as a side effect 
bleeding often occurs (2). Currently, the duration of treatment of venous thrombosis 
with anticoagulants depends on whether the event was provoked or not (3). Most 
provoking risk factors, such as surgery, immobilization, and use of oral contraceptives, 
are of a transient nature. Presence of such a risk factor temporarily increases the 
‘thrombotic potential’ of an individual, and hence the risk decreases once the risk 
factor is gone. This explains, for example, why recurrence risk is low (<1%/year) in 
patients who developed their first event after surgery (4). Patients with provoking 
risk factors are usually treated with anticoagulants for 3-6 months only, while patients 
with unprovoked thrombosis are prescribed anticoagulant treatment for a longer 
period (3). This extended treatment should be seen as prevention of a recurrence, 
which decision is based on its high incidence in patients with unprovoked events 
(30% within 5 years after the 3-6 months of oral anticoagulation) (5). Only 40-50% of 
all thrombosis patients can be classified as patients a first provoked event, which 
leads to a dilemma in the other 50-60%: discontinuing treatment may lead to a new 
thrombotic event, while continuing oral anticoagulant treatment is accompanied with 
a yearly 1-3% risk of major bleeding (2,3). Therefore, novel therapeutic strategies to 
prevent venous thrombosis that are not associated with bleeding complications are 
urgently needed. 
In this review, we will discuss whether statins are causally associated with a decreased 
risk of venous thrombosis. If true, this could be a substantive breakthrough since statins 
are known not to cause bleeding. We will summarize clinical research that studied 
whether statins exert beneficial effects in preventing venous thrombosis. Next, we will 
discuss possible mechanisms from a pathophysiological perspective. Finally, we will 
integrate the knowledge obtained from clinical- and pathophysiological studies into a 
proposal that is needed to sufficiently answer the question if we can prevent recurrent 
venous thrombosis with statin therapy. 
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C L I N I C A L  S T U D I E S
Initial findings
In 2000, Grady and colleagues were the first to report that statin use was associated 
with a 50% reduced risk for development of venous thrombosis in post-menopausal 
women starting estrogen and progestin therapy (6). Since then, many other studies 
have been published on the association between statin use and decreased risk of 
venous thrombosis. For instance, a meta-analysis of seven observational studies 
revealed that statin use was associated with a significantly lower risk of VTE compared 
to non-statin use (odds ratio 0.62, 95% confidence interval (CI), 0.45-0.86) (7). However, 
statin use is associated with several preventive effects in observational studies: it is 
not only associated with lower risks of venous thrombosis, but also with lower risks of 
arrhythmia, multiple sclerosis, Alzheimer’s dementia, infections, AIDS, cancer mortality, 
and even motor vehicle accidents (8-10). Because these effects do not seem to be due 
to lower lipid levels, this raises the suspicion that at least some of the observed 
associations are due to non-causal mechanisms, such as bias.
Bias  
Bias can be defined as a process at any stage of causal inference which tends to produce 
results or conclusions that differ systematically from the truth. The landmark article by 
Sacket in 1979, listed 35 biases, of which we will discuss 3 types that could explain the 
observation that statins are associated with a decreased risk of venous thrombosis (11). 
The first lies in what has been called the “healthy user” effect, i.e. that statins are 
prescribed preferentially to individuals with a favourable risk profile or that the healthiest 
users are analysed in some observational studies (12). However, for venous thrombosis 
it is unlikely that this healthy user effect fully explains the positive association with statin 
use, as (high risk of) arterial cardiovascular disease is an indication for statin use, of 
which some risk factors (age, male sex, obesity, smoking) are shared risk factors for 
both conditions (13). Thus, participants in observational studies who use statins should 
have a less favorable cardiovascular risk factor profile than non-users and are therefore 
at higher (and not lower) baseline risk for venous thrombosis.
However, other types of bias may have contributed to the observed lower risk of venous 
thrombosis while using a statin, for instance in studies that included individuals who 
had been using statins for some time prior to study entry (7). Such “prevalent users” 
can introduce two types of bias: 1) underascertainment of events that occur early after 
starting treatment (survivor bias) and 2) the inability to control for those who do or do 
not adhere to statin treatment (adherence bias) (14,15). 
In terms of survivor bias, for statins there is indirect evidence that the risk for venous 
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thrombosis is increased in the first months of statin treatment, since an indication for 
statin therapy is a recently experienced arterial cardiovascular event. Because it has 
been reported that patients with acute arterial cardiovascular disease are at increased 
risk of subsequent venous thrombosis and death for a short time period, 
underascertainment of venous thrombotic events can result from early attrition of 
patients on statins who are most susceptible but may have died or be too sick to be 
enrolled in an observational study (16,17). 
In terms of adherence bias, prevalent users in a study, by definition, use a statin at 
time of inclusion, while those who had an indication for statin treatment yet failed to 
continue with their treatment are abraded as non-statin users. Adherence to a drug is 
a marker for a constellation of unmeasured factors and likely associated with better 
outcome, independent of the drug use itself. This is true for all drugs, including statin 
use and even for placebo use. For instance, several randomized controlled clinical trials 
in which patients who were adherent to placebo showed 30–60 percent reduced risks 
of death from cardiovascular disease, as compared with non-adherent placebo users, 
which magnitude of the association was not materially affected by adjustment for 
several potential confounders (18-20).   
For these two reasons, it is important to take prevalent users into account when studying 
effects of statin treatment on the risk of venous thrombosis in observational studies. 
For this, one can use a so-called ‘new-user design’ (14). Such a design begins by 
identifying all individuals in a predefined population (both in terms of people and time) 
who for the first time start a course of treatment with a statin. Study follow-up for 
endpoints begins at precisely the same time as initiation of statin therapy or t=0. Data 
for all patient characteristics are obtained at a time just before t=0. Observational studies 
can be performed by initially assembling a cohort consisting of only new users and an 
appropriate comparison group or by identifying new users and the comparison group 
from an existing cohort. This definition is similar to the way in which data are analyzed 
in a clinical trial, where t=0 is the time of randomization (usually just before treatment 
begins), except of course that treatment is not assigned by randomization. A new-user 
design differs from most observational studies in that it excludes prevalent users. For 
this matter it is interesting to note that in aforementioned meta-analysis, only one of 
the seven mentioned studies included statin initiators in their study (new-user design) 
and reported an odds ratio of 1.02 (95% CI, 0.88-1.18), which is in contrast to the overall 
odds ratio of 0.62 (95% CI, 0.45-0.86) (7,9,21). This raises the suspicion that the observed 
association between statin use and a decreased risk of venous thrombosis suffered 
from prevalent users in these studies leading to bias. However, other studies in which 
prevalent user bias was excluded by design have been published, including results from 
a trial and a meta-analysis of trials, which we will discuss below (22,23).
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Class effect?
Side effects of drugs are not necessarily class effects, particularly when the mechanism 
of the side effect differs from the primary mechanism of the drug. It is known that the 
mechanism of statins varies between the types of statins that are currently on the 
market today, showing different reducing effects on LDL, atherosclerosis and 
inflammation. This reduction is the least strong in pravastatin users, followed by 
simvastatin users and atorvastatin users and is strongest in rosuvastatin users (24,25). 
There are some studies that suggest that dyslipidemia, inflammation or atherosclerosis, 
i.e. determinants for arterial cardiovascular disease, also increase the risk of venous 
thrombosis (26-28). Therefore, an analysis done by type of statin to venous thrombosis 
risk seems sensible as, in case of a causal association mediated through dyslipidemia, 
inflammation or atherosclerosis, the effect on venous thrombosis risk should be 
strongest in rosuvastatin and weakest in pravastatin users. As summarized in Table 1, 
in a cohort study of nearly 2 million individuals  from the United Kingdom, in which a 
new-user design was used, authors showed that rosuvastatin use was associated with 
the strongest (approximately 40%) reduced risk of venous thrombosis (29). These 
results closely resemble the results from randomized controlled trials (22,23). For the 
occurrence of venous thrombosis, a pre-defined analysis of a randomized clinical trial 
in which apparently healthy individuals were randomized to rosuvastatin or placebo 
(JUPITER trial) showed a 40% risk reduction when using rosuvastatin as compared with 
placebo (Table 1) (22). In the absence of other randomized trials with venous thrombosis 
as the primary endpoint, Rahimi and colleagues presented a pooled analysis of 29 
randomized statin studies in which venous thrombotic events were reported as serious 
adverse events (23). They failed to confirm a risk reduction of venous thrombosis by 
statin treatment. However, authors found that individuals who were randomized to 
rosuvastatin still had an approximately 40% reduced risk of venous thrombosis (hazard 
Table 1. Effect of statin therapy on venous thrombosis by type of statin 
Observational study [31]
Hazard ratio (95% CI)
Clinical trials [24,25]
Hazard ratio (95% CI)
Women Men Jupiter trial Rahimi et al*
No statin 1       (reference) 1      (reference) 1       (reference) 1       (reference)
Pravastatin 1.05 (0.80-1.38) 1.00 (0.76-1.31) 1.17 (0.81-1.69)
Simvastatin 0.91 (0.83-0.99) 0.88 (0.80-0.97) 0.94 (0.71-1.25)
Atorvastatin 0.86 (0.76-0.99) 0.86 (0.75-0.97) 0.82 (0.56-1.19)
Rosuvastatin 0.61 (0.36-1.03) 0.53 (0.29-0.95) 0.57 (0.37-0.86) 0.65 (0.33-1.28)
Any statin Unavailable Unavailable 0.93 (0.82-1.07)
* Excluding results from the Jupiter trial
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ratio 0.65; 95CI, 0.33-1.28) (Table 1). Albeit confidence intervals were wide in the study 
from Rahimi et al, results from Table 1 suggest a dose response relation where the 
statin that is most related with halting/regression of atherosclerosis, dyslipidemia and 
inflammation (i.e. rosuvastatin) also provides the largest risk reductions for the 
occurrence of venous thrombosis. 
P A T H O P H Y S I O L O G Y
Statins and (early) atherosclerosis
In 2003, the hypothesis was sparked that atherosclerosis leads to venous thrombosis 
(30). As in this study atherosclerosis measurements were performed after venous 
thrombosis occurred, its temporal relation and causality were not entirely clear (31). 
Currently, there is little evidence available that venous thrombosis and atherosclerosis 
are causally associated (13). However, there is some biological evidence that may give 
credence to the causality of this association since the hemostatic system seems to be 
able to accelerate atherosclerosis (31). This was demonstrated in mouse studies with 
hypercoagulable and diminished coagulation phenotypes on an atherosclerotic 
background, where diminished coagulation provided protection against atherosclerosis 
development, whereas hypercoagulable mice developed more severe atherosclerosis 
(32). In human histological studies, it has been shown that a procoagulant state is more 
abundantly present in early-stage atherosclerotic lesions than in advanced 
atherosclerotic lesions (33-35). Why coagulation factors are more abundantly present 
within early atherosclerotic vessels than in advanced atherosclerosis, is as yet unknown, 
but may be attributable to primary protective mechanisms against vascular injury (36). 
With the advent of in vivo carotid MRI screening, one can now distinguish early from 
advanced atherosclerosis (37,38). It is therefore possible to perform clinical studies to 
quantify as to whether both early and/or advanced atherosclerosis increases the risk 
of venous thrombosis. Such studies could clarify why of all the statins that are currently 
available, the most potent anti-atherosclerotic ones, are associated with a lower risk 
of venous thrombosis (22,23,29). As far as we know such studies have not been 
conducted yet. 
Statins and dyslipidemia
As lipid levels can be modulated by lifestyle intervention and statin therapy, the 
potential association between lipids and venous thrombosis and its underlying 
pathophysiology is a relevant issue worth pursuing (39). However, whether lipid levels 
themselves are associated with venous thrombosis is controversial due to different 
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results among epidemiological studies. A previous meta-analysis demonstrated that 
mean levels of total cholesterol were higher and HDL cholesterol levels were lower in 
venous thrombosis patients than in controls (26). However, the majority of the reports 
on lipids and venous thrombosis in this meta-analysis were small case-control studies, 
and individually controlling for several confounders was not possible (26). Moreover, 
there was severe heterogeneity between studies meaning that there was a large 
variation in study outcomes between studies, of which the larger ones found no 
association with lipid levels and venous thrombosis. Several large population-based 
cohort studies have been published since the aforementioned meta-analysis, and these 
additional studies found no association between dyslipidemia and venous thrombosis 
after controlling for confounding factors and competing risk (40-42).  In addition, non-
statin lipid lowering drugs (i.e. fibrates) are not associated with a reduced venous 
thrombosis risk (43). Therefore, we consider it unlikely that statins decrease venous 
thrombosis risk by their lipid lowering activities.
Statins and inflammation
Several lines of evidence, ranging from experimental models to population-based 
studies, support the notion that inflammation is a driver of atherosclerosis (44). From 
an epidemiological perspective, numerous studies have shown that the inflammatory 
marker hs-CRP is not only associated with atherosclerosis, but also with an increased 
risk of venous thrombosis, and with higher levels of procoagulant factor VIII (45-47). 
However, a Mendelian randomization study convincingly showed that hs-CRP levels 
are not a cause of venous thrombosis (47). Still, statins, initially manufactured to target 
dyslipidemia and slow down atherosclerosis, showed that they also have anti-
inflammatory properties (48). Since atherosclerosis can produce both an inflammatory 
and procoagulant response, reduction of inflammation by statins could be a driving 
force behind the reduced venous thrombosis risk that has been observed in statin 
users (31,44). Interestingly, one study of 26 patients who had venous thrombosis found 
that a 3-day administration of atorvastatin reduced inflammation as evidenced by 
reduced interleukin (IL) IL-6, IL-8, and soluble P-selectin, together with increased anti-
inflammatory IL-10, without any significant effect on hs-CRP (49). Because of the short 
time interval this study suggests potential benefits from statin administration with 
regard to reduced venous thrombosis risk that is in part driven by an immediate anti-
inflammatory (i.e. not related with atherosclerosis) effect.
Statins and platelet activation
Another mechanism through which statins may decrease the risk of venous thrombosis 
is by inhibiting platelet activation and consequently aggregation (50). Animal models 
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have shown that platelet activation plays a key role in the initiation of thrombus formation 
in deep vein thrombosis (51,52). Furthermore, in vitro studies indicate that statins inhibit 
platelet activation via several lipid-independent mechanisms including the inhibition of 
thromboxane A2 (TxA2) formation (53). Since enhanced platelet aggregation has been 
reported in patients with venous thrombosis, we recently decided to investigate if there 
is an effect of rosuvastatin on TxA2-mediated platelet activation in individuals with a 
history of venous thrombosis in the START trial (54,55). We randomized 25 individuals 
to rosuvastatin 20 mg daily for 28 days and 25 individuals to no statin, and observed no 
effect of TxA2-mediated platelet activation in rosuvastatin users. These findings show 
that it is unlikely that the association of a decreased risk of venous thrombosis in 
rosuvastatin users is explained by decreased TxA2-mediated platelet activation. However, 
a limitation of this study was that only one assay was used to evaluate platelet function 
(56). Therefore, we cannot exclude potential other antiplatelet effects of rosuvastatin as 
can be measured using different platelet function tests. 
Statins and coagulation
Colli et al were the first in 1997 to report that statins interfere with activation of the 
clotting system and the coagulation cascade (57). In that study, authors observed that 
tissue factor was suppressed in macrophages that were incubated for 20-24 hours 
with simvastatin. Many reports followed, for example by Undas and colleagues who 
showed that once daily use of simvastatin 40 mg given for 3 days in 14 healthy 
volunteers resulted in a reduction of thrombin formation, that was of a similar 
magnitude to that observed after 90 days of statin therapy (58-61).  Another study 
found evidence for rapid alterations in fibrin clot structure/ function induced by statins 
in venous thrombosis patients treated with atorvastatin 40 mg once daily for 3 days 
(62). Based on these reports, the authors suggested that statin use may decrease the 
risk  of  venous thrombosis by downsizing coagulation activation. However, these 
findings should be interpreted with caution as not all studies consistently reported a 
favourable outcome of statin treatment on coagulation factor levels. For example, in 
a randomized study from Dangas et al (n=93), an increase in fibrinogen level was 
observed when individuals were exposed to pravastatin compared with placebo (63). 
Recently published findings from  randomized controlled trials of statin therapy suggest 
some effect of lowering levels of von Willebrand factor and D-dimer (64,65). However, 
funnel plot analyses showed that these positive results might be due to publication 
bias. Furthermore, only one trial (n=60) reported on the potential effects of rosuvastatin 
to the hemostatic system (66). Observational studies that found a possible relation 
between statin use and a decreased level of procoagulant factors, could have been 
hampered by methodological issues such as survivor bias and adherence bias as they 
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included prevalent users (14,67). In addition, none of these studies may be generalizable 
to venous thrombosis patients as they have generally been conducted in patients with 
hyperlipidemia, diabetes or other disease states unrelated with venous thrombosis. 
In an observational study with an active-comparator design, the drug of interest is 
compared with another agent commonly used for the same indication, rather than 
with no treatment (a ‘non-user’ group) (68). This principle helps to ensure that treatment 
groups have similar treatment indications, attenuating both measured and unmeasured 
differences in patient characteristics. Studies that used such a design on the issue as 
to whether coagulation factor levels are influenced by statins, have as far as we know, 
not been reported previously. For the current review, we explored such a study-design 
in the control individuals of the MEGA study of which results are shown in Table 2. We 
analyzed if there was a difference in the median level of several coagulation factors in 
individuals who were treated with lipid lowering drugs, i.e. either statins or fibrate, at 
time of blood sampling. Although from Table 2 it appears that of the lipid lowering 
therapies that were prescribed, statin users had a less hypercoagulable profile than 
fibrate users (with rosuvastatin users having the most favourable coagulation profile), 
we believe that this finding should be interpreted with caution as numbers are small. 
A powerful design not suffering from any of the aforementioned limitations to answer 
the question whether coagulation factors are influenced by statin therapy is a 
sufficiently powered randomized trial in which the primary outcome is change in 
coagulation factor level in patients with prior venous thrombosis. We are currently 
conducting such a trial (START study; www.clinicaltrials.gov NCT01613794) in which 
patients, after having received treatment with anticoagulants for venous thrombosis, 
are randomized to rosuvastatin 20mg once daily for 1 month to study the potential 
anticoagulant properties of statins. The study is powered on coagulation factor VIII, as 
a high factor VIII level is well associated with both first and recurrent venous thrombosis 
(69-71).  Of note, START will only look at the immediate (1 month) effect of rosuvastatin 
treatment to coagulation factor levels. Randomized studies that take longer time effects 
of rosuvastatin therapy to coagulation factor levels into account may be covered by 
the SAVER trial (www.clinicaltrials.gov NCT02679664). 
E X P E R T  C O M M E N T A R Y 
Whether venous thrombosis can be prevented with the use of statins is questionable 
as the available data are scant, controversial and likely biased, with few replicated 
studies. Nevertheless, pathophysiological insights reveal a potential mechanism 
through anticoagulant and/or or anti-inflammatory properties of statins, most notably 
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rosuvastatin, possibly by targeting (early) atherosclerosis. That cheap and accessible 
anti-atherosclerotic drugs, like statins, might prevent venous thrombosis without 
inducing bleeding, offers currently not enough ground to start statin treatment in these 
patients. For this we need more and better evidence.
F I V E  Y E A R  V I E W
The following research questions and accompanying designs are essential to answer 
the question if statins can prevent venous thrombosis.
1. We need to know the pharmacological mechanism of how statins are able to 
decrease the risk of venous thrombosis. This should be studied in sufficiently 
powered randomized clinical trials or in active comparator study designs that are 
externally validated and primarily set up for this reason. We are currently conducting 
the START trial (www.clinicaltrials.gov NCT01613794) to analyze the immediate 
1-month effects on coagulation of 20 mg rosuvastatin use once daily in 250 
randomized patients with prior venous thrombosis. Since rosuvastatin is the statin 
that consistently showed the strongest association between its intake and a reduced 
risk of venous thrombosis, we will consider a negative signal from this trial as 
negative for the whole class of statins (22,23,29). A possible positive signal may not 
rule in potential beneficial effects on the coagulation profile from the other statins 
that are currently on the market. Of note, START can only look at the immediate (1 
month) effect of rosuvastatin treatment to coagulation factor levels. 
2. We need to know if various stages of atherosclerosis can increase the risk of venous 
thrombosis. If so, the culprit behind the supposed causal association between statin 
intake and reduced coagulation could be early atherosclerosis. Of the latter, previous 
research has shown that increased coagulation activity is specifically observed in 
early atherosclerotic lesions, but we do not know if early atherosclerosis increases 
venous thrombosis risk (31,33). To study this, we need to perform a clinical study 
(either case-control or follow-up) in which early and advanced stages of 
atherosclerosis are viewed accurately in vivo, which is now possible with non-invasive 
high resolution MRI (37,38). External validation of results from a previous autopsy 
study, is needed to endorse that early atherosclerosis is also associated with an 
ex-vivo prothrombotic state/venous thrombosis as compared with no atherosclerosis 
or advanced atherosclerosis, with rigorous adjustments for potential confounding 
factors (33). 
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3. If the hypotheses in abovementioned study proposals turn out to be true, this will 
not immediately change clinical practice as for this a randomized trial with clinical 
endpoints is needed. Large randomized trials are not started in a vacuum, but 
require a high prior probability of success, some insight in pathophysiological 
mechanisms, and  need to be performed in specific groups who may benefit the 
most. The results of the studies as proposed in 1) and 2) will provide sufficient 
evidence to determine if such a trial should be conducted. Since the question as to 
whether a therapy is effective is answered by the number needed to treat per year 
(NNT per year), the secondary prevention of venous thrombosis after an unprovoked 
event with statins, where reasonable NNTs may be plausible because of high 
recurrent venous thrombosis event rates, could be feasible (72-75). It is in this aspect 
interesting to note that the current ACCP guideline suggests to discontinue 
anticoagulant treatment in patients with venous thrombosis who are considered to 
be at high risk of anticoagulation related bleeding (3). Although statins are unlikely 
to be as effective as anticoagulant drugs, they do have the major advantage over 
anticoagulants that they do not induce bleeding. Therefore, a drug to prevent 
recurrent venous thrombosis in patients at risk of bleeding that does not induce 
bleeding and in which the NNT for the prevention of recurrence is sufficiently high, 
is a remedy that we should continue to look for, and for which statin therapy might 
be a suitable candidate.
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A B S T R A C T
Purpose
The purpose of the study is to determine the immediate and long-term effect of statins 
on coagulation in patients treated with vitamin K antagonists (VKAs).
Methods
We selected patients on VKAs of two Dutch anticoagulation clinics who initiated 
treatment with a statin between 2009 and 2013. Patients who initiated or stopped 
concomitant drugs that interact with VKAs or were hospitalized during follow-up were 
excluded. The VKA dosage (mg/day) after statin initiation was compared with the last 
VKA dosage before the statin was started. Immediate and long-term differences in VKA 
dosage (at 6 and 12 weeks) were calculated with a paired student t test. 
Results
Four hundred thirty-five phenprocoumon users (mean age 70 years, 60% men) and 
303 acenocoumarol users (mean age 69 years, 58% men) were included. After start of 
statin use, the immediate phenprocoumon dosage was 0.02 mg/day (95% CI, 0.00 to 
0.03) lower. At 6 and 12 weeks, these phenprocoumon dosages were 0.03 (95% CI, 0.01 
to 0.05) and 0.07 mg/day (95% CI, 0.04 to 0.09) lower as compared with the dosage 
before first statin use. In acenocoumarol users, VKA dosage was 0.04 mg/day (95%CI, 
0.01 to 0.07) (immediate effect), 0.10 (95% CI, 0.03 to 0.16) (at 6 weeks) and 0.11 mg/
day (95% CI, 0.04 to 0.18) (after 12 weeks) lower.
Conclusions
Initiation of statin treatment was associated with an immediate and long-term minor 
although statistically significant decrease in VKA dosage in both phenprocoumon and 
acenocoumarol users, which suggests that statins may have anticoagulant properties.
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I N T R O D U C T I O N
Patients on vitamin K antagonists (VKAs) often have or develop arterial cardiovascular 
morbidity, for which they require cardiovascular drugs like statins (1,2). Statins are 
competitive inhibitors of HMG-CoA reductase that reduce cholesterol biosynthesis, but 
may also reduce the risk of venous thrombosis (3-5). However, the anticoagulant 
properties of statins are not well defined and it is unclear how statins could lower the 
risk of venous thrombosis (5). Currently, three randomised studies and one 
observational study have been conducted as to observe if statins have anticoagulant 
properties in VKA users (2, 6–8). These studies showed conflicting results, possibly due 
to the low number of participants enrolled or because (for the observational study) of 
residual confounding (2, 6–8). In addition, it is unclear whether potential anticoagulant 
properties of statins in VKA users are due to drug-drug interactions with VKA or due 
to pharmacodynamic effects of the statins. To gain more insight into the effects of 
statins on coagulation in VKA users, we compared coagulation of patients on VKAs 
before and up till 12 weeks after starting statin therapy.
M E T H O D S
Study design, patient selection, and data collection
Patients’ characteristics and outcomes were collected from the computerised records 
of the anticoagulation clinic Leiden and the Star-Medical Diagnostic Center, Rotterdam. 
At these anticoagulation clinics, all patients are monitored at least every 6 weeks. At 
each visit, a standard questionnaire is performed regarding initiation of concomitant 
medications and planned procedures after which blood is drawn to determine the INR. 
Based on the INR, the VKA dosage until the next visit is set by a trained physician at 
the anticoagulation clinic. 
All patients, who started treatment with VKAs (i.e. phenprocoumon or acenocoumarol) 
between January 2009 and December 2013, were screened. This time period was 
chosen as the coded registration of statin treatment in our databases started in 2009. 
Patients were included who started to use a statin within this period. Patients were 
excluded if they started to use inegy (combination of ezetimibe and simvastatin) 
because it is unknown to which degree both medications are attributable to a possible 
anticoagulant effect. Patients who were already using statins at baseline or started to 
use a statin within the first 2 months of VKA treatment were also excluded. Patients 
were excluded when they were hospitalised between the international normalized 
ratio (INR) measurement before and after statin initiation because for example an 
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acute myocardial infarction may affect coagulation and therefore change the outcome 
(INR and dosage of VKA). Patients were also excluded if they started or stopped any 
interacting medication with VKAs, according to the national interaction list of Dutch 
Anticoagulation Clinics, during their individual observation period within this study (9). 
Neither informed consent nor approval by a medical ethics committee is, according to 
Dutch law, required for studies in which data are collected from the records by the 
treating physician.
Outcome measures
INR and dosage of VKAs were determined on the last visit before and the first visit after 
start of statin use to assess an immediate anticoagulant effect. We determined the 
immediate difference in INR as this reflects the amount of coagulation at a particular 
time point. The immediate change in dosage of phenprocoumon or acenocoumarol 
after first statin use was expected to decrease if statins would increase the INR as VKA 
dosage is based on INR results. To study the long-term effect of statins on coagulation, 
the VKA dosage 6 and 12 weeks after statin initiation was compared with the last dosage 
before statin initiation. If no INR was available at these exact dates, the INR closest to 
the specific date of statin initiation was chosen. The differences in INR and dosage 
were also expressed in percentages. 
Statistical analysis
Data for continuous variables are expressed as means with standard deviations (SDs), 
and categorical data are expressed as numbers with percentages. In this study, patients 
are compared with themselves (cross-over analysis). Therefore, the mean difference 
in INR and VKA dosage with 95% CI was estimated by means of linear regression and 
was adjusted for study centre. The reference category in all analyses was the INR and 
VKA dosage at the last known date before first statin use. All statistical analyses were 
performed with R version 3.1.1.
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R E S U L T S
Clinical characteristics
Thirty-two thousand, two hundred ninety patients used VKAs between 2009 and 2013, 
of which 12,074 used phenprocoumon and 20,216 used acenocoumarol. Of these VKA 
users, 1,273 and 792 initiated a statin during VKA treatment respectively. Statin 
initiators who were not admitted to a hospital and did not initiate or stop drugs that 
interact with VKAs during the study period were included for the analysis, resulting in 
435 and 303 statin initiators on phenprocoumon and acenocoumarol, respectively. 
The mean age of the patients was 70 years (+/- standard deviation 10) when starting 
statin therapy (Table 1). The most common indication for VKAs was atrial fibrillation 
(n=537, 73%) and 438 patients (59%) were male. Simvastatin was the most initiated 
statin (n=516, 70%), while rosuvastatin was not initiated among phenprocoumon users 
in this sample. One patient started fluvastatin therapy among the phenprocoumon as 
Table 1. Clinical characteristics 
  Phenprocoumon Acenocoumarol
Patients 435 303
Age 70 (10) 69 (11)
Men 262 (60) 176 (58)
Indication VKA treatment*
Atrial fibrillation 337 (78) 200 (66)
Venous thrombosis 53 (12) 34 (11)
Mechanical heart valves 13 (3) 24 (8)
Vascular surgery 13 (3) 10 (3)
Ischemic heart disease 20 (5) 23 (8)
Other  12 (3) 1 (0)
Target range INR        
2.5-3.5 404 (93) 242 (80)
3.0-4.0 31 (7) 61 (20)
Type of statin used        
Simvastatin 310 (71) 206 (68)
Atorvastatin 60 (14) 51 (17)
Pravastatin 64 (15) 17 (6)
Rosuvastatin 0 (0) 28 (9)
Fluvastatin 1 (0) 1 (0)
Continuous variables denoted as mean (standard deviation), categorical variables as number (%). * Numbers 
do not add up to 100% as patients may have multiple indications for VKA treatment.
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well as among acenocoumarol users. Clinical characteristics were similar in 
acenocoumarol and phenprocoumon users and all patients kept the same INR target 
range during the study period.
Immediate INR and dosage change
Table 2 shows the INRs and mean VKA dose immediately after starting statin treatment 
in phenprocoumon and acenocoumarol users, respectively. After starting statin 
treatment, patients had an appointment at the anticoagulation clinic after on average 
1 week. The immediate average INR increase in phenprocoumon users was 0.10 (95% 
CI 0.04 to 0.17), or 6% (95% CI 3 to 8%). In acenocoumarol users no immediate change 
in INR was observed (INR 0.02 [95% CI -0.10 to 0.14] increased). The mean difference 
of daily dosage of phenprocoumon users was 0.02 mg per day (95% CI 0.00 to 0.03) 
lower and for acenocoumarol users 0.04 mg per day (95% CI 0.01 to 0.07) lower. 
Stratification by statin type showed that both INR changes and dose changes were 
similar between the different types of statins. 
Long-term dosage change
Table 3 shows the long-term change in VKA dosage after initiating statin therapy in 
acenocoumarol and phenprocoumon users respectively. The mean difference in daily 
dosage of phenprocoumon users was 0.03 (95% CI 0.01 to 0.05) mg per day lower after 
6 weeks and 0.07 (95% CI 0.04 to 0.09) mg per day lower after 12 weeks. The mean 
difference in daily dosage of acenocoumarol users was 0.10 (95% CI 0.03 to 0.16) mg 
per day lower after 6 weeks and 0.11 (95% CI 0.04 to 0.18) mg per day lower after 12 
weeks. After analyses were stratified by statin type, it appeared that a stronger decrease 
of VKA dosage was present in simvastatin (among acenocoumarol and phenprocoumon 
users) and rosuvastatin users (among acenocoumarol users) as compared with the 
other types of statins.
D I S C U S S I O N
The current study investigated the effect on anticoagulant properties within 738 
patients on VKA therapy who initiated statins. Results on immediate INR differences 
showed that the INR increased slightly in phenprocoumon users but not in 
acenocoumarol users. The effect of initiating statin treatment on the INR was also 
investigated in two randomised studies in healthy volunteers (2,6). The study from Yu 
Cu et al showed an INR increase of 0.16 nine days after rosuvastatin initiation, and the 
study by Jindal et al found no INR difference seven days after rosuvastatin initiation 
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(2,6). The results of our study confirm the results of these trials where the immediate 
INR increase was also close to null. In addition, the VKA dosage decreased in both 
phenprocoumon and acenocoumarol users which became apparent for both VKAs 
after 6 to 12 weeks. The results showed that initiating statin treatment is associated 
with a decrease of VKA dosage after 6 and 12 weeks, which suggests that statins interact 
with VKAs or have anticoagulant properties. 
A potential explanation for the decrease of VKA dosage in statin users is confounding. 
However, we did take confounding into account, as we compared patients with 
themselves in which, confounding by fixed (constant) characteristics (e.g. diabetes 
mellitus, hypertension and genetics) is eliminated. At the time that this study was 
conducted, INR ranges in the Netherlands were higher as compared to international 
guidelines. Because patients are compared with themselves and the INR target range 
stayed the same during the study period, INR target range could not have confounded 
our results. However, transient risk factors can introduce (non-fixed) confounding (10). 
For example, one non-fixed confounding factor is the initiation of concomitant 
medication or experiencing a cardiovascular event (e.g. a myocardial infarction). To 
avoid this type of non-fixed confounding, we excluded all patients who started or 
stopped medications that interact with VKAs during the study period or were admitted 
to the hospital. Another non-fixed confounding factor is an acute transient disease for 
example fever (11). However, such a transient disease is unlikely to explain the long-
term (6-12 weeks) effect that statins had on the VKA dosage in our study. A further 
possibility for the decrease in VKA dosage that we found after statin was initiated is 
that statins interact with VKAs. Acenocoumarol and phenprocoumon are racemic 
mixtures where the enantiomer largely responsible for the anticoagulant effect are 
metabolised by CYP3A4 and CYP2C9 (12). Stratification by type of statin showed that 
rosuvastatin and simvastatin were associated with the strongest decrease in VKA 
dosage. Rosuvastatin is only 10% metabolised by CYP2C9, while simvastatin is 
metabolised by CYP3A4 (13). The dosage decrease after initiation of rosuvastatin, which 
is hardly metabolised by CYP2C9, suggests that our results are not likely to be explained 
by drug-drug interactions. In addition, differences in lipophilicity of statins are also 
unlikely to account for the differences found between statins as rosuvastatin is 
hydrophilic while simvastatin is lipophilic. A potential other explanation is that statins 
do reduce coagulation, which was suggested by Sahebkar et al. because D-dimer levels 
decreased after three months of statin therapy and because D-dimer levels are markers 
of coagulation (14). To get more insight whether simvastatin and rosuvastatin have 
anticoagulant properties, a next step would be to investigate the effect of these statins 
on coagulation in patients not on VKAs. 
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Table 2. Immediate effect on INR and dosage after initiation of statin in VKA users
Mean
INR
(95% CI) Mean 
diff.
INR
(95% CI) Percentage
difference
(95% CI) Mean 
dosage
mg/day
(95% CI) Mean diff.
(mg/day)
(95% CI) Percentage 
difference
(95% CI)
Phenprocoumon
Any statin
Last date before start statin use n=435 2.96 (2.72 to 3.20) Reference Reference n=435 1.91 (1.58 to 2.24) Reference Reference
First date after start statin use n=435 3.15 (2.86 to 3.43) 0.10 (0.04 to 0.17) 6 (3 to 8) n=435 1.88 (1.55 to 2.21) -0.02 (-0.03 to 0.00) -1 (-1 to 0)
Simvastatin
Last date before start statin use n=310 3.03 (2.76 to 3.31) Reference Reference n=310 2.10 (1.70 to 2.49) Reference Reference
First date after start statin use n=310 3.18 (2.84 to 3.53) 0.13 (0.05 to 0.22) 6 (4 to 9) n=310 2.06 (1.68 to 2.45) -0.02 (-0.03 to -0.01) -1 (-1 to -1)
Atorvastatin
Last date before start statin use n=60 2.63 (1.85 to 3.41) Reference Reference n=60 1.29 (0.33 to 2.26) Reference Reference
First date after start statin use n=60 2.72 (2.02 to 3.42) -0.01 (-0.17 to 0.16) 3 (-4 to 9) n=60 1.29 (0.35 to 2.23) -0.01 (-0.03 to 0.01) 0 (-1 to 1)
Pravastatin
Last date before start statin use n=64 2.83 (2.69 to 2.98) Reference Reference n=64 2.10 (1.90 to 2.30) Reference Reference
First date after start statin use n=64 2.89 (2.73 to 3.05) 0.06 (-0.10 to 0.21) 4 (-2 to 9) n=64 2.10 (1.89 to 2.30) 0.00 (-0.02 to 0.01) 0 (-1 to 0)
Acenocoumarol
Any statin
Last date before start statin use n=303 2.91 (2.80 to 3.02) Reference Reference n=303 2.66 (2.45 to 2.86) Reference Reference
First date after start statin use n=303 3.04 (2.88 to 3.20) 0.02 (-0.10 to 0.14) 4 (0 to 9) n=303 2.63 (2.42 to 2.83) -0.04 (-0.07 to -0.01) -1 (-3 to 0)
Simvastatin
Last date before start statin use n=206 2.92 (2.78 to 3.05) Reference Reference n=203 2.69 (2.46 to 2.93) Reference Reference
First date after start statin use n=206 3.06 (2.87 to 3.24) 0.02 (-0.11 to 0.17) 4 (0 to 9) n=203 2.66 (2.42 to 2.90) -0.04 (-0.08 to -0.01) -2 (-3 to 0)
Atorvastatin
Last date before start statin use n=51 2.92 (2.62 to 3.21) Reference Reference n=51 2.71 (2.12 to 3.30) Reference Reference
First date after start statin use n=51 2.94 (2.51 to 3.37) -0.01 (-0.34 to 0.32) 6 (-7 to 19) n=51 2.68 (0.35 to 2.23) -0.02 (-0.06 to 0.03) -2 (-3 to 0)
Pravastatin
Last date before start statin use n=17 2.89 (2.54 to 3.24) Reference Reference n=17 2.04 (1.54 to 2.53) Reference Reference
First date after start statin use n=17 3.09 (2.46 to 3.73) 0.17 (-0.37 to 0.70) 8 (-12 to 28) n=17 2.00 (1.54 to 2.45) -0.06 (-0.33 to 0.21) 3 (-19 to 26)
Rosuvastatin
Last date before start statin use n=28 3.15 (2.90 to 3.40) Reference Reference n=28 3.04 (2.49 to 3.60) Reference Reference
First date after start statin use n=28 3.15 (2.88 to 3.43) 0.01 (-0.30 to 0.31) 3 (-7 to 13) n=28 3.02 (2.47 to 2.57) -0.02 (-0.04 to 0.00) -1 (-1 to 0)
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Though the current study is of etiological interest as it gives a lead why statins might 
be able to decrease venous thrombosis risk, its clinical effect appears to be minimal: 
INRs did not increase immediately and only marginally, and the VKA dose reduction 
was also minimal.
A potential limitation of our study is that co-medication was self-reported and the only 
statin reported by the pharmacy to the anticoagulation clinics was rosuvastatin. 
Consequently there may be discrepancies between the medication records of the 
anticoagulation clinics and what the patients used. As patients were compared with 
themselves, we expect that this has not influenced the results. An additional limitation 
is that we excluded patients who were hospitalised between the INR measurement 
before and after statin initiation. We did this because the assumption of the study, that 
there are no other environmental changes present that can affect VKA dosage and/or 
INR in the patient except that the patient started with statin, is otherwise not held. For 
that reason we could have missed patients of more ‘dramatic’ changes of 
anticoagulation, like patients with a major bleed. Furthermore, pharmacokinetics of 
the two studied VKAs do differ, for example phenprocoumon has a longer half-life as 
compared with acenocoumarol (12). However, differences in pharmacokinetics of the 
VKAs tested are unlikely to have contributed to the statin results found in this study 
as results were similar in both acenocoumarol- and phenprocoumon users. Another 
limitation is that we assumed that patients are compliant to their statin therapy. It is 
likely that not all patients were fully compliant as previous studies showed an average 
adherence to statins of 71-77% (15). Our results could therefore be diluted and the 
effects on VKA dosage are likely to be stronger if we could have taken statin adherence 
into close account. A final limitation of our study is that the dosage of statins was not 
registered in the electronic system. Therefore, no analyses could be performed that 
took the dosage of statin into account. 
In conclusion, we found that statin treatment was associated with a minor although 
statistically significant decrease in VKA dosage in both phenprocoumon and 
acenocoumarol users, which suggests that statins may have anticoagulant properties.
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A B S T R A C T
Background
Statins may exert a protective effect to the risk of venous thrombosis (VT), but the 
mechanism is unclear. 
Objectives
In this open label, randomized clinical trial (www.clinicaltrials.gov NCT01613794), we 
aimed to determine the ex vivo effect of rosuvastatin on platelet reactivity in patients 
with a history of VT. 
Methods
Platelet reactivity, in platelet reaction units (PRU), was measured at baseline and after 
28 days with the VerifyNow, which uses arachidonic acid to determine thromboxane-
mediated platelet aggregation, in 50 consecutive patients included in our study (25 
receiving rosuvastatin and 25 without intervention).
Results
Forty-seven out of 50 (94.0%) consecutively enrolled patients had 2 valid PRU 
measurements. Mean PRU in rosuvastatin users was 609 at baseline and 613 at end 
of study (mean change 5; 95% CI, -18 to 27). Mean PRU in non- users was 620 at baseline 
and 618 at end of study (mean change -2; 95% CI, -15 to 12). The mean difference in 
PRU change between users and non-users was 6 (95% CI, -20 to 33). Excluding patients 
who used antiplatelet medication, or had thrombocytopenia, revealed similar results, 
i.e. no apparent effect of rosuvastatin on PRU with a mean difference in PRU change 
between users and non-users of  -1 (95% CI, -20 to 19). 
Conclusions
Rosuvastatin does not affect platelet reactivity using arachidonic acid as agonist in 
patients with a history of VT.
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I N T R O D U C T I O N
Currently, the only effective strategy to prevent recurrent venous thrombosis is to 
continue anticoagulant therapy indefinitely (1). In view of the substantial risk of bleeding 
complications during such long-term use, other treatment modalities are urgently 
needed (2). That statins may exert a protective effect to venous thrombosis risk was 
first sparked in 2000, but remains controversial (3-4). Results from studies suggest a 
20-50% lower risk of venous thrombosis for patients using statins, with a greater risk 
reduction for rosuvastatin as compared with other statin types (5-8). However, the 
mechanism remains unclear (9). Dyslipidemia may be the most plausible culprit to be 
considered. However, as dyslipidemia is not related to an increased risk of venous 
thrombosis, and because non-statin lipid lowering drugs (i.e. fibrates) do not reduce 
venous thrombosis risk, it is unlikely that statins decrease venous thrombosis risk by 
lipid lowering activities (2,10). Another mechanism through which statins may decrease 
the risk of venous thrombosis is by inhibiting platelet activation and consequently 
aggregation (11-13). Animal models have shown that platelet activation plays a key role 
in the initiation of thrombus formation in deep vein thrombosis (11,12). Furthermore, 
in vitro studies indicate that statins inhibit platelet activation via several lipid-
independent mechanisms including the inhibition of thromboxane A2 (TxA2) formation 
(14). Although inhibitory effects of statins on platelet function assessed by ex vivo tests 
of platelet aggregation have been described in patients at risk for cardiovascular 
disease, the effects of statins on platelet function in patients with a history of venous 
thrombosis is unclear (15-17).  Since enhanced platelet aggregation has been reported 
in patients with venous thrombosis, and the VerifyNow assay can measure TxA2-
mediated platelet activation and aggregation, we decided to investigate the effect of 
rosuvastatin on platelet aggregation in patients with a history of confirmed deep vein 
thrombosis or pulmonary embolism as measured by the VerifyNow assay (18).
M E T H O D S
Design
Data from the STAtins Reduce Thrombophilia (START) study were used. START is a 
randomized, controlled, open label, clinical trial on whether the coagulation profile in 
persons with a history of objectively confirmed venous thrombosis will improve when 
using rosuvastatin. START is approved by the Medical Ethics Committee of the Leiden 
University Medical Center,  and registered at www.clinicaltrials.gov as NCT01613794.
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Participants
Patients aged >18 years with confirmed symptomatic deep vein thrombosis or 
pulmonary embolism who completed 3 to 12 months of treatment with vitamin K 
antagonists, and who were allowed to stop anticoagulant treatment by their treating 
physician were eligible for this trial. The study baseline visit was at the time of the last 
regular visit of the patient to the anticoagulation clinic. After written informed consent, 
participants were screened on acquired risk factors for thrombosis through a 
questionnaire and tested on blood parameters that may exclude a patient from taking 
rosuvastatin. After a time window of 28 days (+/- 5 days) (to allow a wear off of 
anticoagulant drugs), a blood sample was drawn at randomization visit, and at time of 
stopping rosuvastatin 28 days later. At randomization, participants were allocated to 
receive either rosuvastatin 20 mg/day for 28 days or no study medication. Blood 
samples were drawn at randomization visit and at the end of the 28-day study period. 
All blood drawings were performed between 08:30 am and 14:00 pm and at the same 
time of day. Platelet reactivity was measured using the VerifyNow Assay (Accumetrics, 
San Diego, CA, USA). The VerifyNow assay is a point-of-care device that measures 
thromboxane A2-mediated platelet activation, in platelet rich plasma, using an optical 
turbidimetry method and converts this into Platelet Reaction Units (PRU). In accordance 
with the manufacturer’s instructions, platelet reactivity was measured in citrated whole 
blood within 4 hours after venipuncture.  
Statistical analysis
The general characteristics of rosuvastatin users and non-users are reported as means 
and ranges. Mean PRU with 95% confidence interval (95% CI) were calculated at time 
of randomization and at the end of the study period. All analyses were performed by 
intention to treat. Changes in platelet reactivity were expressed as the mean difference 
(with 95% CI) in PRU at the end of the study period in rosuvastatin users versus non-
users. Since platelet reactivity was measured at two different time points (i.e. at 
randomization visit and at the end of study visit), we evaluated the change in platelet 
reactivity at an individual level. Mean within person changes in PRU were analyzed 
using a paired samples t-test in both rosuvastatin and non-rosuvastatin users. Mean 
difference in PRU change between rosuvastatin and non-rosuvastatin users was 
assessed using an independent t-test. Linear regression analysis was used to adjust 
mean PRU differences between rosuvastatin and non-rosuvastatin users for age, sex 
and type of index event (provoked or unprovoked). Since use of concomitant medication 
was known for each patient, a restriction analysis was performed excluding participants 
using antiplatelet drugs, or participants with known thrombocytopenia. Based on a 
standard deviation (SD) of 20 PRU, the study was powered to find a difference in PRU 
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change of 12 between 25 statin users vs. 25 non-users, with a 2 sided alpha=0,05 and 
80% power (19). We considered this as sufficiently powered to exclude a possible type 
II error, since a decrease in platelet aggregation in individuals who start to use aspirin 
is on average 200 PRU (19). All analyses were performed using SPSS version 21.0 (IBM 
Corp. Armonk, NY, USA).
R E S U L T S
The participants were included between September 2013-September 2014. For each 
group, the numbers of participants who were randomly assigned, received intended 
treatment, and were analyzed on PRU, is provided in Figure 1. We took 100 blood 
samples from 50 enrolled participants. During the 2 time points, 3 samples (3%) were 
unavailable for analysis: 2 were missing because of technical failure and 1 participant 
Excluded  (n=895)
- Not meeting inclusion criteria (n=473)
- Declined to participate (n=422)
Assessed for eligibility (n=945)
- Received allocated intervention (n=25)
- Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Technical failure (n=0)
Analyzed  (n=25)
- Excluded from analysis (n=0)
-
-
Allocated to non-statin treatment (n=25)
Received allocated intervention (n=25)
Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=1) 
Technical failure (n=2)
Analyzed  (n=22)
- Excluded from analysis (n=0)
Allocation
Analysis
Follow-Up
Randomized (n=50)
Allocated to rosuvastatin (n=25)
Figure 1. Flow diagram of eligible and analyzed START participants 
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was unable to deliver a second blood test at end of follow-up as he encountered a 
recurrent venous thrombotic event. During follow-up 47 out of 50 (94.0%) participants 
had valid PRU measurements at baseline and at the end of study (25 rosuvastatin users 
and 22 non-users). Their clinical characteristics are shown in Table 1. Mean age at 
enrollment was 59 years, and the majority were men. Two of the rosuvastatin users 
used antiplatelet drugs during the study period and 1 of the non-users had 
thrombocytopenia. The mean total cholesterol level in participants allocated to 
rosuvastatin treatment was 5.6 (3.4-9.0) mmol/L (range) at baseline and 3.6 (2.3-5.5) 
mmol/L (range) at end of follow-up (mean difference -2.0, 95% CI, -2.3 to -1.7). For the 
non-users these mean levels were 5.4 (3.5-7.7) mmol/L (range) at baseline and 5.1 (3.6 
to 6.5) mmol/L (range) at end of follow-up.
The effect of rosuvastatin therapy on platelet reactivity is shown in Table 2. Mean PRU 
in rosuvastatin users was 609 at baseline and 613 at end of follow-up (mean PRU 
change 5; 95% CI, -18 to 27). Mean PRU in non-users was 620 at baseline and 618 at 
end of follow-up (mean PRU change -2; 95% CI, -15 to 12).  The mean difference in PRU 
change between rosuvastatin users and non-users was 7 (95% CI, -20 to 33).  Restriction 
analysis showed similar results, i.e. no difference in PRU change between rosuvastatin 
users and non-users (mean difference in PRU change -1; 95% CI, -20 to 19). Adjustment 
for age, sex and type of index event (provoked/unprovoked) did not change these 
results (mean difference in PRU change 1; 95% CI, -19 to 20). PRU change per participant 
in rosuvastatin users and non-users is shown in Figure 2. As shown in this figure, most 
participants had a PRU change that was close to 0. Also the number of rosuvastatin 
users in whom the end of study PRU measurement was lower than the baseline PRU 
(n=14, 56%) was similar as in the non-users (n=11, 50%). 
Table 1. Clinical characteristics 
Rosuvastatin users Non-users
(n=25)          (n=22)
Mean age (range), y 59 (33-77) 59 (21-80)
Male, n (%) 17 (68) 18 (82)
Type of venous thrombosis, n (%)
Deep vein thrombosis 17 (68) 10 (45)
Pulmonary embolism   8 (32) 12 (55)
Unprovoked, n (%) 13 (52) 9 (41)
Provoked, n (%) 12 (48) 13 (59)
Concomitant antiplatelet drug use   2 (8) 0 (0)
Known thrombocytopenia, n (%)   0 (0) 1 (5)
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D I S C U S S I O N
We observed that rosuvastatin 20mg daily for 28 days did not affect arachidonic acid-
mediated platelet aggregation as measured by the VerifyNow assay. Therefore, our 
findings show that it is unlikely that the association of a decreased risk of venous 
thrombosis in rosuvastatin users is explained by decreased arachidonic acid-mediated 
thromboxane synthesis. However, a limitation of our study is that only the VerifyNow 
assay was used to evaluate platelet function. Therefore we cannot exclude potential 
other antiplatelet effects as can be measured using different platelet function tests 
Figure 2. Change in platelet reaction units (PRU) in rosuvastatin users and non-users
* Participant on antiplatelet drugs at or during follow-up (n=2) 
† Participant with thrombocytopenia (n=1)
Table 2. Effect of rosuvastatin therapy on platelet reactivity 
Mean PRU (range)
Baseline End of 
study
Mean change 
(95% CI)
Mean difference
in change (95% CI)
Adjusted mean 
difference in 
change (95% CI) *
Overall
Non-users (n=22) 620 618 -2 (-15 to 11) Reference Reference
Rosuvastin users (n=25) 609 613 5 (-18 to 28) 7 (-20 to 33) 14 (-13 to 40)
Restriction analysis †
Non-users (n=21) 628 624 -4 (-17 to 10) Reference Reference
Rosuvastin users (n=23) 624 619 -5 (-19 to 10) -1 (-20 to 19) 1 (-19 to 20)
* Adjusted for age, sex and index VTE event (provoked/unprovoked). † Excluding participants who use antiplatelet 
drugs at or during follow-up  (n=2), had known thrombocytopenia (n=1), or had extreme outliers (n=1). CI 
denotes confidence interval; PRU: platetelet reaction units.
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(20).  Another limitation of our study is that, due to the relatively small sample size, 
subgroup analyses were not performed. However, within-person changes in platelet 
reactivity were compared between exposures, which at least eliminates fixed-
confounding factors by design.  Furthermore, adjustments for age, sex and type of 
index event, yielded similar results, i.e. no difference in platelet reactivity change 
between rosuvastatin users and non-users. There is a possibility, however, that platelets 
behave differently in patients with a high thrombotic potential, which unfortunately 
we could not further investigate due to small numbers (21). Similarly, we cannot rule 
out the possibility that patients who were not willing to participate in this trial had a 
higher thrombotic potential, yielding different results regarding platelet reactivity in 
rosuvastatin users than we observed. 
Apart from an antiplatelet effect, several other pleiotropic effects of statins on 
coagulation have been described, including inhibition of tissue factor synthesis, 
increased thrombomodulin formation and enhanced fibrinolysis (22).
 The magnitude 
of contribution of these pleiotropic effects of statins on venous thrombosis risk is 
poorly understood and is beyond the scope of the current study. This needs further 
exploration for which we are currently continuing to enrol patients in our START trial 
(registered at NCT01613794). 
In conclusion, in this randomized controlled trial, rosuvastatin used for 28 days did not 
affect platelet reactivity using arachidonic acid as agonist in patients with a history of 
confirmed deep vein thrombosis or pulmonary embolism. 
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A B S T R A C T
Background
Observational studies indicate that statins reduce the risk of recurrent venous 
thrombosis, without increasing the risk of bleeding complications. However, trials have 
not been performed and the mechanism is unknown. Therefore, the aim of the STAtins 
Reduce Thrombophilia (START) trial was to investigate whether statin therapy improves 
the coagulation profile in patients with a history of venous thrombosis.
Methods
Randomized clinical trial (NCT01613794). Patients with prior venous thrombosis, who 
recently discontinued anticoagulant therapy, were randomized to rosuvastatin 20 mg/
day for 4 weeks or no intervention. Blood was drawn at baseline and at end of study. 
The primary outcome (for which the study was powered) was factor VIII:C. In total 5 
coagulation factors were measured: factor (F) VIII:C, von Willebrand factor (VWF:Ag), 
FVII:C, FXI:C and D-dimer.  
Results
Among 247 randomized participants, mean age was 58 years, 62% were women, and 
49% had unprovoked venous thrombosis. For all tested coagulation factors, the mean 
difference in change was lower or tended to be lower at end of study in rosuvastatin 
users versus non-users. Results were most consistent for FVIII:C. In rosuvastatin users, 
mean FVIII:C levels were 7.2 IU/dL (95% CI, 2.9 to 11.5)lower, while among non-users, 
no change in F VIII:C was observed (mean difference -0.1; 95% CI, -3.0 to 2.9). The mean 
age and sex adjusted difference in FVIII:C change was -6.7 IU/dL (95% CI, -12.0 to -1.4) 
in rosuvastatin users versus non-users. Subgroup analyses revealed similar results as 
in the main analysis, with the exception of participants with unprovoked venous 
thrombosis or in those with cardiovascular risk factors. In these participants the 
decrease in coagulation factors by rosuvastatin was more pronounced than in provoked 
venous thrombosis or absence of cardiovascular risk factors, respectively.
Conclusions
Rosuvastatin 20 mg/day improved the coagulation profile among patients with prior 
venous thrombosis. 
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I N T R O D U C T I O N
Venous thrombosis, the collective term for deep vein thrombosis of the leg, pulmonary 
embolism or both, is the third most common vascular disease after myocardial 
infarction and ischemic stroke (1). Venous thrombosis affects 1-2 per thousand people 
per year, has a 2.6% immediate death rate and recurrence rates of 25% within 5 years 
(2). Currently, the only effective strategy to prevent recurrent events is to continue 
anticoagulation indefinitely (3). In view of bleeding complications, safer options to 
reduce the risk of recurrent venous thrombosis are necessary (4). For this statins may 
form a suitable candidate as statins do not induce bleeding but may reduce the risk 
of venous thrombosis (4,5). In this aspect, results from observational studies that 
showed that statins are associated with a 30-50% lower risk of first venous thrombosis 
seem promising, but often included prevalent statin users in their statin exposure 
categories (6-8). Such prevalent users can introduce two types of bias: (1) under-
ascertainment of events that occur early after starting treatment (survivor bias) and 
(2) the inability to control for those who do or do not adhere to statin treatment 
(adherence bias) (9,10). For this matter, it is interesting to note that in a meta-analysis 
of statin use and risk of first venous thrombosis, only one of the seven mentioned 
studies included statin initiators in their study (new-user design) and reported an odds 
ratio of 1.02 (95% confidence interval [CI], 0.88 to 1.18), which is in contrast to the 
overall odds ratio of 0.62 (95% CI, 0.45 to 0.86) (7,8). This suggests that the observed 
association between statin use and a decreased risk of first venous thrombosis may 
have been biased due to the inclusion of prevalent users. However, other studies in 
which prevalent user bias was excluded by design have been published. In a cohort 
study of nearly 2 million individuals from the United Kingdom, in which a new-user 
design was used, the authors showed that rosuvastatin use was associated with a 
strongly (approximately 40%) reduced risk of venous thrombosis (11). That result closely 
resembles those from a randomized clinical trial in which apparently healthy individuals 
were randomized to rosuvastatin or placebo (JUPITER trial) where a 40% risk reduction 
when using rosuvastatin compared with placebo was found (12). In the absence of 
other randomized trials with venous thrombosis as the primary end point, Rahimi and 
colleagues presented a pooled analysis of 29 randomized statin studies in which venous 
thrombotic events were reported as serious adverse events (13). Although they failed 
to confirm a risk reduction of venous thrombosis by statin treatment, the authors 
found that individuals who were randomized to rosuvastatin still had an approximately 
40% reduced risk of venous thrombosis (hazard ratio, 0.65; 95% CI, 0.33 to 1.28) (13). 
Based on a report that showed that statins can reduce factor VIII, one would suspect 
that statin use protects to some extent against venous thrombosis by downsizing 
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coagulation activation (14). This finding should be interpreted with caution as it comes 
from a non-randomized study. Recently published findings from randomized clinical 
trials of statin therapy suggest some effect of lowering levels of von Willebrand factor 
and D-dimer (15,16). However, funnel plot analyses revealed that these positive results 
might be due to publication bias (15,16). Furthermore, no randomized clinical trials 
have investigated the impact of statin therapy on the risk of recurrent venous 
thrombosis. Not knowing a clear pathophysiological mechanism behind the supposed 
causal association between statin use and a reduced risk of recurrent venous 
thrombosis, may explain the lack of conducting such a costly and endeavoring trial. 
Therefore, the aim of the STAtins Reduce Thrombophilia (START) trial was to investigate 
whether statin therapy improves the coagulation profile in patients with a history of 
venous thrombosis. For this purpose, the effect of rosuvastatin use on several 
coagulation markers was assessed. Rosuvastatin 20 mg/day was chosen as the study 
drug as rosuvastatin consistently showed the strongest association between its intake 
and a reduced risk of venous thrombosis (11-13). 
M E T H O D S
Trial design
START is a multicenter, randomized, controlled, open label, clinical trial that investigates 
whether the coagulation profile in persons with a history of venous thrombosis will 
improve when using rosuvastatin. The open label design was chosen as it was 
considered unlikely that knowledge as to whether a participant received rosuvastatin 
or non-statin could affect the outcome (change in coagulation) one month later. We 
undertook the study in accordance with the Declaration of Helsinki and International 
Conference on Harmonization guidelines for Good Clinical Practice. All participants 
gave written informed consent prior to participation. START was approved by the 
Medical Ethics Committee of the Leiden University Medical Center, Leiden, the 
Netherlands, and is registered at www.clinicaltrials.gov as NCT01613794.
Participants
Participants were recruited at three anticoagulation clinics in the Netherlands ( Leiden, 
Hoofddorp and Rotterdam), which monitor anticoagulant treatment with vitamin K 
antagonists of patients with venous thrombosis in well-defined geographic areas. 
Individuals aged 18 years or older with (initial or recurrent) confirmed symptomatic 
proximal deep vein thrombosis or pulmonary embolism who were allowed to stop oral 
anticoagulant treatment by their treating physician, were eligible for the study. Reasons 
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for exclusion were: individuals already using statins or lipid lowering drugs, or any 
other contraindications for rosuvastatin 20 mg/day use as provided by the instruction 
leaflet of the manufacturer (17).
Intervention
Informed consent was obtained at the study baseline visit. The study baseline visit was 
defined at the time of the last regular visit of the patient to the anticoagulation clinic. 
After informed consent, participants were screened on acquired risk factors for 
thrombosis through a questionnaire and tested on liver and kidney function. At 
randomization, participants were allocated to receive either rosuvastatin 20 mg/day 
or no study medication. Allocating participants to treatment/no treatment was 
performed using randomisation. 
The duration of the study was 28 days. Such a treatment period was considered long 
enough to identify an effect of rosuvastatin on the coagulation system as some small, 
non-randomized, studies showed beneficial effects of statins on the coagulation system 
as early as after a 3-day statin administration (18).
Measurements
After a time window of 28 days (+/- 5 days) when patients stopped using their vitamin 
K antagonist (to allow a wear off of anticoagulant drugs), a blood sample was drawn 
at randomization visit and at the end of the 28-days study period. All blood drawings 
were performed between 08:00 am and 15:00 pm. Blood was collected in tubes 
containing sodium citrate (3.2%) and centrifuged within 3 hours of venepuncture at 
2500 g for 15 minutes at 18°C, after which plasma was immediately stored at -80°C. 
Laboratory technicians, who were unaware of which participants were rosuvastatin-
users, performed the assays after all participants had completed the study.
From these blood samples, levels of coagulation markers that are related to liver 
function (factor [F] VII:C,  FXI:C), and endothelial function (FVIII:C and von Willebrand 
factor [vWF]:Ag), and one global assay (D-dimer) were assessed (19,20). We decided to 
use this set of coagulation assays as these could globally indicate if and by which 
mechanism rosuvastatin reduces thrombophilia. 
All laboratory measurements (FVII:C, FVIII:C, FXI:C, D-dimer, VWF:Ag), were analyzed on 
the ACL-Top 700 analyzer (Instrumentation Laboratory).  FVIII:C, and FXI:C levels were 
measured using modified activated partial thromboplastins time assays using 
immunodepleted plasmas. Similarly, FVII:C was determined using a modified 
prothrombin time. VWF:Ag and D-dimer levels were measured using an automated 
latex enhanced immunoassay using the HemosIL VWF:Ag and the HemosIL D-dimer 
HS 500 reagent kit, respectively.
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Study size
Because high FVIII:C levels are strongly associated with recurrent venous thrombosis, 
the sample size was powered on FVIII:C (21,22). In a prior study from our group we 
observed that patients with venous thrombosis have a mean FVIII:C of 141 IU/dL 
(standard deviation 48) (21). With a number of 2*125=250 participants, we would be 
able to find a mean (between participants) difference of 17 IU/dL FVIII:C with a 2-sided 
alpha of 0.05 and 80% power.
Compliance
Adherence to the study protocol was assessed in 2 ways. First, participants who were 
randomized for rosuvastatin took the first tablet within the presence of an investigator. 
Second, compliance of rosuvastatin use was monitored by measuring total cholesterol 
levels at baseline and at end of study in all participants.
Statistical analysis
The general characteristics of the participants are reported as means and ranges. The 
mean levels with 95% confidence interval (95% CI) of the coagulation factors were 
calculated at time of randomization and at the end of the study period. Coagulation 
factors were log-transformed if not normally distributed (this happened to be the case 
for D-dimer). All analyses were done by intention to treat. Changes of coagulation 
factors were first expressed as the mean difference (with 95% CI) of coagulation factors 
at the end of study period in rosuvastatin users versus non-rosuvastatin users. Since 
we observed that more men were randomized to non-rosuvastatin use and that non-
rosuvastatin users were slightly older than those who were randomized to rosuvastatin, 
we a-priori decided to perform both unadjusted and age and sex adjusted analysis by 
means of linear regression methods to determine the between participant difference 
of various coagulation factors. Furthermore, we evaluated the change in coagulation 
factor levels at an individual level. Prespecified exploratory subgroup analyses included 
the following potential or established prognostic determinants of recurrent venous 
thrombosis: male/female sex, unprovoked/provoked first event, deep vein thrombosis 
or pulmonary embolism, and presence or absence of self-reported arterial 
cardiovascular risk factors (23-25). One post hoc analysis was performed in which we 
excluded all participants who reported signs or symptoms of an infection during the 
study, as infections can influence coagulation factors (26). 
All analyses were performed with SPSS version 24.0 (IBM, Armonk, NY, USA).
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R E S U L T S
Study population
The START trial was completed as planned; Figure 1 shows the trial profile. A total of 
255 participants were randomized between December 2012 and December 2016, with 
131 assigned to the rosuvastatin-therapy group, and 124 to the non-rosuvastatin group. 
As eight participants did not complete the study (5 rosuvastatin users and 3 non-
rosuvastatin users), follow-up was thus in 97% complete.  The reported reasons for 
not completing the study are noted in Figure 1. Table 1 presents baseline characteristics. 
Mean age was 57 years (range 19-82) in rosuvastatin users and 59 years (range 21-81) 
in non-rosuvastatin users; 68 (54%) of participants allocated to rosuvastatin were men, 
while this number was 84 (69%) in participants allocated to no treatment. Other 
reported exposures were balanced at baseline. Rosuvastatin treatment reduced mean 
cholesterol levels with 1.96 mmol/L (95% CI, 1.83 to 2.09), while this was 0.19 (95% CI, 
0.10 to 0.27)  in the participants who received no treatment. 
Figure 1. Trial profile
* One participant admitted to hospital with a diagnosis of acute asthma exacerbation
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Outcomes
For all tested coagulation factors in non-users, no difference was observed between 
the baseline value taken shortly after stopping VKA and the second blood sample drawn 
after 28 days. In contrast, in rosuvastatin users, coagulation factors decreased after 
28 days of treatment compared to baseline. (Figure 2 and Supplementary Table 1). 
In rosuvastatin users, mean FVIII:C levels were 7.2 IU/dL, (95% CI 2.9 to 11.5) lower, 
while among non-users, no change in FVIII:C was observed (mean difference -0.1; 95% 
CI -3.0 to 2.9). The mean difference in FVIII:C change also differed between rosuvastatin 
users and non-users (-7.2 IU/dL; 95% CI -12.4 to -1.4), with similar results adjusted for 
age and sex (adjusted mean difference in change (-6.7 IU/dL; 95% CI -12.0 to -1.4). For 
Table 1. Baseline characteristics
  Rosuvastatin users
(n=126)
Non-users
(n=121) 
General        
Age (years) 57 (19-82) 59 (21-81)
Male  68 (54) 84 (69)
Body mass index (kg/m2) 27.4 (19.2-43.5) 27.7 (17.2-43.2)
Baseline cholesterol (mmol/L) 5.61 (2.95-8.99) 5.59 (3.33-7.89)
Venous thrombosis characteristics      
Type of venous thrombosis      
 Deep vein thrombosis 72 (57) 65 (54)
 Pulmonary embolism 54 (43) 56 (46)
Unprovoked 57 (45) 64 (53)
Provoked, by 69 (55) 57 (47)
 Surgery/ Trauma/ Immobilization 32 (25) 31 (26)
 Travel > 4 hrs 22 (18) 14 (12)
 Estrogen use (% in women) 24 (41) 14 (38)
 Pregnancy/ puerperium (% in women) 0 (0) 2 (5)
 Malignancy 2 (2) 8 (7)
Recurrent venous thrombosis 10 (8) 8 (7)
Cardiovascular risk factors    
Current smoking 18 (14) 17 (14)
Hypertension 24 (19) 21 (17)
Diabetes 3 (2) 0 (0)
Overweight 54 (43) 51 (42)
Obesity 29 (23) 35 (29)
Continuous variables denoted as mean (range), categorical variables as number (%).
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FVII:C and FXI:C, results were very similar as for the FVIII:C analyses. VWF:Ag levels did 
not differ significantly by rosuvastatin use (mean difference -3.1 IU/dL; 95% CI, -9.5 to 
3.2 in the paired analysis and -1.4 IU/dl; 95% CI, -8.7 to 6.0 in the between comparison 
analysis). For natural log-transformed (Ln) D-dimer levels the mean change was 0.01 
ng/mL. (95% CI, -0.08 to 0.10) in rosuvastatin users and the between participants change 
in Ln D-dimer was -0.15 ng/mL (95% CI, -0.32 to 0.01).
In a post hoc analysis, where 8 participants who reported an infection during follow-up 
were excluded, a reduction of VWF:Ag levels by rosuvastatin use was revealed. In these 
participants without infection, the mean difference of VWF:Ag level in rosuvastatin 
users was -7.0 (95% CI -10.8 to -3.2), while among non-users, no change in VWF:Ag was 
observed. Similarly, the adjusted mean difference in VWF:Ag change differed between 
rosuvastatin users and non-users (adjusted mean difference in change -5.5 IU/dL (95% 
CI -10.6 to -0.4). Other coagulation factor outcomes were not materially affected by 
excluding these 8 participants with infection. 
Figure 2. Effects of rosuvastatin on measures of coagulation
In the posthoc analysis, 8 participants who reported an infection at end of study were excluded within person 
difference in rosuvastatin vs non-users, adjusted for age and sex
p between person difference in non-statin users
 between person difference in rosuvastatin users
¢ within person difference in rosuvastatin vs non-users, adjusted for age and sex
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Subgroup analyses revealed similar results as in the main analysis (Figure 3 for FVIII:C 
outcomes and Supplementary Table 2 for all measures of coagulation), with the 
exception of participants with unprovoked venous thrombosis or with cardiovascular 
risk factors. In these participants the decrease in coagulation factors by rosuvastatin 
was more pronounced than in those with provoked venous thrombosis or without 
cardiovascular risk factors, respectively. 
D I S C U S S I O N
This randomized study showed that one month of treatment with rosuvastatin 20 mg/
day led to an improved coagulation profile as compared with non-statin users in 
patients with prior venous thrombosis. Of all tested measures of coagulation, FVIII:C, 
for which the study was powered, showed the most robust results since rosuvastatin 
decreased FVIII:C not only within persons, but also between persons and in various 
subgroups. Other measures of coagulation also showed a shift to a less procoagulant 
state in participants treated with rosuvastatin, although not always on the level of 
Figure 3. Effects of rosuvastatin on measures of factor VIII:C in prespecified subgroups
p between person difference in non-statin users
 between person difference in rosuvastatin users
¢ within person difference in rosuvastatin vs non-users
DVT=Deep vein thrombosis, PE=Pulmonary embolism, VT=Venous thrombosis, CVD=Cardiovascular disease
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statistical significance. Interestingly, the decrease in coagulation factors appeared 
strongest in participants with unprovoked venous thrombosis and in those with 
cardiovascular risk factors. This could make sense from a pathophysiological 
perspective as previous studies showed that patients with unprovoked venous 
thrombosis more often have endothelial dysfunction or atherosclerosis than patients 
with provoked venous thrombosis or control individuals (27,28). Statins can modify 
endothelial function as early as after 28 days of treatment. This is of importance since 
endothelial dysfunction is associated with a procoagulant state (29,32).  Nevertheless, 
these subgroup analyses must be handled with caution as the study was not designed 
or powered to analyze differences in subgroups (33).
We observed 2 outliers for VWF:Ag, of which one participant (on rosuvastatin) had an 
increase of 300 IU/dL at end of study as compared with baseline and another (also on 
rosuvastatin) had an increase of 103 IU/dL. Both reported an infection at end of study, 
which may have caused this strong increase in VWF:Ag, and which made us decide to 
exclude all participants who reported an infection during the study period of 28 days 
(26). By doing so, VWF:Ag level changes were similar to FVIII:C. This is as expected 
because VWF is the carrier protein for FVIII in the blood circulation (34). In our study, 
FXI:C and FVII:C also decreased after treatment with rosuvastatin, which suggests that 
the anticoagulant activity of rosuvastatin is not only related to measures of coagulation 
that are affected by endothelial function, but also with liver function (19,20,35). D-dimer 
levels only showed an effect between participants. For natural log-transformed D-dimer 
levels, the adjusted mean difference between rosuvastatin users and  non-users was 
-0.13 (95% CI -0.30 to 0.03). Interestingly, this difference was not driven by a lowering 
of D-dimer levels, but by the absence of an increase in D-dimer in patients using 
rosuvastatin. Other studies suggest that the initial high risk of recurrent venous 
thrombosis is due to a rebound phenomenon of several markers of coagulation 
including D-dimer levels (36-38). Halting an increase in D-dimer by rosuvastatin may 
therefore be beneficial in patients with previous venous thrombosis in which 
anticoagulation is withdrawn. Larger studies with longer follow-up (e.g. the Saver trial, 
registered at www.clinicaltrials.gov as NCT02679664) are however needed to confirm 
this hypothesis as confidence intervals around the differences in D-dimer levels were 
wide and included unity.
We showed an overall mean decrease in FVIII:C levels of 7-8 IU/dL in rosuvastatin users, 
and a 10-12 IU/dL decrease of FVIII:C in participants with unprovoked venous 
thrombosis. This could be clinically relevant, as every 10 IU/dL decrease in FVIII:C levels 
is associated with a 15% (95% CI 7% to 22%) decrease in the risk of venous thrombosis 
(22). In addition, the anticoagulant effect of rosuvastatin was not limited to FVIII:C, but 
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was shown for several measures of coagulation that are associated with venous 
thrombosis. This suggests that the reduction of venous thrombosis in the JUPITER trial 
when using rosuvastatin, and the 25-50% lower risk of recurrent venous thrombosis 
in observational studies, may be mediated by an improved coagulation profile due to 
statin use (12, 39-41).    
A few issues about this trial warrant comment. First, we noticed a difference in 
distribution of sex and age after randomization, for which we a-priori decided to correct 
our analysis for these potential confounding factors. These adjustments did not 
influence our results. Second, previous observational studies and trials consistently 
showed that, of all statins, rosuvastatin was associated with the strongest risk reduction 
for venous thrombosis (11-13). For this reason, rosuvastatin 20 mg/day was the statin 
of choice in START and we cannot rule out that other statins differently or do not affect 
coagulation. The reason why rosuvastatin is able to improve coagulation, is beyond 
the scope of this study in which we wanted to show that rosuvastatin improves 
coagulation. It nevertheless may have to do with the fact that of all statins that are 
currently available on the market, rosuvastatin is most related with halting/regression 
of atherosclerosis, dyslipidemia, and inflammation (31,42,43). Some studies suggest 
that dyslipidemia, inflammation, or atherosclerosis, i.e. determinants for arterial 
cardiovascular disease, also increase the risk of venous thrombosis (27,44,45). The 
prime mover may therefore be found in one or more of these exposure categories, 
for which additional studies are warranted.
In order to definitively answer the question whether rosuvastatin should be used for 
the prevention of recurrent venous thrombosis, an adequately powered randomized 
clinical trial, with recurrent venous thrombosis as primary end point, should be 
conducted. The results of this trial support the conduction of such a trial from a 
pathophysiological perspective.
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CHAPTER 13
PART THREE  |  STATINS FOR PREVENTION OF RECURRENT VENOUS THROMBOSIS
Optimization of monitoring and 
management of anticoagulant therapy
Joseph Siegmund Biedermann
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Patients suffering from venous thrombosis or patients with atrial fibrillation, who are 
at risk of thrombotic complications, require anticoagulant therapy to prevent 
progression or onset of thrombotic events. Several anticoagulant agents are currently 
available, registered for different thrombotic indications. Of these, atrial fibrillation, 
venous thromboembolism and mechanical heart valves are the most common. 
Anticoagulant therapy is initiated in these patients to reduce coagulation capacity 
(thrombin generation). However, due to this change in the hemostatic balance, 
treatment with anticoagulants is accompanied by an increased risk of bleeding. 
Therefore, individual assessment of the risk of thrombotic versus bleeding complications 
is warranted before initiating anticoagulant therapy. Furthermore, during treatment 
with anticoagulants, patients should be managed adequately to continuously balance 
the risk of thrombotic and bleeding complications. Due to the relatively high bleeding 
risk associated with currently available anticoagulants, ongoing research focuses on 
development of safer anticoagulant strategies with similar efficacy. 
The aim of this thesis was to study current monitoring and management of 
anticoagulation therapy, especially therapy with vitamin K antagonists (VKA), in order 
to further improve the efficacy and safety of anticoagulant therapy in the future. 
Therefore, we first investigated the accuracy and safety of point-of-care INR monitoring, 
using the CoaguChek XS system, as a more patient-friendly alternative to laboratory 
INR monitoring in patients on VKA. We also evaluated the sensitivity of different 
thromboplastins, including the one incorporated in the CoaguChek XS test strips, 
regarding sensitivity to clotting factor VII, an important determinant of INR stability 
during VKA therapy. Next, we performed studies focusing on current VKA management. 
We evaluated the bleeding risk associated with the use of different low-molecular-
weight heparin (LMWH) agents during combined treatment with VKA in a large cohort 
of patients with new onset venous thrombosis. Furthermore, we investigated the 
agreement between two commonly used methods to estimate the quality of 
anticoagulation control during VKA therapy and we identified predictors of oral cavity 
bleeding and evaluated clinical outcome after dental procedures in patients on VKA. 
Finally, we investigated anticoagulant effects of statin therapy in patients with a history 
of venous thrombosis to explore the potential use of statins as a safer strategy to 
prevent recurrent venous thromboembolism.
Point-of-care monitoring in patients on vitamin K antagonists
In this thesis we have shown, in chapter 2, in a study cohort of nearly 3000 patients on 
VKA, that point-of-care (POC) INR results from the CoaguChek XS correlate strongly 
with the laboratory STA-R Evolution (Hepato Quick) INR results, especially in the 
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therapeutic INR range. This is in line with previous smaller studies comparing this POC 
device with different laboratory methods (1-6). Our findings implicate that INR results 
from the CoaguChek XS are interchangeable with different currently used laboratory 
methods. In daily practice a POC test is mainly used by self-monitoring patients, but 
our study indicates that VKA dosing schedules do not need adjustment to POC results. 
Therefore, thrombosis services can relatively easy implement this method for routine 
INR measurement in patients unwilling or incapable to perform INR self-monitoring 
(e.g. non-self-monitoring patients). In our study we did find some INR discrepancies 
between Coaguchek XS and STA-R Evolution (Hepato Quick) INR results (1). We observed 
that the CoaguChek XS slightly underestimated the INR at subtherapeutic levels 
(INR<2.0) and increasingly overestimated the INR at supratherapeutic levels (INR>4.5) 
compared to this laboratory method, a pattern that has been previously reported in 
literature (1, 7-9). It is important to mention though that the INR is, strictly speaking, 
only valid up until an INR of 4.5, since only plasma samples with an INR between 1.5-4.5 are 
used during the calibration process of any reagent-instrument combination used for INR 
measurement (10). Furthermore, similar INR discrepancy patterns have also been 
reported between different validated laboratory methods, including in comparisons 
where the same analyzer was used in combination with thromboplastin reagents from 
different sources (e.g. recombinant vs. tissue-derived) (11,12). Thus, it is likely that the 
INR differences are mostly thromboplastin reagent dependent rather than instrument 
dependent (12). 
Apart from satisfactory accuracy, measurement methods should also be precise 
enough in terms of reproducibility. In chapter 3 we have shown that the CoaguChek 
XS is precise enough for INR monitoring of both self-monitoring and non-self-monitoring 
patients (e.g. INR measured by a clinic) in relation to the biological variation of the INR 
during VKA treatment (13). The biological INR variation is based on the total within-
subject INR variation during stabile treatment, corrected for the analytical imprecision 
of the used measurement method (14). The analytical imprecision, defined as the 
imprecision coefficient of variation, should, preferably, not exceed 50% of the biological 
variation of the analyte (15, 16). The reported imprecision coefficient of the CoaguChek 
XS in high quality studies is approximately 2-4%, which is similar to the 2.9% we 
observed in our own study (1,2,7,9).  The biological INR variation in both self-monitoring 
and non-self-monitoring patients on acenocoumarol (approximately 10%) or 
phenprocoumon (approximately 8%) we found in our study was therefore in agreement 
with these goals. This implies that CoaguChek XS INR values are not only accurate, but 
also that the CoaguChek XS system is precise enough for clinical use in terms of 
reproducibility. Furthermore, the biological INR variation we observed during 
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CoaguChek XS monitoring of non-self-monitoring patients was comparable with the 
biological INR variation as observed in a previous study in laboratory monitored 
patients on warfarin (17). This suggests that our findings regarding biological variation 
in non-self-monitoring patients are likely to be also valid for patients on warfarin, 
enhancing the generalizability of our findings. Importantly, we have shown in chapter 
4 that, apart from satisfactory analytical performance, POC INR monitoring using the 
CoaguChek XS by a thrombosis service is a safe and effective alternative for laboratory 
INR monitoring in non-self-monitoring patients in terms of clinical outcome (e.g. 
thrombotic and bleeding complications) (18). This is highly relevant since POC INR 
measurement requires far less logistics than laboratory INR measurement for which 
a venous blood sample needs to be drawn, transported and processed. In addition, 
the POC INR result is immediately available making it possible to adjust VKA dose more 
rapidly. Furthermore, previous studies have shown that POC monitoring, either 
community based or through self-monitoring or self-management, is associated with 
increased patient satisfaction and experienced quality of life compared to routine 
monitoring (19-22). Therefore, POC monitoring in non-self-monitoring patients can 
improve the quality of life and eliminate the burden of venous blood sampling in the 
vast majority of patients currently on VKA. Finally, since patients become familiar with 
this method for INR measurement, more patients may be tempted to consider INR 
self-monitoring or even INR self-management due to their repeated experiences with 
the device. This may potentially further improve quality of care in these patients, since 
INR self-monitoring and self-management are associated with better anticoagulation 
control and a decreased risk of thrombotic complications (23). 
Some remarks should be made. First, several other POC devices have become available 
for INR monitoring. The results of this thesis cannot be directly translated to all 
situations where a different POC device is used, since suboptimal accuracy of some of 
these devices has been reported (24). Reliable INR results are pivotal to determine the 
need for dose adjustment in patients on VKA, which directly influences anticoagulation 
control and therefore the risk of complications during treatment. Thus, it is important 
that the accuracy and adequacy of these devices, including the used test strips, are 
continuously and systematically monitored. External quality assessment (EQA) 
programs for POC devices have been established and these programs contribute to 
the continuous safe use of these devices (25). Summarizing, the above-mentioned 
findings suggest that the use of this more patient-friendly monitoring method is 
suitable for virtually all patients on VKA, if adequate quality control of the POC device 
and test strips is established. However, POC monitoring in one specific group of patients 
should be discussed. The accuracy of POC INR results, including CoaguChek XS results, 
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has been questioned in patients with the antiphospholipid syndrome (APS). This has 
been triggered by reports of significant INR discrepancies between POC devices and 
laboratory assays in APS patients, although conflicting results on this subject have also 
been reported (26-28). 
It is good to emphasize though that similar INR discrepancies are also present when 
comparing different laboratory assays in APS patients, especially when results are 
obtained with thromboplastins from different sources (e.g. recombinant vs. tissue-
derived) (29). One study comparing INR results of different assays amongst each other, 
including the CoaguChek XS, in APS-patients and APL-negative controls, showed that 
the agreement between CoaguChek XS results and laboratory methods was dependent 
on the used thromboplastin in the laboratory assay (30). Agreement between 
CoaguChek XS results and a laboratory method was better when a recombinant 
thromboplastin (Innovin), similar to the one incorporated in the CoaguChek XS test 
strip, was used (30). Irrespective of the assay comparison, it is good to note that the 
“true” INR that best reflects the anticoagulant state of any patient, including those with 
APS, is unknown. To date, no studies have been conducted relating different monitoring 
methods to clinical outcome in APS patients. Although we found no differences 
regarding clinical outcome in unselected patients after switching from a tissue-extract 
thromboplastin (Hepato Quick) to a recombinant thromboplastin (CoaguChek XS) 
monitoring, we cannot definitively exclude such an effect in patients with APS (18). 
Currently, the subcommittee on anticoagulation control of the International Society of 
Thrombosis and Haemostasis advises to be cautious when interpreting INR results 
from POC devices in patients with APS and to validate the accuracy of POC readings 
before systematic use in these patients (31). Future studies should investigate the 
impact of POC monitoring on treatment quality and clinical outcome in patients with 
the anti-phospholipid syndrome. 
Reagent-dependent differences in INR stability due to differences in FVII 
sensitivity
Despite the safety of POC INR monitoring, we found that anticoagulation control, 
defined as percentage of time spent within the therapeutic range (TTR%), was 
statistically significantly poorer during POC monitoring as compared with standard 
laboratory monitoring (Chapter 4) (18). It should be emphasized that despite the slightly 
lower quality of anticoagulation control during POC monitoring, treatment quality 
remained satisfactory in the cohort of patients we studied, as reflected by high mean 
individual TTR results during POC monitoring and similar patient outcomes as during 
laboratory monitoring (18). Therefore, the question is whether the statistically 
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significant difference in TTR we observed in our study is of any clinical importance. It 
is likely that the lower TTR during POC monitoring we observed in our study can be 
explained by the difference in thromboplastin reagent incorporated in the test strips 
of the CoaguChek XS (recombinant human), compared to the reagent used in the 
laboratory method (tissue-derived). Similar differences in TTR have been observed 
between patients monitored with laboratory methods using thromboplastins from 
different sources (32).  The fact that we found no thromboplastin-dependent difference 
in quality of anticoagulation control in patients on phenprocoumon, was a strong 
indicator that differences in FVII sensitivity between reagents might explain this 
difference, since FVII levels fluctuate far less in patients on phenprocoumon than in 
patients on acenocoumarol (14,18,33). Previous studies have suggested that FVII 
fluctuations can, to a large extent, explain the variability of the INR in patients treated 
with warfarin and acenocoumarol (34). Therefore, reagent-dependent differences in 
FVII-sensitivity would explain the negative impact of POC monitoring on TTR in patients 
on acenocoumarol, while not affecting TTR in patients on phenprocoumon, when 
switching from a tissue-derived thromboplastin to a recombinant thromboplastin, as 
we observed in our study (18). Although differences in FVII-sensitivity have been clearly 
demonstrated between non-commercial thromboplastins, this has not been the case 
for different commercial thromboplastins used for patient monitoring in daily practice 
(35). In chapter 5, we demonstrated that differences in FVII-sensitivity also exist between 
commercially used thromboplastins, even despite optimal calibration (36). This 
implicates that FVII-mediated INR stability is affected both by the type of VKA used by 
the patient, as well as the reagent incorporated in the method used for monitoring. 
These insights obtained from our studies can be used to minimize FVII-mediated INR 
fluctuations and their impact on anticoagulation control during VKA treatment.
Strategies to negate FVII-mediated INR fluctuations
Recently, a new thromboplastin reagent for laboratory INR measurement has been 
introduced, completely insensitive to FVII, and thus also to FVII-mediated INR 
fluctuations (37). This reagent, the Fiix-PT, has shown to be non-inferior to routine 
laboratory monitoring regarding clinical outcome, both in terms of efficacy (thrombotic 
risk) and safety (bleeding risk), but improved INR stability and reduced the number of 
required dose adjustments in patients on warfarin (38). Since INR stability is related to 
the monitoring frequency, also the average required monitoring frequency in these 
patients was reduced (38). Furthermore, Fiix-PT was associated with a shorter time 
until stable VKA dose in warfarin naïve patients (38, 39). It would be interesting to 
explore whether this reagent can be incorporated in a POC device, to improve INR 
stability and reduce the measure frequency during POC monitoring.
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A different strategy to improve INR stability and anticoagulation control would be to 
reduce the occurrence and magnitude of FVII fluctuations in patients on VKA. FVII 
fluctuations are strongly dependent of the half-life of the used VKA agent. Medium to 
large fluctuations have been observed in acenocoumarol and warfarin treated patients, 
while in patients on the long-acting phenprocoumon FVII levels fluctuate far less during 
stabile treatment (33, 40). Therefore, switching patients from acenocoumarol and 
warfarin to phenprocoumon may improve INR stability, especially benefiting patients 
monitored with recombinant thromboplastins (32). In general, clinicians should be 
aware that the combination of thromboplastin reagent used for monitoring, and the 
half-life of the used VKA by their patients, affects the average quality of anticoagulation 
control in their patient population. Regarding this, it should also be mentioned that 
switching unselected patients from a tissue-derived thromboplastin (Hepato Quick) to 
a human recombinant reagent (CoaguChek XS) was safe and not associated with poorer 
clinical outcome in our study despite lower TTRs (18). Similarly, despite consistently 
higher TTR and less INR variability as observed during phenprocoumon treatment, the 
risk of bleeding and thrombotic complication is equal or even lower in patients treated 
with acenocoumarol than in patients treated with phenprocoumon (41, 42). Large 
cohort studies, following these patients over a longer period, may be needed to 
definitively exclude whether these small FVII-mediated differences in TTR do affect 
long-term clinical outcome. 
It has also been postulated that TTR and INR stability could be improved by routine 
supplementation of fixed low doses of vitamin K, to decrease dietary-induced FVII 
fluctuations (43). Several studies on this topic have been performed using different 
vitamin K doses, mostly showing minor or no improvement in TTR (44-49). Furthermore, 
these studies also failed to demonstrate lower rates of bleeding or thrombotic 
complications, although most of these studies were underpowered for clinical 
outcomes. Therefore, routine supplementation of fixed dose vitamin K is currently not 
recommended based on the available evidence (48, 50). 
Lastly, INR stability can also be influenced by cytochrome P450-mediated drug and 
food interactions. Recently, a new VKA agent that is metabolized by esterases, 
tecarfarin, has been tested in a randomized controlled trial in patients on warfarin (51). 
However, this new VKA was not associated with higher TTR compared to warfarin, or 
with a lower risk of thrombotic or bleeding complications (51). Nevertheless, in general, 
reducing the number of food and drug interactions of VKA may improve long-term 
clinical outcome and can reduce the required monitoring frequency in these patients.
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Management of VKA therapy
In the HARM study, van den Bemt et al. identified oral anticoagulants as one of the 
most important sources of preventable hospital admissions related to medications 
(52). Due to the many food and drug interactions of VKA, and their unpredictable 
anticoagulant effect, these drugs require monitoring and constant management to 
reduce the risk of complications during exposure. Also, it is well known that patients 
on anticoagulants are at increased risk of thrombotic and bleeding complications in 
the perioperative period. Therefore, standardized management strategies, 
incorporating both the risk of the procedure, as well as the thrombotic and bleeding 
risk of the individual patient, have been proposed (53,54). In order to reduce 
periprocedural complications, we evaluated the perioperative management strategy 
and identified several predictors of bleeding after low-risk and high-risk dental 
procedures (Chapter 6).  We found that most predictors of postoperative bleeding were 
specifically related to the followed perioperative management strategy and that the 
risk of bleeding increased when guideline recommendations were not followed. This 
underlines the importance of adherence to management guidelines to optimize clinical 
outcome in VKA treated patients undergoing invasive procedures. In general, 
perioperative management guidelines might be able to be refined through further 
risk-stratification of specific procedures. This is in line with current developments in 
the field, where specific low-risk procedures such as colonoscopies and pacemaker 
implantations are now being performed at therapeutic INR levels (54,55). To achieve 
this, information exchange between hospitals and anticoagulation clinics would also 
need further improvement and standardization. Currently, a study is being conducted 
investigating whether in-hospital antithrombotic stewardship can improve the efficacy 
and safety of antithrombotic therapy during and after hospitalization (56). The 
outcomes of this study may also improve future VKA management immediately after 
hospitalization, since patients are also at an increased bleeding risk during the first 
three months of VKA therapy (57). Part of this increased risk can be explained by the 
concomitant usage of low-molecular-weight heparin (LMWH) therapy, which is 
continued until an adequate INR is reached. These patients are therefore shortly 
exposed to dual anticoagulant therapy. Moreover, due to standard VKA startup dosing 
schedules, some patients already present themselves with supratherapeutic INR levels 
at anticoagulation clinics before LMWH treatment is discontinued, also associated with 
an increased bleeding risk (57). We evaluated the bleeding risk during combined LMWH 
and VKA therapy in patients with acute venous thrombosis, and investigated whether 
differences between LMWH agents existed regarding the risk of bleeding. (Chapter 6). 
It was reassuring that the absolute bleeding risk during combined VKA and LMWH 
therapy was low, and not dependent on the used LMWH agent. Our findings suggest 
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that twice daily LMWH dosing is associated with an increased bleeding risk, which was 
also recently reported in patients initiating VKA treatment and enoxaparin for acute 
venous thrombosis (58). This was a propensity-score matched study, making it less 
likely that confounding could explain the increased bleeding risk of twice daily LMWH 
dosing compared to once daily dosing in these patients, although residual confounding 
by indication can never be completely excluded in non-randomized studies. Together 
though, these two studies strengthen the observation of two meta-analyses reporting 
a trend towards an increased bleeding risk associated with twice daily LMWH dosing 
(59,60). An adequately powered randomized controlled trial may be needed to confirm 
or exclude this definitively.
Finally, we compared two different methods (the cross-sectional proportion (CSP) of 
INR results within therapeutic range and the time in therapeutic range (TTR) according 
to Rosendaal) to assess therapeutic quality control in several different groups of patient 
on VKA (61). The TTR is calculated based on linear interpolation between consecutive 
INR measurements, while the CSP is defined as the percentage of patients for whom 
their last INR result was within the therapeutic range (61). Both methods have their 
advantages and disadvantages, but both are suitable to estimate the average quality 
of anticoagulation control of a group of patients, which can be used as a marker of 
quality of care by health care providers. In almost all comparisons, both methods 
showed nearly identical results, suggesting that the results of both methods can be 
used interchangeably (61). This is convenient since the Rosendaal method is not always 
available, especially in low-resource countries, which can use the CSP method as an 
alternative to estimate the quality of care they provide. An important limitation of the 
CSP method is that it cannot be used for individual risk assessment of thrombotic and 
bleeding complications, since it provides no information on individual longitudinal 
anticoagulation control (62). Several other parameters of anticoagulation control have 
been linked to clinical outcome during VKA therapy in individual patients, including the 
percentage of INR results in the therapeutic range (PPINR) and the variability of the 
INR (63, 64). Multiple studies have reported that these parameters may provide 
additional prognostic information, apart from the TTR, regarding the risk of bleeding 
and thrombotic complications (65, 66). However, these findings have also been disputed 
by a recent study showing limited additional predictive value of INR variability when 
combined with TTR (67). Regardless of the used method to estimate therapeutic quality 
control, monitoring individual patients on VKA, based on the achieved quality of 
anticoagulation control during treatment, enables caretakers to adjust therapy 
accordingly. 
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Anticoagulant effects of statins
The interest for statins as potential anticoagulant treatment strategy was triggered in 
2000 based on the results of the prospective cohort study from Grady and colleagues 
and further amplified by results from the Jupiter trial in 2009 (68,69). In this trial, 
rosuvastatin use was associated with a 43% reduction in the risk of a first VTE in healthy 
men and women with low cholesterol levels and high levels of C-reactive protein (67). 
Since this trial, multiple observational studies have also related statin use to decreased 
risk of both first and recurrent VTE (70-72). However, strong VTE risk reductions through 
statin use have also been disputed (73-75) Apart from epidemiological studies with 
clinical end points, animal studies and in vitro studies have also been performed linking 
statin use to anti-inflammatory and antithrombotic effects (76). However, there is 
currently no evidence from randomized studies that directly relate statin therapy to a 
reduced risk of recurrent VTE. An important reason for the lack of clinical trials in this 
area is that a clear pathophysiological mechanism through which statins could reduce 
VTE risk has not been established (77).  Evidence from clinical trials and consequent 
meta-analyses relating statin use to changes in hemostatic thrombotic risk factors has 
been inconsistent, difficult to interpret due to the use of different statins in different 
dosages, likely subjected to publication bias, and not performed in the intended target 
population  (e.g subjects at risk of recurrent VTE) (78-80). 
We explored the anticoagulant effect of rosuvastatin in patients with a history of venous 
thrombosis after termination of anticoagulant treatment. The fact that statins do not 
increase the risk of bleeding makes them a potentially attractive therapeutic strategy 
for VTE prevention, especially in patients with a high risk of bleeding complications 
(82,83). In addition, these drugs may be considered as adjuvant therapy in patients 
who experienced recurrent VTE during anticoagulation therapy. Furthermore, insight 
in the anticoagulant effects of these drugs may also lead to new mechanistic insights, 
particularly in the crosstalk between inflammation, atherosclerosis and hemostasis 
(84,85).
In our START trial, we observed that rosuvastatin use did not affect arachidonic acid-
mediated platelet reactivity (Chapter.11), but was associated with clear reductions in 
FVIII, FXI and VWF levels (Chapter 12) (86). High levels of these clotting factors have 
each been related to an increased VTE risk (87-90). Therefore, reductions in these 
clotting factors provide a pathophysiological rationale behind statin-mediated VTE risk 
reduction, if truly present.  We observed no increases in other coagulation parameters 
associated with VTE risk, such as FVII or D-dimer levels. This suggests that rosuvastatin 
exerts a net anticoagulant effect, although we did not measure each of the individual 
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clotting factors. Similarly, maintenance dosages of both acenocoumarol and 
phenprocoumon also decreased after initiation of statin therapy in VKA users (Chapter 
10), also suggesting a decrease in thrombin generation (91). A possibility to assess the 
net effect of rosuvastatin on the hemostatic balance would be to compare thrombin 
generation potential before and after initation of statin therapy. The net impact of 
these relatively small reductions in prothrombotic coagulation factors, in relation to 
recurrent VTE risk, is impossible predict. In order to definitively answer the question 
whether statins should be used for recurrent VTE prevention, an adequately powered 
randomized controlled trial with recurrent VTE as primary end point, should be 
conducted. Our studies support the conduction of such a trial from a pathophysiological 
perspective.
DOACs and future anticoagulant therapy strategies
Direct oral anticoagulants (DOACs) have been introduced over the last decade for 
several different thrombotic indications including atrial fibrillation and venous 
thrombosis. These agents reduce thrombin generation through either direct inhibition 
of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban). It is expected 
that these DOACs will increasingly replace VKAs for the majority of patients requiring 
anticoagulant therapy, due to their similar efficacy, combined with their comfort of 
use, predictable pharmacokinetics and their favorable bleeding risk profile compared 
to VKAs (92). These agents are associated with a significant reduction in the risk of 
intracranial bleeding, at the cost of a slight increased risk of gastro-intestinal bleeding 
(93). Due to the shift in bleeding localization, the risk of fatal bleeding is also lower 
during DOAC therapy compared to VKA therapy (93). The stable and predictable 
anticoagulant effect of DOACs ensures no routine requirement for monitoring of these 
agents (94,95). However, the lack of a need for monitoring may also be a potential 
pitfall. In case of suboptimal adherence or non-adherence, patients are exposed to an 
increased risk of thrombotic complications (96,97). Furthermore, since most patients 
requiring these drugs are older, decline in renal function and poor DOAC adherence 
due to decline in cognitive function, may also impose a threat to the continuous safe 
use of these drugs. Periodical) evaluation of patients treated with DOACs, including 
assessment of renal function, is warranted to ensure safe use of these agents. Although 
routine monitoring of DOAC concentrations is not required and currently not 
recommended, knowledge of DOAC concentrations in emergency settings may be 
useful. In case of major bleeding, urgent surgery or the need for thrombolysis in 
ischemic stroke patients, DOAC concentrations may directly influence the risk of 
bleeding and should therefore be incorporated in clinical decision making if possible 
(94). Measurement of DOAC plasma concentrations, however, is not always available, 
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let alone in emergency setting with a very limited time window. Point-of-care tests to 
measure DOAC concentrations or the anticoagulant effects of DOACs have been 
developed and may improve outcome of DOAC users in these emergency setting in 
the future (98, 99).
For patients with mechanical heart valves, dabigatran was shown to be inferior to 
warfarin, both in terms of efficacy (e.g. ischemic stroke risk) and safety (e.g. bleeding 
risk) (100). These patients need to be treated with VKA, since no other DOAC studies 
have been conducted in these patients. Therefore, future studies on optimal VKA 
management should specifically focus on patients with mechanical heart valves.  
The superiority of DOACs over well-managed VKAs remains somewhat debatable since 
quality of anticoagulation control in several DOAC trials in patients with atrial fibrillation 
was suboptimal, directly affecting the risk of adverse events in the warfarin arms 
(101,102). Observational studies have shown a low risk of adverse events in well-
managed warfarin patients, some even lower than reported in many of the DOAC trials 
(67,103,104). Furthermore, it has even been suggested that INR self-monitoring is a 
more cost-effective approach than treatment with dabigatran for long-term 
anticoagulant prophylaxis (105). Regardless of the superior efficacy of either VKA or 
DOACs, the risk of major and fatal bleeding complications during exposure, although 
lower with DOACs, remains present for both classes of drugs. Several developments 
are currently ongoing in the search for even safer anticoagulants with similar efficacy. 
The contact activation pathway, and especially factor XI, has been recognized as an 
attractive new target for anticoagulant drug development (106-108). In the landmark 
trial by Büller and colleagues, it was shown that a Factor XI antisense oligonucleotide 
was at least as effective as low-molecular-weight heparin in preventing venous 
thromboembolism in patients undergoing total knee arthroplasty, and, importantly, 
was associated with significantly fewer bleeding complications (109). Future clinical 
studies should demonstrate the efficacy and safety of FXI targeting drugs in the 
treatment of acute venous thrombosis or for stroke prophylaxis in patients with atrial 
fibrillation. Apart from factor XI, several other potential targets for antithrombotic 
treatment have been identified, predominantly agents affecting local and systemic 
inflammation (110). Increasing evidence suggests that inflammatory cytokines 
(interleukines) or a pro-inflammatory state, contributes to both the pathogenesis of 
atherothrombosis as well as venous thrombosis (85). Currently, different phase 3 and 
4 trials are ongoing evaluating the effects of different anti-inflammatory agents (IL-1β 
IL-6, TNF-α blockers and low-dose methotrexate), on (recurrent) thrombotic events in 
patients with or at risk of cardiovascular disease (85). These studies and further insight 
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into the working mechanisms of these targets may eventually lead to the development 
of the ideal anticoagulant drug; a highly effective agent with (virtually) no bleeding 
complications. Until that time, the optimal use of current available agents is the best 
strategy for effective and safe anticoagulant treatment. Individual risk and benefit 
assessment should guide the choice for a particular anticoagulant strategy in close 
consultation with the patient. 
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S U M M A R Y 
Patients at risk or suffering from arterial or venous thrombosis require anticoagulant 
therapy to prevent the onset, progression or recurrence of thrombotic events. Although 
currently available agents are effective, their protective effects come at a high cost, 
since patients are exposed to an increased bleeding risk during treatment. We have 
performed several studies focusing on current monitoring and management of 
anticoagulation therapy, in order to improve the safety and efficacy of monitoring and 
management of anticoagulant agents in the future. 
The first part of this this focuses on the monitoring of treatment with vitamin K 
antagonists (VKA). In chapter 1, the general introduction, we present an overview of 
current monitoring and management of anticoagulation therapy. Next, in chapter 2, 
we compared the analytical and clinical agreement between point-of-care (CoaguChek 
XS) and laboratory (STA-R Evolution, Hepato Quick) INR results in a cohort of over 3000 
patients treated with VKA. We found that INR results from both methods correlated 
strongly (R=0.901, P<0.001), especially in the therapeutic INR range. The numerical 
difference between methods increased with increasing INR. The mean INR difference 
between methods ranged from -0.18 (95%CI, -0.20 to -0.16) INR point for point-of-care 
results 2.0-3.0, up to 1.14 (95%CI, 0.87 to 1.42) INR point for point-of-care results 7.1-
8.0. Overall, clinical agreement regarding therapeutic range was generally satisfactory 
(88%), but disagreement did occur at both subtherapeutic and supratherapeutic INR 
levels. In chapter 3, we assessed the within-subject biological INR variation (CV in %) 
in self-monitoring (n=322) and non-self-monitoring (n=123) patients who received a 
stable dose of either acenocoumarol or phenprocoumon. All patients monitored 
themselves or were monitored by staff using the CoaguCheck XS system. In the self-
monitoring patients, median within-subject CV was significantly higher in patients on 
acenocoumarol than in patients on phenprocoumon (10.2 vs. 8.6%, P=0.001). In patients 
receiving low-intensity acenocoumarol no difference in median within-subject CV was 
observed between self-monitoring and non-self-monitoring patients (10.4 vs. 10.2%, 
P=0.690). The approximate imprecision coefficient of variation of the CoaguChek XS 
system as reported in literature (4%), should not exceed half of the observed biological 
variation in any of the studied patient groups in order to be suitable for monitoring 
these patients.  Based on the biological INR variation we observed in this study, the 
analytical performance of the CoaguChek XS system is satisfactory for INR monitoring 
in these patients. Next, in chapter 4, we investigated the impact of point-of-care (POC) 
INR monitoring on quality of treatment in non-self-monitoring patients on VKA. We 
evaluated both the quality of anticoagulation control, as well as clinical outcome, by 
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comparing two non-self-monitoring patient cohorts of almost 2000 patients. Regarding 
the quality of anticoagulation control, median time in therapeutic range (TTR%) was 
significantly lower during POC monitoring (77.9% [95%CI, 67.2 to 87.4]) than during 
laboratory monitoring (81.0%, [95%CI, 71.1 to 90.5]; P<0.001). Similarly, the percentage 
of patients with poor anticoagulation control (TTR<60%) was higher during POC 
monitoring than during laboratory monitoring (10.7% vs. 14.5%, P<0.001). Overall, 
median TTR remained satisfactory according to Dutch guideline recommendations. 
We found no differences in the risk of major bleeding, ischemic stroke, hospitalization 
and all-cause mortality between the two cohorts (all adjusted hazard rates around 
unity), indicating that point-of-care INR monitoring was safe in these patients and non-
inferior to standard laboratory monitoring regarding clinical outcome. In chapter 5 
we explored the sensitivity of 6 different commercial thromboplastin reagents (three 
human recombinant and three tissue-derived) to Factor VII (FVII). We spiked five 
different pooled plasma samples of patients on VKA with three different concentration 
of purified human FVII (0.006, 0.012, and 0.062 μg/mL plasma) or buffer as control.  We 
measured dose-dependent INR decreases after spiking with FVII with all six reagents. 
A significant difference in FVII-induced proportional INR change was observed between 
the six thromboplastins (P=0.004). In contrast, proportional INR changes did not differ 
amongst the tissue-derived (P=0.575) or the recombinant (P=0.085) reagents. Pooling 
of the data from the two thromboplastin types (e.g. human recombinant vs. tissue-
derived) revealed that FVII-induced INR changes were significantly greater when 
measured with a recombinant reagent. These data confirm that recombinant human 
thromboplastins are more sensitive to FVII than tissue-derived thromboplastins.
The second part of this thesis focuses on the management of anticoagulation therapy. 
In chapter 6 we evaluated the major bleeding risk of different low-molecular-weight 
heparins (LMWH) during combined treatment with VKA in almost 13,000 out-hospital 
patients with new onset venous thrombosis. Overall, the risk of major bleeding was 
low with a cumulative incidence of 2.5 per 1000 patients (95%CI, 1.7 to 3.5). Cumulative 
incidences of major bleeding did not significantly differ between LMWHs using 
nadroparin once daily as reference, and ranged from 2.1 per 1000 patients for 
nadroparin once daily to 3.8 per 1000 patients for enoxaparin. A trend towards an 
increased major bleeding risk was observed when comparing once daily with twice-
daily nadroparin dosing (relative risk 1.98; 95%CI, 0.76 to 5.14). The absolute increased 
risk of major bleeding associated with twice daily nadroparin dosing was 0.13% resulting 
in a number needed to harm of 767.  Next, in chapter 7, we studied the agreement 
between two different methods for assessment of therapeutic quality control in 
different patient groups on VKA. The percentage of time in therapeutic range (TTR%) 
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was compared with the cross-sectional proportion of INR results within the therapeutic 
range (CSP%) using data reported by members of the Federation of Dutch Thrombosis 
Services between 2010 and 2013.  Overall, TTR results were slightly, but consistently 
higher than CSP results. Good correlation was observed between methods in patients 
on acenocoumarol and excellent correlation between methods in patients on 
phenprocoumon. In long-term patients on acenocoumarol, median TTR was significantly 
higher than CSP (80.0% vs. 78.7% respectively, P<0.001), while patients on 
phenprocoumon no difference between methods was observed. The differences 
between methods in patients on acenocoumarol in contrast to patients on 
phenprocoumon may be explained by differences in INR variability between consecutive 
INR results within the therapeutic range. In chapter 8, we evaluated the perioperative 
management strategy, identified predictors of post-procedural oral cavity bleeding 
and assessed clinical outcome after 2329 dental procedures performed in over 2000 
patients VKA. We found that guideline adherence was suboptimal as demonstrated by 
heterogeneous VKA management.  Patients undergoing low-risk dental procedures 
during which VKA was continued in combination with a local prohemostatic agents 
(tranexamic acid mouthwash) in line with local guidelines, had a significantly lower 
bleeding risk to those where VKA was continued without a prohemostatic agent 
(OR=0.41; 95%CI, 0.23 to 0.73) or where VKA was interrupted and bridged with LMWH 
(OR=0.49; 95%CI, 0.24 to 1.00) and not a significant increased risk compared to complete 
interruption of anticoagulant therapy (OR 1.44; 95%CI, 0.62 to 3.64). In contrast, VKA 
continuation was associated with a 3-fold increased bleeding risk after high-risk dental 
procedures compared to VKA interruption. Multivariate analysis revealed that most 
risk factors for post-procedural bleeding were specifically related to the followed 
perioperative management strategy.  The risk of thromboembolic complications after 
dental procedures was low (0.2%) and not related to management strategy or procedure 
risk.
The third and final part of this thesis focuses on the anticoagulant effects of statins 
and their potential use as an alternative and safer antithrombotic treatment strategy 
for patients with venous thromboembolism. First, in chapter 9, currently available 
evidence for prevention of (recurrent) venous thromboembolism with statins is 
reviewed from an epidemiological perspective, specifically addressing potential forms 
of bias in prior clinical studies. Next in chapter 10, we performed a retrospective cohort 
study, evaluating the impact of initiation of statin therapy on VKA maintenance dosage 
in 435 patients on phenprocoumon and 303 patients on acenocoumarol. Maintenance 
dosages before initiation of statin treatment were compared with maintenance dosages 
immediately, 6 weeks and 12 weeks after initiation of statin treatment. In 
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phenprocoumon users, mean dosages were 0.02 (95% CI, 0.00 to 0.03), 0.03 (95% CI, 
0.01 to 0.05) and 0.07 mg/day (95% CI, 0.04 to 0.09) lower compared to the mean 
dosage before treatment. In acenocoumarol users mean dosages were 0.04 (95%CI, 
0.01 to 0.07), 0.10 (95%CI, 0.03 to 0.16) and 0.11 (95% CI, 0.04 to 0.18) mg/day lower 
respectively. Statin therapy was therefore associated with minor, but statistically 
significant, changes in immediate and long-term VKA maintenance dosages, irrespective 
of VKA type. Although these dosage changes were of little clinical relevance by 
themselves, these might be explained by anticoagulant effects op statins. In chapters 
11 and 12 we performed a randomized controlled clinical trial evaluating the short-
term (1 month) effect of rosuvastatin therapy on platelet reactivity and several markers 
of coagulation in patients with a history of deep vein thrombosis or pulmonary 
embolism. In the ‘statins reduce thrombophilia‘ (START) trial, patients with an objectified 
venous thrombotic event, who were allowed to discontinue VKA treatment after 3-12 
months, were included.  First in chapter 11, we measured platelet reactivity, before 
and after rosuvastatin therapy or no intervention, in 50 consecutive patients included 
in the START trial. Arachidonic acid mediated platelet reactivity, in platelet reaction 
units (PRU), was measured using the VerifyNow system.  In total, 47/50 patients (94.0%) 
had valid baseline and end of study PRU measurements.  We observed no difference 
in mean PRU at end of study (mean PRU 613) compared to baseline (mean PRU 609) 
in rosuvastatin users (mean change 5; 95% CI, -18 to 27). Similar results were observed 
in non-users. Furthermore, there was no difference in PRU change between rosuvastatin 
users and non-users (mean difference in change 6, 95% CI, -20 to 33). After exclusion 
of patients using antiplatelet drugs or with thrombocytopenia, similar results were 
obtained (mean difference in change -1; 95% CI, -20 to 19). Therefore, rosuvastatin 
therapy did not affect arachidonic acid mediated platelet reactivity in patients with a 
history of venous thrombosis. In chapter 12, we investigated the effect of rosuvastatin 
therapy on coagulation parameters associated with liver function (clotting factors VII 
and XI), fibrinolysis (D-dimer) and endothelial function (Factor VIII and Von Willebrand 
factor).  In total, 255 patients, of whom 131 to rosuvastatin and 124 to no intervention, 
were included between December 2012 and December 2016. Eight participants (5 
rosuvastatin users and 3 non-users) did not complete follow-up. In total 126 rosuvastatin 
users and 121 non-users were included for final analysis. At baseline, no differences 
in coagulation parameters were observed between rosuvastatin users and non-users. 
At end of study, mean factor VIII levels were significantly decreased in rosuvastatin 
users (-7.2 IU/dL, (95% CI -11.5 to -2.9). No change in Factor VIII was observed in non-
users (mean difference -0.1; 95% CI -3.0 to 2.9). Adjustment for age and sex did not 
change these findings. Similarly factor XI levels also decreased in rosuvastatin users 
(-5.9 IU/dL, (95% CI -9.0 to -2.7). Log-transformed D-dimer levels were higher at end of 
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study in non-users (mean difference 0.15, 95% CI 0.02 to 0.29), but unchanged in 
rosuvastin users (mean difference 0.01, 95% CI -0.08 to 0.10). No significant changes 
in Factor VII and Von Willebrand Factor were seen in the intention-to-treat analysis. 
Restriction analysis revealed that, after exclusion of participants reporting an infection 
during the study, Von Willebrand Factor antigen levels also decreased in rosuvastatin 
users (mean change -7.0; 95% CI -12.7 to -3.2), but not in non-users (mean change -1.0; 
95% CI -4.3 to 2.4). Prespecified subgroup analyses revealed similar results as the main 
analyses. However, the anticoagulant effects of rosuvastatin were more pronounced 
in participants with deep vein thrombosis, unprovoked venous thrombosis or with 
cardiovascular risk factors compared to participants with pulmonary embolism, 
provoked venous thrombosis or in participants without cardiovascular risk factors. In 
conclusion, rosuvastatin use was associated with reductions in several coagulation 
factors that are associated with an increased risk of venous thrombosis. These 
anticoagulant effects of rosuvastatin provide a rationale for statin-mediated risk 
reduction of venous thrombosis. An adequately powered randomized controlled trial 
should be conducted to definitively answer whether rosuvastatin should be used for 
the prevention of recurrent venous thrombosis. Finally, in chapter 13 we discussed 
the findings of the studies described in this thesis and give suggestions for further 
studies to optimize anticoagulant therapy in the future.
225
SUMMARY 
14
N E D E R L A N D S E  S A M E N V A T T I N G
Patiënten die risico lopen op of lijden aan arteriële of veneuze trombose behoeven 
behandeling met antistolling om het ontstaan, de progressie of het terugkeren van 
trombose te voorkomen. Hoewel de bestaande middelen hiervoor effectief zijn, hebben 
zij het nadeel dat patiënten een verhoogd bloedingsrisico hebben tijdens de 
behandeling. Wij hebben verschillende studies uitgevoerd die zich richtten op de 
huidige monitoring en het management van antistollingsbehandeling. Hiermee kan 
mogelijk de veiligheid en effectiviteit van antistollingsbehandeling in de toekomst 
verbeterd worden.
In hoofdstuk 1, de algemene introductie, presenteren wij een overzicht van de huidige 
manier van monitoren en managen van antistolling therapie.
Vervolgens hebben wij in hoofdstuk 2 de analytische en klinische overeenkomstigheid 
van INR-resultaten, verkregen middels een point-of-care apparaat (CoaguChek XS) en 
een laboratoriumbepaling (STA-R Evolution, Hepato Quick), vergeleken in een cohort 
van ruim 3000 patiënten op vitamine K antagonisten. Wij vonden een sterke correlatie 
tussen de uitslagen van deze 2 methoden (R=0.901, P<0.001), met name in het 
therapeutische INR-gebied. De numerieke verschillen tussen de methoden namen toe 
naarmate de INR hoger werd. Het gemiddelde verschil tussen de methoden liep van 
-0.18 INR punt (95% BI, -0.20 tot -0.16) voor resultaten met een point-of-care INR tussen 
de 2.0 en 3.0, tot 1.14 INR punt (95% BI, 0.87 tot 1.42) bij point-of-care resultaten tussen 
de 7.1 en 8.0. De klinische overeenkomstigheid tussen de resultaten met betrekking 
tot of de uitslag, in, onder of boven het therapeutische gebied van de patiënt lag, was 
adequaat (88%), hoewel het relatief frequent voorkwam, zowel bij te lage als te hoge 
uitslagen, dat er klinisch geen overeenkomstigheid was tussen INR-resultaten.  
In hoofdstuk 3 hebben we de biologische binnen-persoons variatie (CV%) in 
zelfmetende (n=322) en niet-zelfmetende (n=123) patiënten, die een stabiele dosis 
acenocoumarol of fenprocoumon kregen geanalyseerd. Al deze patiënten werden 
gemonitord of monitorden zichzelf met het CoaguChek XS systeem. In zelfmetende 
patiënten was de mediane binnen-persoons variatie significant hoger in patiënten op 
acenocoumarol dan in patiënten op fenprocoumon (10.2 vs. 8.6%, P=0.001). Bij 
patiënten op acenocoumarol was geen verschil in mediane binnen-persoons variatie 
tussen zelfmetende en niet zelfmetende patiënten (10.4 vs. 10.2%, P=0.690). De 
variatiecoëfficiënt van de CoaguChek XS (4%), zoals gerapporteerd in de literatuur, zou 
niet hoger moeten zijn dan de helft van de biologische variatie om geschikt te zijn voor 
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gebruik in de bestudeerde patiëntgroepen. Op basis van de biologische INR-variatie 
die wij vonden in onze studie, voldoet de CoaguChek aan dit criterium en is deze 
methode precies genoeg voor de monitoring van deze patiënten. 
Vervolgens hebben wij in hoofdstuk 4 het effect van de invoering van routine point-
of-care (POC) INR-bepaling op de kwaliteit van zorg in niet-zelfmetende patiënten op 
vitamine K-antagonisten bestudeerd. Hierbij hebben wij zowel naar de kwaliteit van 
instelling van de patiënten gekeken als naar het risico op complicaties. Dit hebben wij 
gedaan door twee cohorten van ongeveer 2000 niet-zelfmetende patiënten met elkaar 
te vergelijken. Met betrekking tot de therapeutische instelling zagen wij dat het mediane 
percentage tijd in het therapeutische gebied (TTR%) significant lager was gedurende 
POC INR-bepaling (77.9% [95% BI, 67.2 tot 87.4])  dan tijdens laboratorium INR-bepaling 
(81.0%, [95% BI, 71.1 tot 90.5]; P<0.001). Ook het percentage patiënten dat een slechte 
therapeutische instelling had (TTR<60%) was hoger tijdens POC INR bepaling dan tijdens 
laboratorium INR-bepaling (10.7% vs. 14.5%, P<0.001). De mediane TTR tijdens POC 
INR-bepaling bleef echter adequaat en conform aanbevelingen in de Nederlandse 
richtlijnen. Wij vonden geen verschil in het risico op een majeure bloeding, herseninfarct, 
ziekenhuisopname of overlijden tussen de twee cohorten. Dit suggereert dat POC 
INR-controle net zo veilig is als laboratorium INR-controle met betrekking tot het risico 
op complicaties. 
In hoofdstuk 5 hebben wij van 6 verschillende commerciële thromboplastines (waarvan 
3 humaan recombinant en 3 weefselextract) de gevoeligheid voor Factor VII (FVII) 
vergeleken. Wij hebben 3 verschillende hoeveelheden humaan FVII (0.006, 0.012, en 
0.062μg/mL plasma) en buffer als negatieve controle, aan 5 gepoolde patiënten 
plasma’s toegevoegd. Wij zagen dosis-afhankelijke INR-verlagingen bij alle 6 gebruikte 
thromboplastines. Er was een significant verschil in de FVII-geïnduceerde INR- verlaging 
tussen de 6 thromboplastines (P=0.004). Daarentegen zagen wij geen verschillen tussen 
de recombinante thromboplastines onderling (P=0.575) of de weefselextract 
thromboplastines onderling (P=0.085). Samenvoeging van de data van de twee type 
thromboplastines (recombinant en weefselextract) toonde aan dat de FVII-geïnduceerde 
INR-verlaging sterker was wanneer een recombinant humaan thromboplastine werd 
gebruikt dan wanneer een weefsel extract thromboplastine werd gebruikt. Deze data 
bevestigt dat recombinant humane thrombomplastines gevoeliger zijn voor FVII dan 
weefselextract thromboplastines.
In hoofdstuk 6 hebben we gekeken of er verschillen zijn in het risico op een majeure 
bloeding tussen verschillende laag-moleculair-gewichts heparines (LMWH) bij gelijktijdig 
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gebruik met een vitamine K-antagonist. Wij hebben dit onderzocht in een cohort van 
bijna 13.000 ambulante patiënten die recent een veneuze trombose hadden gehad. 
Het risico op een ernstige bloeding was laag met een cumulatieve incidentie van 2.5 
per 1000 patiënten (95% BI, 1.7 tot 3.5). Er was geen onderling verschil in cumulatieve 
incidentie tussen de LMWH’s wanneer men nadroparine eenmaal daags als referentie 
gebruikte. De cumulatieve incidentie liep van 2.1 per 1000 patiënten voor eenmaal 
daags nadroparine tot 3.8 bij het gebruik van enoxaparine.  Het bloedingsrisico leek 
wel hoger bij tweemaal daags gebruik van LMWH vergeleken met eenmaal daags 
gebruik (relatief risico van 1.98, 95% BI 0.76 tot 5.14). De absolute toename in 
bloedingsrisico bij tweemaal daags nadroparine gebruik was 0.13%, met een number 
needed to harm van 767.
Vervolgens hebben wij in hoofdstuk 7 gekeken naar de overeenkomstigheid tussen 
2 verschillende methoden die gebruikt worden voor het meten van de therapeutische 
instelling van patiënten op VKA. Wij hebben dit in verschillende patiëntengroepen 
gedaan. Het percentage tijd in de therapeutische range (TTR%) werd hierbij vergeleken 
met de proportie patiënten van wie de laatste INR in het therapeutisch gebied was 
(CSP %). Hiervoor werd gebruik gemaakt van data gerapporteerd tussen 2010 en 2013 
door leden van de Federatie van Nederlandse trombosediensten. Over het algemeen 
waren de TTR resultaten gemiddeld consequent iets hoger dan de CSP resultaten. In 
long-term patiënten op acenocoumarol was de mediane TTR significant hoger dan de 
CSP (80.0% vs. 78.7%, P<0.001). Bij long-term patiënten op fenprocoumon was er 
daarentegen geen verschil tussen beide methoden. De verschillen tussen de methoden 
in patiënten op acenocoumarol kunnen mogelijk verklaard worden door verschillen in 
de variabiliteit van de INR tussen opeenvolgende metingen binnen de therapeutische 
range.
In hoofdstuk 8 hebben wij het perioperatieve antistollingsbeleid, risicofactoren voor 
nabloedingen en de klinische uitkomsten na 2329 tandheelkundige ingrepen in ruim 
2000 patiënten die behandeld werden met vitamine K-antagonisten geëvalueerd. De 
richtlijnen rondom deze ingrepen werden vaak niet opgevolgd, hetgeen zich uitte in 
heterogeen perioperatief antistollingsbeleid. Patiënten die een laag-risico 
tandheelkundige ingreep ondergingen, waarbij conform de richtlijn de VKA 
gecontinueerd werd in combinatie met tranexaminezuur mondspoeling, hadden een 
lager bloedingsrisico vergeleken met patiënten waarbij geen tranexaminezuur was 
gegeven (OR) of patiënten waarbij de VKA was gestopt en werd overbrugd met heparine. 
Het bloedingsrisico was even hoog als bij patiënten waarbij de VKA was gestopt en er 
niet was overbrugd met heparine. Bij hoog-risico tandheelkundige ingrepen was het 
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bloedingsrisico ruim 3 maal zo hoog als de VKA gecontinueerd werd ten opzichte van 
wanneer er gestopt werd met de VKA voor de ingreep. Multivariaat analyse toonde 
aan dat de meeste risicofactoren voor een nabloeding na een tandheelkundige ingreep 
specifiek gerelateerd waren aan het gekozen perioperatieve beleid. Het risico op 
trombo-embolische complicaties was laag na tandheelkundige ingrepen, ongeacht het 
risico van de procedure of de gekozen perioperatieve behandelstrategie.
Hoofdstuk 9,10, 11 en 12 gaan over de anticoagulante effecten van statines en het 
mogelijk gebruik van deze middelen als alternatieve en veiligere behandeloptie voor 
veneuze trombose.
In hoofdstuk 9 wordt het huidige bewijs voor preventie van veneuze trombose middels 
statines uiteengezet vanuit een epidemiologisch perspectief, waarbij er specifiek wordt 
ingegaan op potentiële vormen van bias in eerdere klinische studies. 
Vervolgens, in hoofdstuk 10, hebben we een retrospectieve cohortstudie gedaan naar 
het effect van statinetherapie op de VKA-onderhoudsdosering in 435 patiënten op 
fenprocoumon en 303 patiënten op acenocoumarol. De onderhoudsdosering VKA vóór 
de start met statine behandeling werd vergeleken met de onderhoudsdosering direct 
na start, na 6 weken en na 12 weken statinetherapie. In fenprocoumon gebruikers was 
de gemiddelde onderhoudsdosering   0.02 (95% BI, 0.00 to 0.03), 0.03 (95% BI, 0.01 to 
0.05) en 0.07 mg/dag (95% BI, 0.04 to 0.09) lager in vergelijking met de onderhoudsdosis 
vóór aanvang van de statinetherapie. In acenocoumarol gebruikers waren deze 
doseringen respectievelijk 0.04 (95% BI, 0.01 to 0.07), 0.10 (95% BI, 0.03 to 0.16) en 0.11 
mg/dag (95% BI, 0.04 to 0.18) lager. Behandeling met statines was derhalve geassocieerd 
met minimale, maar statistisch significante veranderingen in VKA-onderhouds-
doseringen, onafhankelijk van het gebruikte type VKA. Hoewel deze dosisveranderingen 
op zichzelf klinisch niet relevant zijn, zouden deze mogelijk wel verklaard kunnen 
worden door een anticoagulant effect van statines. 
In hoofdstukken 11 en 12 worden de bevindingen van een gerandomiseerde studie 
naar de korte termijneffecten van behandeling met rosuvastatine op bloedplaatjes 
reactiviteit en verschillende stollingsparameters in patiënten die een recente diep 
veneuze trombose of longembolie hebben doorgemaakt uiteengezet. In de ‘Statins 
Reduce Thrombophilia‘ (START) studie werden patiënten geïncludeerd met een 
geobjectiveerde veneuze trombose die na 3-12 maanden hun behandeling met VKA 
mochten staken.
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Allereerst, in hoofdstuk 11, hebben wij de plaatjesreactiviteit voor en na behandeling 
met rosuvastatine vergeleken in 50 opeenvolgende patiënten die geïncludeerd waren 
in de START-trial. Arachidonzuur-gemedieerde plaatjesreactiviteit (PRU) werd gemeten 
met het VerifyNow system. In totaal hadden 47 van de 50 (94.0%) patiënten een valide 
PRU-meting bij inclusie en aan het einde van de studie.  We vonden geen significant 
verschil in PRU na afloop van de studie in rosuvastatine gebruikers, noch in de 
controlegroep. Bovendien was er geen verschil in PRU-verandering tussen de 
rosuvastatine gebruikers en de controlegroep. Exclusie van deelnemers die 
antiplaatjestherapie gebruikten of die trombopeen waren, veranderde deze conclusie 
niet. Derhalve concludeerden wij dat rosuvastatine gebruik geen effect heeft op 
arachidonzuur-gemedieerde plaatjesreactiviteit.
In hoofdstuk 12 hebben we het effect van rosuvastatine behandeling op verschillende 
stollingsparameters onderzocht die samenhangen met leverfunctie (stollingsfactor VII 
en XI), fibrinolyse (D-dimeer) en endotheelfuntie (Factor VIII en Von Willebrand factor). 
In totaal werden voor deze studie 255 patiënten geïncludeerd tussen december 2012 
en december 2016, van wie er 131 werden behandeld met rosuvastatine en 124 waar 
geen interventie in plaats vond. Acht van deze deelnemers (5 rosuvastatine gebruikers 
en 3 controles) voltooiden de studie niet. Derhalve werden in totaal 126 rosuvastatine 
gebruikers en 121 controles geïncludeerd voor de definitieve analyses. Op baseline 
waren er geen verschillen tussen de groepen qua onderzochte stollingsparameters. 
Aan het eind van de studie was het gemiddelde Factor VIII gehalte significant gedaald 
in de rosuvastatine gebruikers (gemiddeld verschil -7.2 IU/dL, 95% BI -11.5 to -2.9), 
maar niet in de controlegroep (gemiddeld verschil -0.1; 95% BI -3.0 to 2.9). Correctie 
voor leeftijd en geslacht veranderden deze resultaten niet. Analoog hieraan was ook 
het gemiddelde Factor XI gehalte lager geworden in de rosuvastatine gebruikers (-5.9 
IU/dL, (95% BI -9.0 to -2.7). Log-getransformeerde D-dimeer waarden waren significant 
gestegen in de controlegroep (gemiddeld verschil 0.15, 95% BI 0.02 to 0.29), maar 
onveranderd in de rosuvastatine gebruikers (gemiddeld verschil 0.01, 95% BI -0.08 to 
0.10). Er werden geen significante veranderingen in Factor VII of Von Willebrand factor 
gezien in de intention-to-treat analyses. Restrictie-analyse daarentegen, waar patiënten 
die een infectie rapporteerden tijdens de studie geëxcludeerd werden, toonde een 
significante daling van het Von Willebrand factor gehalte in rosuvastatine gebruikers 
(gemiddeld verschil -7.0; 95% BI -12.7 to -3.2), maar niet in de controlegroep (gemiddeld 
verschil -1.0; 95% BI -4.3 to 2.4). Vooraf gedefinieerde subgroep analyses toonden allen 
vergelijkbare resultaten. De anticoagulante effecten waren echter het meest 
uitgesproken in patiënten met een diep veneuze trombose van het been, patiënten 
met een niet uitgelokte trombose en in patiënten met cardiovasculaire risicofactoren 
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ten opzichte van patiënten met respectievelijk een longembolie, een uitgelokte 
trombose of zonder cardiovasculaire risicofactoren. Concluderend was het gebruik 
van rosuvastatine geassocieerd met een reductie van verschillende stollingsfactoren 
in het bloed die geassocieerd zijn met een verhoogd risico op veneuze trombose. Deze 
anticoagulante effecten bieden een verklaring voor een statine-gemedieerd verlaagd 
risico op veneuze trombose. Een adequaat gepowerd en gerandomiseerd onderzoek 
zou verricht moeten worden om definitief uitsluitsel te geven of statinegebruik het 
risico op een recidief veneuze trombose kan verlagen.
Tenslotte hebben wij in hoofdstuk 13 de resultaten van de onderzoeken in dit 
proefschrift bediscussieerd en doen wij aanbevelingen voor verdere onderzoeken om 
de behandeling met antistolling in de toekomst verder te verbeteren.
231
SUMMARY 
14
APPENDICES
Optimization of monitoring and 
management of anticoagulant therapy
Joseph Siegmund Biedermann
List of publications
Dankwoord
Curriculum Vitae
PhD portfolio
APPENDICES
234
L I S T  O F  P U B L I C A T I O N S
van der Hulle T, Cheung WY, Kooij S, Beenen LFM, van Bemmel T, van Es J, Faber LM, 
Hazelaar GM, Heringhaus C, Hofstee H, Hovens MMC, Kaasjager KAH, van Klink RCJ, 
Kruip MJHA, Loeffen RF, Mairuhu ATA, Middeldorp S, Nijkeuter M, van der Pol LM, 
Schol-Gelok S, Ten Wolde M, Klok FA, Huisman MV; YEARS study group. Simplified 
diagnostic management of suspected pulmonary embolism (the YEARS study): a 
prospective, multicentre, cohort study. Lancet. 2017;390(10091):289-297. 
van Rein N, Biedermann JS, van der Meer FJM, Cannegieter SC, Wiersma N, Vermaas 
HW, Reitsma PH, Kruip MJHA, Lijfering WM. Major bleeding risks of different low-
molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute 
venous thrombosis. J Thromb Haemost. 2017;15(7):1386-1391. 
Biedermann JS*, Rademacher WMH*, Hazendonk HCAM, van Diermen DE, Leebeek 
FWG, Rozema FR, Kruip MJHA. Predictors of oral cavity bleeding and clinical outcome 
after dental procedures in patients on vitamin K antagonists. A cohort study. Thromb 
Haemost. 2017;117(7):1432-1439. 
* Contributed equally as first author
Biedermann JS, van den Besselaar AM, van der Meer FJ, Adriaansen HJ, Leebeek FW, 
Kruip MJ. Control of anticoagulation with VKAs: overestimation of median TTR when 
assessed by linear interpolation: Reply. Thromb Haemost. 2017;117(4):820-821. 
Biedermann JS, van den Besselaar AM, de Maat MP, Leebeek FW, Kruip MJ. Monitoring 
of treatment with vitamin K antagonists: recombinant thromboplastins are more 
sensitive to factor VII than tissue-extract thromboplastins. J Thromb Haemost. 
2017;15(3):500-506. 
Lijfering WM, Biedermann JS, Kruip MJ, Leebeek FW, Rosendaal FR, Cannegieter SC. 
Can we prevent venous thrombosis with statins: an epidemiologic review into 
mechanism and clinical utility. Expert Rev Hematol. 2016;9(11):1023-1030. 
van Rein N, Biedermann JS, Bonafacio SM, Kruip MJ, van der Meer FJ, Lijfering WM. 
Statin use decreases coagulation in users of vitamin K antagonists. Eur J Clin Pharmacol. 
2016;72(12):1441-1447. 
235
APPENDICES 
 
Biedermann JS, van den Besselaar AM, Leebeek FW, Kruip MJ. Impact of point-of-care 
international normalized ratio monitoring on quality of treatment with vitamin K 
antagonists in non-self-monitoring patients: a cohort study: reply. J Thromb Haemost. 
2016;14(11):2312-2314.
van den Besselaar AM*, Biedermann JS*, van der Meer FJ, Adriaansen HJ, Leebeek FW, 
Kruip MJ. Control of anticoagulation with vitamin K antagonists: overestimation of 
median time in therapeutic range when assessed by linear interpolation. Thromb 
Haemost. 2016;116(4):679-686. 
* Contributed equally as first author
Biedermann JS, Cannegieter SC, Roest M, van der Meer FJ, Reitsma PH, Kruip MJ, 
Lijfering WM. Platelet reactivity in patients with venous thrombosis who use 
rosuvastatin: a randomized controlled clinical trial. J Thromb Haemost. 2016;14(7):1404-
1409.
Biedermann JS, van Rein N, van den Besselaar AM, Buhre PN, de Maat MP, van der 
Meer FJ, Leebeek FW, Kruip MJ. Impact of point-of-care international normalized ratio 
monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring 
patients: a cohort study. J Thromb Haemost. 2016;14(4):695-703. 
ten Cate-Hoek AJ, Weitz JI, Gailani D, Meijer K, Philippou H, Bouman AC, Whitney Cheung 
Y, van Mens TE, Govers-Riemslag JW, Vries M, Bleker S, Biedermann JS, Stoof SC, Buller 
HR. Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) 
and post thrombotic syndrome (PTS). Thromb Res. 2015;136 Suppl 1:S13-8. 
van den Besselaar AM, Biedermann JS, Kruip MJ. Point-of-care testing and INR within-
subject variation in patients receiving a constant dose of vitamin K antagonist. Thromb 
Haemost. 2015;114(6):1260-1267.
Biedermann JS, Leebeek FW, Buhre PN, de Lathouder S, Barends JP, de Maat MP, van 
der Meer FJ, Kruip MJ. Agreement between Coaguchek XS and STA-R Evolution (Hepato 
Quick) INR results depends on the level of INR. Thromb Res. 2015;136(3):652-657.
APPENDICES
236
D A N K W O O R D
Dit proefschrift is tot stand gekomen met de hulp van vele collega’s en inmiddels 
vrienden. Graag wil ik van de gelegenheid gebruik maken om iedereen te bedanken 
die dit mogelijk heeft gemaakt.
Allereerst mijn promotor, beste prof. dr. Leebeek, beste Frank, als vreemde 
Amsterdammer kwam ik bij jou terecht voor een nieuw onderzoeksproject. Jouw inzet 
voor de wetenschap en de dagelijkse patiëntenzorg bewonder ik.  Ik waardeer de manier 
waarop jij mensen verbindt en voor een fijne sfeer in onze onderzoeksgroep zorgt.
Mijn copromotor, beste dr. Kruip, beste Marieke. Wat ben ik blij dat jij mij de kans 
hebt gegeven dit mooie onderzoeksproject samen met jou te mogen uitvoeren. Bijna 
4 jaar lang hebben wij ontzettend fijn samen gewerkt om alle onderzoeken uit dit 
proefschrift te publiceren. Jouw scherpe analytische blik en duidelijke feedback heb ik 
altijd heel fijn gevonden in onze discussies!  Ook als ik het even niet meer zag zitten, 
zag jij altijd helder perspectief.   
Speciale dank aan prof. dr. H. ten Cate, prof dr. S.C. Cannegieter en prof dr. K. 
Meijer voor het plaatsnemen in de kleine commissie. 
Beste dr. van den Besselaar, beste Ton.  Heel veel dank dat jij afgelopen jaren al jouw 
expertise met mij hebt willen delen! Onze experimenten in het lab en de fijne overleggen 
onder een goed bakje koffie zullen mij altijd bij blijven. Vooral hoop ik dat jij vanaf nu 
heerlijk zult genieten van jouw welverdiende pensioen!
Ook de collega’s van de afdeling klinische epidemiologie van het LUMC en de 
trombosedienst Leiden wil ik graag bedanken. Willem Lijfering, Nienke van Rein, 
Prof. Cannegieter, Prof. Rosendaal en dr. van der Meer veel dank voor de fijne 
samenwerking de afgelopen jaren! 
Grote dank gaat ook uit naar alle collega’s bij de trombosedienst van STAR-SHL 
waarmee ik afgelopen jaren heb mogen samenwerken. Heidi, Alja, Jan-Paul, Mies en 
alle andere doseer artsen en adviseurs, dank voor jullie steun, inzichten en alle hulp 
afgelopen jaren.
Ik wil ook de collega’s van het Academisch Centrum Tandheelkunde Amsterdam (ACTA) 
bedanken voor de samenwerking. Beste prof. F. Rozema, dr. D. van Diermen en 
237
APPENDICES 
 
Willem Rademacher dank voor het delen van jullie expertise van tandheelkundige 
ingrepen.
Uiteraard wil ik ook al mijn collega’s in het Erasmus MC  bedanken. Beste dr. de Maat, 
beste Moniek, dank voor alle keren dat ik met jou heb mogen sparren over mijn lab 
resultaten. Dick, Shirley, Simone, Shiraaz en alle collega’s van het hemostaselab 
dank voor de fijne samenwerking afgelopen jaren op de afdeling. Beste Albert, wat 
hebben we geknokt voor die data van ons predictiemodel. Onwijs knap hoe jij jouw 
opleiding tot apotheker met promoveren combineert. We doen snel weer een bakje 
koffie in het Reinier!
Graag wil ik ook nog enkele woorden wijden aan mijn directe collega’s en (ex-)
kamergenoten: Lieve Carina, ik weet nog goed hoe fijn jij mij opving op mijn 1e werkdag. 
Dank voor alle gezelligheid, steun en fijne gesprekken en discussies die wij gehad 
hebben samen afgelopen jaren. Geniet met Maarten van jullie mooie nieuwe huis in 
Barendrecht! Lieve Carolien, ik bewonder enorm hoe jij altijd voor iedereen klaar staat 
met een lach, zelfs als je het zelf stiekem veel te druk hebt.  Ook konden wij altijd 
heerlijk sparren samen over statistiek. Heel veel succes met het veiligstellen van jouw 
plekje bij de kindergeneeskunde!  Lieve Michelle, heerlijk hoe jij altijd vrolijk bent, wat 
er ook gebeurt. Ik hoop jou binnenkort weer eens te zien bij de internisten dagen! Lieve 
Janske en Yvonne, hoewel ik maar relatief kort met jullie heb mogen samenwerken, 
stonden jullie altijd klaar om mij te helpen de eerste maanden, dank!  Lieve Iris, Johan 
en Caroline, mijn trouwe koffiekameraden, wat heb ik met jullie gelachen afgelopen 
jaren om al jullie (en bij vlagen mijn eigen) slechte grappen. Hoe serieus of hard we 
ook werkten er was altijd tijd voor een welverdiende koffiepauze of een muzikaal of 
cabaret intermezzo. Ik hoop jullie snel weer te zien! Lieve Lisette, hoewel jij liever thee 
dronk (onbegrijpelijk maar waar) maakte jij onze gezellige kamer natuurlijk compleet. 
Heel veel succes bij het afronden van jouw mooie project.
Lieve Mama en Brent, geweldig was jullie steun en toewijding afgelopen jaren. Mama, 
mijn discipline en kracht om door te zetten heb ik zeker van jou meegekregen. Brent, 
dank voor alle goede adviezen en steun op de moeilijke momenten, ik heb er veel van 
geleerd. Papa, hoewel jij helaas dit alles nooit hebt mogen meemaken, hoop ik dat ik 
ook jou trots heb kunnen maken met deze prestatie. 
Lieve Dominique, mijn steun en toeverlaat. Al die jaren ben jij, ondanks mijn regelmatige 
gemopper, er voor mij geweest. Nu wonen wij heerlijk samen in Delft en blijven we 
bouwen aan onze toekomst samen. Dank dat jij er altijd voor mij was en bent!
APPENDICES
238
Als laatste wil ik graag mijn paranimfen bedanken. Lieve Eveline en Joost bedankt 
voor al jullie hulp met de voorbereidingen op mijn promotie. Joost, al 15 jaar zijn we 
trouwe vrienden. Van avonden uit tot aan de ontbijttafel bij jouw grootouders om een 
potje te kaarten. Ondanks dat we elkaar niet meer dagelijks zien, weet ik dat ik altijd 
bij jou terecht kan. Dank voor jouw vriendschap!
Eveline, lieve zus, wat was jij enthousiast om paranimf te mogen worden! Een goede 
psychiater aan je zijde op zo een spannende dag is natuurlijk nooit weg. Lang heb ik 
jouw goede voorbeeld gevolgd, maar nu heb ik toch echt mijn eigen route gekozen. 
Dank dat jij er altijd voor me bent!
239
APPENDICES 
 
C U R R I C U L U M  V I T A E
Joseph Siegmund Biedermann werd op 25 april 1989 geboren te Amstelveen. Na het 
behalen van het gymnasium diploma aan het Vossius Gymnasium te Amsterdam, 
studeerde hij vanaf 2007 geneeskunde aan de Vrije Universiteit in Amsterdam. In 2013 
heeft hij 6 maanden wetenschappelijk onderzoek verricht bij de afdeling endocrinologie 
van het VU-medisch Centrum onder begeleiding van dr. E.M. Eekhoff, naar de effecten 
van lichamelijke conditie op overleving en cardiovasculaire mortaliteit in ouderen. Na 
zijn afstuderen begon hij in November 2013 aan zijn promotie onderzoek onder 
supervisie van Dr. M.J.H.A. Kruip en Prof. Dr. F.W.G Leebeek. Dit promotie onderzoek 
heeft geleid tot het proefschrift dat voor u ligt. Sinds 1 april 2017 is hij werkzaam als 
arts-assistent Interne Geneeskunde in het Reinier de Graaf Gasthuis te Delft.
APPENDICES
240
P H D  P O R T F O L I O
P H D  T R A I N I N G
Year Workload 
(ECTS)
General academic skills
Biomedical English Writing Course 2015 3,0
Course Research Integrity 2013 0,3
Research skills
Basic course on Regulations and Organization for Clinical 
Investigators (BROK)
2015 1,5
Open Clinica training 2015 0,3
In-depth courses (e.g. Research school, Medical Training)
COEUR course: Cardiovascular Medicine 2013 1,5
COEUR course: Pathophysiology of ischemic heart disease 2014 1,5
COEUR course: Cardiovascular Clinical Epidemiology 2014 1,5
3x NVTH courses on Thrombosis and Hemostasis 2014-2016 3,0
Presentations
Dutch Hematology Congress 2015 0,8
ECTH 2016 0,8
NVTH 2015 0,8
ECAT symposium (invited speaker) 2016 1,2
Impact of Point-of-Care INR monitoring, Roche Diagnostics, 
Almere (invited speaker)
2015 0,8
2x FNT meeting on quality control and assurance (invited 
speaker)
2014, 2016 0,8
Nurses symposium on anticoagulation 2x (invited speaker) 2014, 2016 1,6
4x poster presentations (2x ISTH 2015, 1x SSC 2016, 1x 
ECTH 2016)
2015 1,2
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Conferences and symposia
ISTH 2015 1,8
2x NVTH 2014, 2015 1,2
Dutch Hematology Congress 2015 0,3
2x Federation of Dutch Thrombosis Services 2014,2016 0,6
ECTH 2016 0,9
2x AMSTOL symposium 2014, 2016 0,6
COEUR PhD day 2014 0,5
Clinical Chemistry Symposium 2016 0,3
Maastricht consensus conference on thrombosis 2015 0,3
Seminars and workshops
2x COEUR research seminar 2013, 2014 1,0
5x COEUR lecture 2013-2016 1,5
16th regional post-graduate course for hematologists, 
Rotterdam 
2014 0,3
NVTH PhD day 2014 0,4
Hematology PhD training 
Work discussions and literature discussions (weekly) 2013-2017 5,0
T E A C H I N G  A C T I V I T I E S 
Lecturing 
2x Education for thrombosis service physicians (FNT) 
(invited speaker)
2014, 2016 1,6
10x Coagulation lecture for nurses (EMC) 2013-2017 1,0
Supervision of medical students
Review 2nd year medical students during elective course on 
blood coagulation for 2nd year medical students (EMC)
2016, 2017 0,5
Other
Scientific editing and meetings for FNT 2015-2017 2,0
Total 40,5
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